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Summary
Even though hypertension had been long identified as a major cardiovascular 
risk factor affecting up to 20-25 % of the Scottish adult population (Hawthorne et al 
1974), follow-up care had continually been shown to be inadequate (Hawthorne et al 
1974, Miall & Chinn 1974, Heller & Rose 1977a,b). By 1981, nurse practitioner 
care, which had been established in the United States, had been judged to be at least 
equivalent to physician follow-up care in the ambulatory care setting (Sox 1979). In 
addition, microcomputer systems were being developed to facilitate data collection, 
standardisation, retrieval and information analysis (Lilford & Chard 1981).
Therefore, a project was initiated to evaluate the effectiveness of a nurse practitioner 
hypertension follow-up clinic with a microcomputer patient information system. 
Additional research projects were generated directly from the patient problems 
revealed with long-term follow-up, and carried out within this alternative care 
setting.
Over 8 years, 1091 patients were admitted to the clinic with 705 (65%) 
continuing to attend at the end of Year 8 and only 11 % of the population were lost 
due to non-attendance (Chapter 3). Blood pressure control was achieved in a 
substantial percentage of the population from the first year and was maintained 
throughout (Chapter 3), with slight improvements between Year 6 and Year 8 for 
those attending both years, concurrent with a change in emphasis of care from 
hypertension to multiple risk factor intervention (Chapter 7). There was greater 
blood pressure control in the nurse practitioner clinic patients compared with age/sex 
matched controls attending conventional hypertension clinics (Chapter 4).
The identification of increasing lipids in a population attending continuously 
for 4 years, and the high incidence of other risk factors, lead to the Cholesterol/Diet 
Study (Chapter 5) and the Guar Gum Study (Chapter 6). The effect of intensive lipid 
lowering dietary advice by dietitians over a 6 month period, in hyperlipidemic 
hypertensive patients, was shown to be limited with only a 2% greater reduction in 
mean cholesterol in the Advice Group compared to the No Advice Group. At the end
(xiv)
of the study 56% of the Advice Group and 57% of the No Advice Group continued to 
have a total cholesterol > 6 . 5  mmol/1 (Chapter 5).
The soluble fibre guar gum was shown to have no effect on weight or blood 
pressure. A 6% reduction in total cholesterol in the lipid sub-group was non­
significant in comparison with no change in the bran control. In addition, there was a 
high incidence of socially unacceptable side effects (Chapter 6).
Levels of reported smoking decreased over time in the clinic and were less 
than the Scottish population averages. The average weight in the clinic did not 
change, but clinically modest, but statistically significant reductions, were observed 
in those with Body Mass Index > 30. There were no changes in reported levels of 
alcohol intake (Chapter 3 and Chapter 7).
In conclusion, nurse practitioner care is as good as conventional hypertension 
care for the long term follow-up of hypertensive patients and may be more effective 
in terms of maintaining follow-up and adherence to management protocols. A 
microcomputer patient information system can facilitate the every day management 
of an outpatient clinic as well as providing data for research and audit. This system is 
capable of responding to and integrating the developments in knowledge and 
understanding which demand change in the provision of care. Finally, the success of 
current strategies for decreasing overall cardiovascular risk by decreasing levels of 
established risk factors, such as increased total cholesterol, smoking, excess weight 
and excessive alcohol consumption is limited.
(xv)
Chapter 1. Introduction and Background 
1.0 Introduction
Hypertension has been estimated to affect up to 20%-25% of the Scottish adult 
population (Hawthorne et al 1974, Smith et al 1990) and is a well established risk 
factor for cardiovascular mortality (Pooling Project 1978, MacMahon et al 1990). 
Cardiovascular disease, particularly coronary heart disease (CHD), is a leading cause 
of death in adults, and the rates in Scotland are amongst the highest in the world 
(Tunstall-Pedoe et al 1986). In addition, the north Glasgow centre of the World 
Health Organisation’s (WHO) international Monitoring of Trends and Determinants 
in Cardiovascular Disease study (MONICA) had the highest coronary mortality rate 
in women of all the centres in the 1983-1984 survey (Principal Investigators 1987).
Treatment trials have shown significant decreases in cerebrovascular mortality 
and morbidity with the lowering of blood pressure (Collins et al 1990). These 
positive effects have also been seen in the elderly (SHEP 1991, Dahlof 1991, MRC 
Working Party 1992)
Unfortunately, conventional hypertension care has been repeatedly shown to be 
inadequate in terms of follow-up, even up to the present day (Hawthorne et al 1974, 
Ritchie & Currie 1983, Smith et al 1990). Less than half of the women and only a 
quarter of the men identified as being hypertensive in the Scottish Heart Health 
Survey were found to have satisfactorily controlled diastolic blood pressure of 85-90 
mmHg (Smith et al 1990). Thus, alternative, more effective forms of care are 
needed.
Nurse practitioners have been operating successfully in a number of settings in 
the United States since the 1960's. When compared with medical follow-up in 
ambulatory care settings, nurse practitioner follow-up has been judged to be at least 
equivalent (Sox 1979). However, this alternative was not widely publicised in the 
United Kingdom until Stilwell's work was described in 1982 in the Nursing Times, 
the year after this project was initiated (Stilwell 1982).
Computerised patient information systems have been shown to facilitate data
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collection, standardisation, retrieval and information analysis (Slack et al 1966, 
Whiting-O'Keefe et al 1985, McDonald & Tierney 1988). The advent of small and 
relatively cheap desk top personal microcomputers, provided the opportunity for 
further exploration of the usefulness of such systems (Lilford & Chard 1981).
Thus these elements were brought together in an innovative approach to the 
long term follow-up care of hypertensive patients. The basis of this thesis is the 
description, assessment, comparison and evaluation of this approach. In addition, 
several research projects were generated directly from the patient problems revealed 
with long-term follow-up, and were carried out within this alternative care setting, 
and these are also presented.
1.1. Epidemiology of hypertension
During the first half of this century, interest in the measurement of blood 
pressure and its importance, grew with the establishment in 1905 by Korotkov of a 
method of auscultation using the device invented by Riva Rocci in 1898 (Korotkov 
1905). It was also advanced with the identification of 'essential hypertension' by 
Allbutt (Allbutt 1915). Thereafter followed a series of reports with increasing 
scientific rigour as the century progressed. Anecdotal summaries of clinical 
experience lead to population surveys and comparisons of hypertensive and 
normotensive populations. The early studies are important for their identification of 
the link between hypertension and increased mortality, frequently due to a 
cardiovascular event.
In 1913, Janeway reported anecdotally on 458 patients with elevated blood 
pressure whom he had treated over a nine year period. By the end of nine years,
53.1 % of the men and 32.5% of the women had died. Despite this apparent high 
level of mortality, he felt that blood pressure did not predict life expectancy (Janeway 
1913).
Paullin reported on a series of 39 men and 37 women with elevated blood 
pressures whom he followed for up to 17 years. At analysis, 48.7% of the men and
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9.2% of the women had died. Of the 54 survivors, 16 (30%) had experienced a 
cardiovascular event (heart failure, myocardial infarction, stroke, transitory 
ischaemic attack, angina or renal failure) (Paullin 1926).
Using a population approach, Blackford and Wilkinson in 1932 reported on the 
ten year mortality of 202 hypertensives with blood pressure >  170/100 mmHg. 
These patients were identified from a review of 10,000 consecutive patients 
examined in their clinic for a problem that necessitated a general examination, but 
who had not been referred for care of their hypertension. Approximately two-thirds 
of the sample was women and the overall mortality was 60%, with female mortality 
of 50% and 82% for men (Blackford & Wilkinson 1932).
Much effort went into classifying or grading levels of blood pressure and 
related physical findings. In 1939 Keith, Wagener and Barker from the Mayo Clinic 
published a retrospective analysis of 219 hypertensives whom they had followed for 
5-9 years or until death. Patients were classified by blood pressure and physical 
findings, particularly retinal changes, and it was found that mortality increased with 
increasing severity of grading. Only 9% of their patients were alive at the end of the 
study period (Keith et al 1939).
Interest in the course of hypertensive disease, as described in the above 
American reviews, was also present in Europe. Frant and Groen followed 418 
outpatients with initial blood pressures > 155/100 mmHg for nine years. Female 
total mortality was 25% compared with the male of 40%, with the median age range 
of death being 50-59 years for men and 60-69 years for women. Mortality was 
directly related to blood pressure and also to retinal changes. Finally, these mortality 
rates were more than twice the rates for the Dutch population at that time (Frant & 
Groen 1950).
Bechgaard, Kopp and Neilsen reported on a series of 1,038 Danish patients, 
followed for 16-22 years, who were first referred to a general medical clinic, and 
most of whom were previously unknown moderate hypertensives (>160/100 mmHg 
or systolic blood pressure > 1 8 0  mmHg). Again the differences between men and
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women were apparent. Women with systolic blood pressure <  200 mmHg 
experienced a normal mortality rate while the men's rate was twice that of the 
women for an equivalent entry blood pressure. The mortality rate in the men with 
systolic blood pressure > 200 mmHg was also twice that of the women. These 
mortality rates are higher than in Frant and Groen's study and this may well have 
been due to the higher entry blood pressures in this population (Bechgaard et al 
1956).
The above sample of reports from the first half of this century indicates that 
the clinical course of untreated hypertension was repeatedly noted to be associated 
with high morbidity and mortality, particularly in men. Unfortunately, such 
retrospective assessment and reporting of clinical data has limitations in that the 
patients described may well have been referred selectively to these specialist centres 
and would, therefore, not be representative of the 'true' hypertensive population. 
These studies do provide a basis and justification for the prospective epidemiological 
surveys that followed which attempted to assess the occurrence of hypertension in a 
variety of cultures and countries, and the impact that increasing blood pressure has 
on cardiovascular morbidity and mortality.
By the mid-1970's, prospective epidemiological studies had identified and 
confirmed the relationship between elevated blood pressure and increased mortality. 
From the United States came the large Society of Actuaries' Build and Blood 
Pressure Study in 1959 (Society of Actuaries 1959) and the Metropolitan Life 
Insurance Company's study published in 1961 (Metropolitan Life Insurance 
Company 1961).
The first major 'meta-analysis' (pooling of results) of prospective 
epidemiological surveys, which had a great impact on the clinical understanding of 
hypertension and other cardiovascular risk factors was the Pooling Project. It was 
undertaken by the Council on Epidemiology of the American Heart Association and 
pooled data from 8,422 white men aged 40-64 from 5 prospective studies. Data were
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used from the Albany Cardiovascular Health Center, Chicago Peoples Gas Co, 
Chicago Western Electric Co, Framingham Heart Disease Epidemiology and 
Tecumseh Community Health Studies. This was the first time that the cardiovascular 
risk from blood pressure was identified as consistent, graded, and independent as 
well as predictive (Pooling Project Research Group 1978).
The Seven Countries Study's importance stems from its multi-cultural 
population and longevity. Over 15 years, 11,579 men aged 40-59 years from 7 
countries were followed. Variability in mortality in the total cohort and amongst the 
countries was analysed in relation to a number of known cardiovascular risk factors 
(blood pressure, cholesterol, and smoking). Blood pressure was the only factor which 
helped to explain the variance in 'all cause' mortality amongst all the countries (Keys 
et al 1984).
The Whitehall study screened 18,403 male British civil servants aged 40-64 
years. The 10 year coronary heart disease mortality correlated with blood pressure, 
but was more strongly associated with systolic than diastolic blood pressure, thus 
corroborating the impact of blood pressure in a British population (Lichtenstein et al
1985).
The ongoing Framingham Heart Study is the most important cardiovascular 
epidemiological study ever conducted. Not only has it continued to collect mortality 
data on a screehed population of both sexes, but the health information has been 
updated on a regular basis for more than 30 years. Between 1949 and 1953, 5,209 
men and women residents of Framingham, Massachusetts, USA, aged 35 to 65 years 
were recruited (McGee 1973), and surviving participants have been examined bi- 
annually since recruitment. After 16 years of follow-up, 6 year mortality rates were 
calculated, and systolic blood pressure was shown to be associated with an increase 
risk of developing cardiovascular disease (Wilson et al 1987). This was true also for 
those over the age of 65 years, particularly when the systolic blood pressure was > 
160 mmHg at previous examinations (Harris et al 1985).
The largest single population prospectively studied was the Multiple Risk
5
Factor Intervention Trial (MRFIT) screenees. Unfortunately, they were all the same 
sex. The 325,348 middle-aged white men were followed-up for 6 years, and there 
were 2,426 deaths attributed to coronary heart disease from a total of 6,968 deaths.
In this population, blood pressure was found to independently contribute to coronary 
risk (Kannel et al 1986).
Smaller and less well known surveys have shown that the prognostic value of 
casual blood pressure recordings in regards to cardiovascular complications is greater 
in men than in women (Miall & Chinn 1974), and increasing blood pressure is 
associated with an increased death rate from cardiovascular disease (Paul 1971, 
Tverdah 1987).
In the largest meta-analysis to date, the impact of diastolic blood pressure on 
incidence of stroke and coronary heart disease was evaluated by MacMahon et al. 
Data were pooled for 418,343 people from 9 prospective epidemiological studies, 
90% of which were from men. The studies used were the MRFIT Screenees,
Chicago Heart Association, Whitehall, Puerto Rico, Honolulu, Lipid Research Clinic 
Prevalence, Framingham, Western Electric, and People's Gas studies. Each study 
did not make an equal contribution, and the MRFIT screenees were the largest group 
by a factor of 10. An important aspect was that the analysis included a correction of 
the 'regression dilution' bias inherent in such data. The authors concluded that 
prolonged differences in diastolic blood pressure of 5, 7.5 and 10 mmHg were 
associated with at least a 34%, 46% and 56% difference in the risk of stroke and 
21%, 29% and 37% in the risk of coronary heart disease (MacMahon et al 1990).
The Renfrew and Paisley survey is one of the most relevant for this study. It 
was conducted in the West of Scotland and is one of the few studies which included 
women as well as men. More than 15,000 men and women were followed for 15 
years to study the impact of a number of cardiovascular risk factors as well 
differences between the sexes. The sexes had similar blood pressures and relative 
risk associated with increased diastolic blood pressure. Women's absolute risk
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associated with rising blood pressure was less than the men's (Isles et al 1992). This 
result supports the concept that cardiovascular risk from hypertension is present in 
both sexes, albeit to different degrees.
The epidemiological role which hypertension plays as a risk factor for 
cardiovascular disease has been outlined. The conclusions drawn from these surveys 
must be evaluated in the light of several limitations. Most studies have been of 
middle-aged, middle class white men with only a comparatively small number of 
women and men of other ethnic origins. When women have been included, as in the 
Paisley-Renfrew study, a difference in the relative risk of cardiovascular mortality 
was revealed (Isles et al 1992). Results are based on one-off datasets, except in the 
Framingham study, which does not allow for the natural variability of results, 
including regression to the mean (although this had been addressed in MacMahon et 
al's 1990 meta-analysis), seasonal variations and changes in lifestyle which may have 
been instituted since the initial survey. The meta-analyses frequently contain the 
same datasets, with the Framingham study not only appearing in Paul's report in 
1971, but in the Pooling Project of 1978 and MacMahon et al's reviews in 1986 and 
1990.
Finally, hypertension is only one of a number of cardiovascular risk factors 
(Hopkins & Williams 1981). It's relationship to the other known cardiovascular risk 
factors is presented and discussed in section 1.3.
1.2. Impact of anti-hypertensive treatment
1.2.1. Clinical review of anti-hypertensive care
A number of reports of long term clinical follow-up of treating hypertensive 
populations have yielded data indicating that lowering blood pressure improves 
survival, with decreases particularly in cerebrovascular and cardiovascular mortality. 
Hodge et al reported on up to 8 years of follow-up of 497 treated and 156 untreated 
New Zealand hypertensives who had refused treatment during the 1950's. The 
groups were sub-divided by sex and the aforementioned retinal grading system of 
Keith, Wagener and Barker. Mortality was significantly greater in all untreated
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controls for each sex/retinal sub-group (Hodge et al 1961).
Hamilton et al cared for 30 treated and 31 untreated hypertensives with 
diastolic blood pressure greater than 110 mmHg but without symptoms of arterial 
disease at entry. After 2-6 years of follow-up, there were significantly fewer events 
in those of the treated group who had blood pressure lowered (Hamilton et al 1964).
In Scandinavia, Berglund et al reported on improved overall mortality, but not 
coronary heart disease, after 4.3 years of follow-up in a group of 635 treated 
hypertensive men aged 47-54 years compared with a control group of 391. Both 
groups had blood pressures >  175/115 mmHg and were part of the intervention and 
control groups of the larger primary prevention trial (Berglund et al 1978).
The DHSS Hypertension Care Computing Project, in a follow-up report of 
6,216 patients, identified that the relative hazard rate for death from ischaemic heart 
disease increased with diastolic blood pressure in men and women under the age of 
60 years. It was noted that a positive relationship for systolic blood pressure 
continued into old age (Bulpitt et al 1992). The Glasgow Blood Pressure Clinic 
reported that 'all cause' and stroke 6-year mortality were reduced by treatment since 
those with the greatest reductions in blood pressure had the least mortality (Isles et al
1986).
Community based studies have also shown the relationship between anti­
hypertensive treatment and decreased mortality. Tuomilehto et al studied the 
mortality from stroke in two areas of Finland from 1972-1977 and 1977-1982. Rates 
declined for men and women in relation to anti-hypertensive drug treatment, and, 
where drug treatment declined and blood pressure increased, stroke rates increased 
(Tuomilehto et al 1985). Lindholm and his colleagues have been following up a 
community based hypertensive population in Sweden since 1972 (Lindholm et al 
1984) and, after 15 years of follow-up, they found a relative risk of myocardial 
infarction in male hypertensives of 3.8 in comparison to a normotensive population 
from the same community (Lindholm 1991). Al-Roomi et al conducted a case control
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study in Western Australia comparing pre-myocardial infarction and pre-stroke blood 
pressures with blood pressures of other treated hypertensives who had not yet 
suffered an event. Blood pressure was higher for those experiencing an event than 
for those who had not (Al-Roomi et al 1990).
Hart et al analysed the screening and follow-up data over a 21 year period of 
25 men and 16 women under the age of 40 who were hypertensive, in his general 
practice in Wales. Each was matched retrospectively with a normotensive age/sex 
control. The hypertensive group experienced greater cardiovascular mortality and 
morbidity than the control group, with hypertensive men having higher rates than 
hypertensive women (Hart et al 1993).
1.2.2. Controlled clinical trials of anti-hypertensive drug treatment
Despite the positive reports of clinical experience as indicated above, it is the 
accepted standard to look to prospective, randomised controlled clinical trials for 
definitive evidence. It was well established by 1980 that lowering blood pressure 
improved cardiovascular mortality, particularly cerebrovascular mortality. The 
United States Veterans Administration Study showed improved morbidity and 
mortality in treated hypertensives over placebo treated controls with diastolic blood 
pressures between 90-129 mmHg. The first report studied a sub-group of 143 men 
who had diastolic pressures between 115-129 mmHg (VA Cooperative Study Group 
1967). The second presented the results from 380 men with levels between 90-114 
mmHg (VA Cooperative Study Group 1970).
However, subsequent trials produced somewhat mixed results. One of the 
major negative studies of anti-hypertensive treatment was conducted in 452 stroke 
survivors, 80% of whom were black and 60% were male. Half were randomised to 
a deserpidine/methyclothiazide combination tablet or placebo after the first 6 weeks 
of the study when all participants received active drug treatment. There was no 
difference in stroke recurrence after 3 years of follow-up despite blood pressure 
reductions of 25/12 mmHg in the drug treatment group. These poor results may well 
be due to racial differences, the high risk nature of the population, the long effect of
9
6 weeks of active drug treatment in the placebo group at the beginning of the study, 
poor compliance with drug treatment or some other detrimental physiological effect 
of drug treatment, such as increased lipid levels (Hypertension-Stroke Cooperative 
Study Group (HSCSG) 1974).
Another negative study was the International Prospective Primary Prevention 
Study in Hypertension (IPPPSH) involving 288 centres in 6 countries and 6,357 men 
and women randomised to oxprenolol or placebo. Entry diastolic blood pressures 
were between 100-125 mmHg. Diuretic treatment was added to 67% in the 
oxprenolol group and 82% in the placebo group. Despite a statistically significant 
difference in the reduction in achieved mean blood pressure between the groups, this 
was clinically minimal at 3.8 mmHg/1.2 mmHg. The minimal blood pressure 
reductions, which were one third to one half the reductions achieved in following 
studies, and the fact that both groups were treated with active treatment, including 
the same agent, may well have contributed to there being no difference in any of the 
standard measures of mortality in this study. Non-smoking men on oxprenolol had 
the lowest mortality (IPPPSH 1985).
The more positive studies included the American Hypertension and Detection 
Follow-up Program (HDFP), which studied 5,901 hypertensive men and 5,039 
women with diastolic blood pressures of 90-115 mmHg who received either specialist 
'stepped care' treatment or were referred to their usual source of care. Diastolic 
blood pressure reduction in the specialist stepped care group was 5 mmHg lower than 
in the referred care group 5 years after entry. They also experienced fewer 'all 
cause' deaths in this time (HDFP Cooperative Group 1979).
The Oslo study randomised 785 men 40-49 years of age to treatment with a 
diuretic with or without methyldopa, or propranolol and to a control group. The 
control group did not receive a placebo. Entry systolic pressures were 150-179 
mmHg with diastolic blood pressure < 110 mmHg. Despite blood pressure 
reductions of 17/10 mmHg, only the incidence of cerebrovascular mortality was
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reduced in the treatment group. There was no difference in 'overall', cardiovascular 
or coronary mortality (Helgeland 1980).
The Australian National Blood Pressure Study (ANBPS), a therapeutic trial in 
mild hypertension, reported a significant reduction in cardiovascular mortality over 4 
years, in a group of 3,527 male and female hypertensives, without overt vascular 
disease, and aged 30-69 years and who were randomised to treatment or placebo. 
There was no significant difference in ischaemic heart disease rates. Entry diastolic 
blood pressures were 95-110 mmHg and systolic blood pressure < 200 mmHg, and 
the average decrease in diastolic blood pressure was 6 mmHg greater in the active 
treatment group compared with the placebo group (Management Committee 1980).
The Medical Research Council (MRC) trial of treatment of mild hypertension 
used propranolol or bendrofluazide in 17,354 men and women aged 35-64 years of 
age. Entry diastolic blood pressures were between 90-109 mmHg. At 5 years, blood 
pressure was reduced on average by 15/6 mmHg more in the bendrofluazide group, 
and 10/4 mmHg more in the propranolol group than in the control group. After 
85,572 patient years of observation, there were significant reductions in stroke rates 
and cardiovascular events in the treatment versus placebo group. 'All cause' 
mortality and coronary events were not significantly reduced. There was no 
significant reduction in coronary event or cardiovascular rates for those taking 
bendrofluazide or for smokers taking propranolol. However, non-smokers taking 
propranolol did experience a significant reduction in coronary and cardiovascular 
events (MRC Working Party 1985).
More recently, treatment of hypertension in the elderly has been demonstrated 
to be clinically important, whereas earlier work had indicated that treatment had little 
effect in this age group (Spackling et al 1981). The European Working Party on High 
blood pressure in the Elderly Trial (EWPHE) randomised 840 men and women over 
the age of 60 to either diuretic treatment or placebo. Entry diastolic blood pressures 
were 90-119 mmHg and systolic blood pressures 160-239 mmHg. After 5 Years, the 
average blood pressure in the active treatment group was 19/5 mmHg less than in the
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placebo group. There was a significant reduction in cardiovascular mortality but not 
’all cause' mortality. This was due to a significant reduction in cardiac mortality 
while cerebrovascular mortality reductions were not significant (Amery et al 1985). 
The lack of effect on cerebrovascular mortality is at variance with the following 
studies' results.
Coope and Warrender's open study of 884 men and women between the ages 
of 60-79 years in primary care, compared treatment with atenolol and/or 
bendrofluazide and/or additional therapy to control blood pressure with untreated 
controls. Entry blood pressures were systolic >  170 mmHg and/or diastolic >  105 
mmHg. After 4.4 years of follow-up, the average blood pressure in the treatment 
group was 18/11 mmHg less than in the untreated control group. The treatment 
group demonstrated a significant reduction in stroke rate, but not in the incidence of 
myocardial infarction or 'overall' mortality (Coope & Warrender 1986).
The Systolic Hypertension in the Elderly Program (SHEP) randomised 4736 
men and women over the age of 60 years to diuretic with or without beta blocker 
treatment, or to placebo. Entry systolic blood pressures were between 160-219 
mmHg and diastolic blood pressure < 90 mmHg. The average blood pressure 
reduction in the treatment group was 12/4 mmHg greater than in the placebo group. 
The occurrence of stroke after 5 years was significantly reduced in the treatment 
group compared to the placebo group, as was cardiovascular morbidity and 
mortality, but there was no significant reduction in 'all cause' mortality (SHEP 
1991).
In another smaller placebo controlled study, the Swedish trial in old patients 
with hypertension (STOP-Hypertension), followed 1627 patients between the ages of 
70-84 years for an average of 25 months. Entry systolic blood pressure was between 
180-230 mmHg and diastolic blood pressure < 90 mmHg. Patients in the active 
treatment group received a beta blocker or diuretic or combination of the two. The 
average blood pressure in the treatment group was 29/8 mmHg less than in the
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placebo group at the end of the study. There was a significant reduction in stroke 
morbidity and mortality and 'all cause' mortality in the treatment group (Dahlof et al 
1991). This is one of the few mortality studies showing a significant effect on 'all 
cause' mortality.
The MRC trial of hypertension in the elderly followed nearly 5,000 older adult 
men and women aged 65-74 years. Entry systolic blood pressures were between 160- 
209 mmHg and diastolic blood pressure < 1 1 5  mmHg. The difference in blood 
pressure reduction between the drug treatment and placebo groups, was 
approximately 15/5 mmHg. There were significant reductions in stroke, coronary 
events and all cardiovascular events. This was confined to non-smokers and those 
taking the diuretic. There was no difference in 'all cause' mortality (MRC Working 
Party 1992).
Finally, in a companion paper to MacMahon et al (MacMahon et al 1990), 
Collins et al evaluated the short-term reductions in blood pressure obtained in 14 
unconfounded randomised trials of anti-hypertensive drug treatment (mostly diuretic 
and/or beta blocker). These included the 2 VA studies, USPHS, HSCSG, HDFP, 
Oslo, ANBPS, MRC (mild hypertension), EWPHE, and studies by Coope, Carter 
and Wolff. Thus information from 36,908 patients, who had an average reduction of 
6 mmHg in diastolic blood pressure in the active treatment groups compared with 
placebo or control groups, was pooled. The stroke rate in the treatment group was 
reduced by 42%, which is in keeping with the potential predicted by the 
observational studies quoted above. Coronary Heart Disease mortality was reduced 
by 14% in the pooled treatment groups, less than predicted. The authors point out 
that most of these studies were of relatively short duration (2-3 years of treatment), 
and it is unknown whether this is a small, large or full portion of the effect to be 
expected from the blood pressure lowering under study (Collins et al 1990).
Further aspects of these studies will be discussed in the impact of treatment 
summary section (1.2.4.). In this way, these results can be considered with the 
results from clinical reports and the non-pharmacological treatment trials.
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1.2.3. Controlled clinical trials of non-pharmacological anti-hypertensive 
treatment
A number of studies have evaluated the effectiveness of a variety of non- 
pharmacological or nutritional-hygienic advice on blood pressure, including salt 
restriction. Such advice has been compared with controls receiving no intervention or 
drug treatment or in addition to drug treatment as well as after withdrawal of drug 
treatment.
Most of these studies have involved relatively small groups and have lasted 
from a few months to a number of years. Reisin et al evaluated weight reduction with 
dietary advice given bi-weekly by a dietitian over 6 months. There were significant 
reductions of blood pressure in two weight reduction groups, one of which was 
normotensive (n=24) and the other treated hypertensives (n=57), compared with a 
'drug treatment only' group (n=25), and this correlated with weight reduction in 
these groups (Reisin et al 1978).
A report from an Australian hypertension clinic in which patients were 
allocated to one of 5 groups, where blood pressure was monitored and either:
(a) no other treatment received (n=31),
(b) a low sodium diet advised (70-100 mmol/day) (n=31),
(c) received treatment with chlorothiazide with or without methyldopa (n=31) or
(d) treated with propranolol and a diuretic (n=31),
demonstrated that those on a low salt diet had less blood pressure reduction than the 
drug treatment groups, but had a greater reduction than those on no treatment. 
Almost a third of the diet group had diastolic blood pressures <  90 mmHg after 2 
years of diet, despite minimal differences in measured sodium excretion for those 
who provided data. Only 16% of the monitored group had diastolic blood pressures 
<  90 mmHg at the end of 2 years (Morgan et al 1978).
Morisky et al reported on a complicated sequential randomised evaluation of 
three regimens with sub-groups of a 400 patient population attending their clinics,
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91 % of whom were black and 70% female. They identified 8 groups of 50 who 
received either none, one or a combination of interventions: exit interview, 
instructional family support session with a 'significant other1 person, and a series of 
3 one hour group sessions with a social worker. Blood pressure, weight and 
appointment keeping were all improved in the intervention groups compared with the 
controls. There were 18% more people in the interventions groups with diastolic 
blood pressure <  90 mmHg than in the controls at the end of 5 years, but absolute 
changes in blood pressure were not reported. 'All cause' mortality and 'hypertension 
related1 mortality was significantly reduced in the intervention groups compared to 
the control group (Morisky et al 1983).
Wright et al measured the blood pressure of individuals who were identified in 
a dietary survey, in which participants weighed all food consumed for three days, to 
have high (n=49) or low fibre (n=45) intakes. The fibre consumed and used in 
subsequent interventions were wholemeal bread and added bran, non-water soluble 
fibres. Those habitually consuming a high fibre diet had significantly lower blood 
pressures. In follow-up studies, a high fibre group (n = l l )  significantly increased 
their blood pressure after consuming a low fibre diet for 4 weeks, and a low fibre 
group (n=17) statistically significantly lowered their blood pressure after 4 weeks on 
a high fibre diet. However, a group of 12 treated hypertensives with a habitually low 
fibre diet, who consumed a high fibre diet for 4 weeks, did not significantly decrease 
their blood pressures, which, unfortunately, had a wide degree of variability (Wright 
et al 1979).
Silman reported briefly on a study of 112 middle-aged men which correlated 
the reported fibre intake and blood pressure and concluded that there was no 
association between blood pressure and fibre intake (Silman 1980).
Stamler et al have reported on a number of larger and longer studies carried 
out in the Chicago area. They first reported on two groups of men who participated 
in the Chicago Coronary Prevention Evaluation Program (CPEP) over 10 years. 
There were 115 with baseline diastolic blood pressure > 90 mmHg, and 101 with
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levels between 80-89 mmHg. In those who continued for 5 years with the program of 
weight reduction, moderation of salt intake and rhythmic exercise, there were 
significant reductions in weight and blood pressure compared to baseline (Stamler et 
al 1980).
The second study was a four year assessment of withdrawal of drug treatment 
and substitution of nutritional interventions (weight, sodium, saturated fat and alcohol 
intake reduction) called the Hypertension Control Program. A group of 97 patients 
who had controlled blood pressure on drug treatment, and were receiving non- 
pharmacological treatment, was compared with a group taken off drug treatment 
(n=44) and another continuing on drug treatment (n=48). Approximately 65% of 
each group was male. Almost 90% of the participants in this study were part of the 
HDFP study. After 4 years, 39% of the intervention group had controlled blood 
pressure and were not receiving drug treatment. Weight and sodium intake also 
decreased (Stamler et al 1987).
In a further study, Stamler et al assessed the effect of lowering weight, salt and 
alcohol intake and increasing physical activity on the development of hypertension. 
They identified 201 individuals (86% men) aged 30-44 years with diastolic blood 
pressures 85-89 mmHg after a second work site screening. Over 5 years, a 
significantly higher percentage of control group participants became hypertensive and 
required drug treatment (19.2% vs 8.8%). The intervention group lost weight (2.7 
kg) on average and decreased their sodium (p<  0.001) and alcohol intake (n.s.) 
compared with changes in control group. More smokers stopped smoking in the 
control group, which was their only intervention in addition to being monitored 
(Stamler et al 1989).
Anderson et al compared blood pressure and glycaemic control in a group of 
12 diabetic men when taking their usual low fibre diet, and then taking one high in 
carbohydrates and fibre. Blood pressures were significantly lower by 10%, 
cholesterol by 26% and average insulin doses were 73% less when the men were on
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the high carbohydrate/high fibre diet (Anderson 1983).
Pacy et al randomised 50 untreated mildly hypertensive diabetics (25 men and 25 
women) to either a high fibre (30-45g/day), low fat (15% of daily calories), low 
sodium (40-50 mmol/day) diet or treatment with bendrofluazide 10 mg, to compare 
the hypotensive and metabolic effects of each treatment. Blood pressure was reduced 
significantly in both groups by 16/9 and 21/6 mmHg and weight by 2.9 and 1.5 Kg 
respectively. Glycosylated haemoglobin significantly decreased in the diet group and 
significantly increased in the bendrofluazide group. In a sub-group analysis of those 
with hyperlipidaemia, total cholesterol significantly decreased, by 1.1 mmol/1 on 
average, in the diet group and increased, but non-significantly, by 0.5 mmol/1 in the 
bendrofluazide group (Pacy et al 1984).
In a 4 year follow-up of an 8 week relaxation programme in 60 men and 39 
women compared with 58 male and 35 female controls aged 35-64 years, Patel et al 
showed greater reductions in blood pressure in the relaxation group compared with 
the control group. There were significantly fewer morbid vascular events 
(electrocardiogram changes, reported angina, myocardial infarction, etc) in those 
followed up at 4 years (Patel et al 1985).
Langford et al randomised 496 middle aged men and women from the 
Hypertension Detection and Follow-up Program to continued therapy (obese 
patients), continued therapy (not overweight patients), drug withdrawal alone (obese 
patients), drug withdrawal alone (not overweight patients) or with weight reducing 
diet (obese patients), sodium restriction (obese patients), sodium restriction (not 
overweight patients). The nutritional interventions were conducted in weekly, then 
monthly group sessions, and after a year there were significantly more patients 
normotensive on no drug therapy in the weight reduction and the normal weight 
sodium restriction groups (Langford et al 1985).
An Australian 14 week parallel group study investigated the effects of diet on 
blood pressure in 58 untreated mild hypertensive men and women randomised to 3 
groups. In the first 2 weeks, all groups took their usual diet. Group 1 acted as
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control consuming their normal diet for the next 12 weeks, while group 2 consumed 
a ovo-lacto-vegetarian (OLV) diet for the next 6 weeks, then their usual diet for the 
last 6 weeks alternating with group 3 which took the OLV diet for the last 6 weeks of 
the study. Mean systolic blood pressure fell on average by 5 mmHg while subjects 
were on the OLV diet (Margetts et al 1985).
In a follow-up study this group carried out a randomised, controlled, cross­
over study with 88 (51 men, 37 women) healthy normotensive omnivores changing 
from their usual diet to a high fibre diet or vice versa for 6 week periods. Blood 
pressure and lipids did not change over the course of the study (Margetts et al 1987).
Two Danish studies were undertaken with 60 and 45 obese females placed on 
weight reducing diets with fibre or placebo supplementation taken with 300 ml of 
water 30 minutes before each meal. The first study lasted for 2 months with mean 
weight loss of 7 kg in the fibre group and 6 kg in the placebo group (p<0.05). Mean 
blood pressure decreased by 10/5 mmHg in the fibre group and by 13/5 mmHg in 
placebo (p<0.01). The second lasted for 3 months with a mean weight loss of 6.2 kg 
in the fibre group and 4.1 kg in placebo group (p<0.05). Blood pressure decreased 
from baseline by 6/3 mmHg in the fibre group and 6/0 mmHg in the placebo group 
(p<  0.05 for diastolic blood pressure in the fibre group). It was not reported if the 
fibre was insoluble or soluble or a mixture (Rossner et al 1986).
A 12 week dietary intervention study was conducted in 200 mild hypertensives 
(diastolic blood pressure 90-100 mmHg) by the Australian National Health and 
Medical Research Council. They were randomised to a normal diet (n=55), high 
potassium diet (n=52), low sodium diet (n=52), or high potassium/low sodium diet 
(n=53). Blood pressure fell significantly greater (3.5-5 mmHg systolic/ 2.5-4 mmHg 
diastolic blood pressure) in all three diet interventions compared to normal diet, with 
no apparent additive effect of the high potassium/low sodium combination (Chalmers 
et al 1986).
A Birmingham study assessed the effect on blood pressure and weight in 20
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men and 14 women with poorly controlled essential hypertension, of (a) a high fibre, 
low fat and low sodium diet group (N=17) compared with (b) a usual dietary control 
group (N=17). Despite a significant reduction of 18/12 mmHg of blood pressure, 
and 1.9 kg in weight on average in the high fibre, low fat, low sodium diet group, 
these reductions were not significantly different from the reductions in the control 
group. However, there was a significant increase in the number of patients in the 
high fibre, low fat, low sodium diet group with controlled blood pressure at the end 
of the treatment period. There was no change in the cholesterol values in either 
group, all of whom were normo-lipid initially (Dodson et al 1989).
The Hypertension Prevention Trial Research Group randomised 841 healthy 
men and women 25 to 49 years of age with diastolic blood pressures 78 to 89 mmHg 
to either one of four dietary groups or a control group. The dietary groups were seen 
in group sessions for caloric restriction alone, reduced sodium alone, caloric 
restriction with reduced sodium, or reduced sodium with increased potassium. After 
3 years the greatest reductions (2/2 mmHg) were seen in the caloric restriction 
group, and non-significant changes were seen in the sodium restriction groups 
(Hypertension Prevention Trial Research Group 1990).
Sciarrone et al used a factorial design to investigate the effect of salt restriction 
and a low-fat/high-fibre diet, in hypertensive subjects. Sodium or sodium-placebo 
was added to normal-fat/normal-fibre and low-fat/high fibre groups over 8 weeks. 95 
hypertensives were randomised to the 2x2 design. Supine systolic blood pressure was 
significantly reduced by the low sodium diet compared to changes in low-fat/high- 
fibre group, and cholesterol was significantly reduced by the low-fat/high fibre diet. 
Weight decreased slightly in all groups, non-significantly (Sciarrone et al 1992).
The Trials of Hypertension Prevention (TOHP) Collaborative Research Group 
randomised 2,182 men and women 30-54 years to 7 different interventions with a 
control group for each intervention. Weight reduction (3.9 kg after 18 months) 
lowered blood pressure by 3/2 mmHg, and sodium intake reduction lowered it on 
average by 2/1 mmHg. Stress management or supplement with either calcium,
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magnesium, fish oil or potassium did not affect blood pressure (TOHP Collaborative 
Research Group 1992).
Non-pharmacological interventions, primarily dietary, have also been 
compared to drug treatment. Berglund et al compared dietary treatment (weight 
reduction, sodium and alcohol restriction, increase potassium intake and ratio of 
polyunsaturated to saturated fat) with drug treatment in 61 men aged 40-69 years. 
After one year, drug treatment significantly lowered blood pressure, but dietary 
treatment significantly lowered the other cardiovascular risk factor, lipids, but not 
blood pressure (Berglund et al 1989).
In a complicated study design, Oberman et al evaluated the effect of usual, low 
sodium-high potassium or weight loss diet with placebo, chlorthalidone or atenolol. 
The study was called the Trial of Anti-hypertensive Interventions and Management 
(TAIM). In all, 692 men and women between 21-65 years of age were randomised to 
9 different treatment groups and change in risk was assessed using the Framingham 
model. Risk was found to be reduced, except in the 'chlorthalidone alone' group, 
with the greatest reduction being in the 'weight loss diet taking atenolol' group 
(Oberman et al 1990).
Non-pharmacological therapy, including a reduced calorie diet, low-salt diet, 
low intensity exercise and mental relaxation (n=33) was compared with propranolol 
(n=23) or placebo (n=23) over 12 weeks, in men over the age of 30 years, with 
entry diastolic blood pressures 95-105 mmHg and weight no greater than 135% of 
ideal. In addition to blood pressure changes, exercise performance, lipoprotein levels 
and quality of life variables were evaluated. Non-pharmacological treatment lowered 
blood pressure as well as propranolol. It also significantly lowered body mass index, 
total cholesterol, low density lipoprotein (LDL) cholesterol, increased exercise 
tolerance, and participants reported that they felt more energetic and had greater 
sexual satisfaction (Kostis et al 1992).
All of the drug studies described in the previous section have included
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mortality analysis. Excluding Morisky's study (Morisky et al 1980) and Patel et al 
(Patel et al 1985), there have been few such reports evaluating the ultimate impact of 
non-pharmacological or nutritional-hygienic advice.
In a recent study, the Treatment of Mild Hypertension Study Research Group 
used non-pharmacological treatment (lowering weight, sodium intake, alcohol intake 
and increased physical activity) as the control intervention in a multi-drug trial in 
which all drug regimens included this as well. The drugs evaluated were 
chlorthalidone, acebutolol, doxazosin, amlodipine and enalapril. All groups were 
followed for an average of 4.4 years. Drug treatment groups had greater blood 
pressure lowering and significantly fewer cardiovascular and other clinical events 
than the nutritional hygiene group (Neaton et al 1993).
Finally, there have been reviews of the effects of various non-pharmacological 
interventions which have helped to shed light on the effectiveness of such 
interventions. In a review of the effect that weight reduction has on blood pressure, 
Berchtold et al concluded that weight reduction does lower blood pressure in most 
obese patients with hypertension. They advocate its use as the 'first and most 
important step of any rational therapeutic strategy' for any obese hypertensive patient 
(Berchtold et al 1982). Staessen et al agreed with this view in a similar review 
(Staessen et al 1985).
In a wide ranging review of the effects of vegetarian diet on blood pressure, 
Rouse and Beilin presented a factor analysis of data from their controlled vegetarian 
studies and showed that blood pressure changes were significantly related to the 
factor representing increased intake of polyunsaturated fat, fibre, vitamin C, Vitamin 
E, calcium, magnesium and a fall in the intake of protein (Rouse & Beilin 1984).
In 1986, the Royal Society of Medicine convened a round table discussion in 
London on the role of dietary salt in hypertension care and its implications for public 
health policies. Experts reviewed the evidence which had accumulated to that time, 
and concluded that, although the effect of sodium intake on blood pressure was well 
established, it was relatively small, and the profound problems with compliance
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mediated against full effects being achieved (Wood 1986). This was the conclusion 
drawn by Pickering in his classic text 'High Blood Pressure' nearly 20 years 
previously (Pickering 1968). Despite this conclusion, a number of researchers have 
continued to use this as an intervention strategy for evaluation in larger groups and 
for extended periods.
1.2.4. Impact of anti-hypertensive treatment - summary
A number of issues need to be addressed when considering the effect of 
treatment. They can be summarised as follows: the comparison of the effect of anti­
hypertensive treatment with population surveys, study population size, the level to 
which blood pressure should be reduced, the cost of such reductions to individuals 
and society as well as the effect of specific agents.
There are difficulties in assessing the full potential of treatment when 
comparing achieved levels of pressure with the levels of blood pressure from 
prospective epidemiological surveys. The vast majority of data from these surveys 
are for men, while most of the intervention trials have included women. The 
Renfrew and Paisley survey, which does include women, highlights the very 
different cardiovascular experience of women (Isles et al 1992). In addition, the 
surveys such as Framingham and the Whitehall study indicate that systolic blood 
pressure has the stronger correlation with cardiovascular/coronary heart disease 
mortality, yet many of the drug studies reviewed above focused on the reductions in 
diastolic blood pressure.
Another issue is the underlying assumption of a number of commentators that, 
if one reduces blood pressure, the subsequent reduction in risk ought to be equivalent 
to the risk associated with that lower level of blood pressure in the prospective trials 
(Weber 1987, Reid 1988, Fletcher & Bulpitt 1992). If the vascular damage due to 
raised blood pressure develops over an extended period of time, is it logical to 
assume it to be reversed entirely (or at all) with the lowering of that pressure in a 
limited number of years.
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There has been an increase in the size of study populations over the years. The 
VA studies included 143 men in the moderate/severe hypertension study (VA 
Cooperative Study Group 1967) and 380 men in the mild/moderate study (VA 
Cooperative Study Group 1970). The MRC trial in mild hypertension had 17,354 
(MRC Working Party 1985) and the elderly study had 4,396 participants (MRC 
Working Party 1992). Unfortunately, there has not been a proportional increase in 
the clarity of results. It is only with meta-analysis that broader conclusions can be 
drawn (MacMahon et al 1990, Collins et al 1990).
How far particularly diastolic blood pressure should be lowered has generated 
a great deal of debate. Cruickshank first raised this concern in 1987 (Cruickshank et 
al 1987) and in a further paper in 1988 (Cruickshank 1988). A rise in coronary heart 
disease mortality at levels below 75 mmHg were found in the DHSS Computing 
Project population (Fletcher et al 1988) and also in the Glasgow Blood Pressure 
Clinic population (Waller et al 1988). MacMahon's meta-analysis refutes this 
concern (MacMahon et al 1990), but in a well argued review of the relevant clinical 
and trial data, Fletcher and Bulpitt conclude that it is still unclear how far below 85 
mmHg diastolic blood pressure should be lowered (Fletcher & Bulpitt 1992).
Despite the above difficulties, the majority of anecdotal, retrospective and 
prospective studies indicate that, even in the mild range of blood pressure elevation, 
treatment demonstrates some cardiovascular benefits, particularly 
cerebrovascular,which are particularly pronounced in older populations. Therefore, 
such results should be incorporated into clinical practice and continue to be so as 
they emerge.
However, there are experts who argue against this without first evaluating the 
individual and societal 'cost1. Ramsay voices caution in the light of drug side effects 
and, based on the trial results at that time, the need to treat 25 people for 20 years in 
order to postpone one cardiovascular death (Ramsay 1985). Yet, Smith, in an 
economic analysis of the societal benefits of lowering stroke rates with 
anti-hypertensive drug treatment (based on the rates obtained in the VA studies),
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postulated substantial economic benefit for the United Kingdom (Smith 1990). 
Maynard estimates the cost of anti-hypertensive drug treatment to prevent stroke 
between the ages of 45-65 years to be £940/Quality Adjusted Life year (QALY). In 
comparison, cholesterol testing and lowering by diet in all adults aged 40-69 years is 
estimated to cost £220/QALY, or by drug treatment in all adults 25-39 years as 
£1,480/QALY (Maynard 1992). Fletcher identifies a number of variables and basic 
assumptions that affect economic analysis in a review of these techniques, and 
advises caution in their interpretation (Fletcher 1992).
Finally, what is the most appropriate drug? Most of the previously reviewed 
drug treatment studies used thiazide diuretics or beta-blockers alone or in 
combination or in comparison. At the moment, in light of the positive studies in the 
elderly, diuretics appear to be the most beneficial. Future studies are required to 
identify whether the newer classes of agents, including the angiotension converting 
enzyme inhibitors and calcium antagonists, have equivalent or superior effects with 
fewer side effects.
1.3. Epidemiology of hypertension and other cardiovascular risk factors
What are these other 'indicators of CHD risk'? Hopkins and Williams in a far 
ranging review in 1981 found evidence for 246 suggested coronary risk factors in the 
literature at that time! However, they concluded that hypertension, 
hypercholesterolaemia, cigarette smoking, diabetes, age, sex and strong familial 
predisposition were the generally accepted major risk factors for early occurrence of 
CHD (Hopkins & Williams, 1981).
The DHSS Hypertension Care Computing Project and the Glasgow Blood 
Pressure Clinic have shown that there are factors that statistically correlate with 
mortality/survival in their populations of hypertensive patients observed over a 
number of years. In the 1979 review of 'risk factors for death...', the DHSS project 
identified age, impaired renal function, smoking and systolic blood pressure before 
treatment as well as proteinuria, history of myocardial infarction, retinal changes of
24
accelerated hypertension as independent risk factors for cardiovascular death. 
Increased weight and serum cholesterol were not associated independently in this 
analysis (Bulpitt et al 1979).
By 1986, with nearly twice the hypertensive population to review (5,451 vs 
2,587) and nearly three times the number of deaths to analyse (411 vs 156), the 
DHSS project staff assessed their data from a survival point of view. Survival was 
impaired by cigarette smoking, previous history of myocardial infarction or stroke, 
diagnosis of angina, impaired renal function and raised blood sugar. Again serum 
cholesterol was reported as not being an independent risk factor. However, 
cholesterol values were available for only 49% of the study population (Bulpitt et al
1986).
The Glasgow Blood Pressure Clinic review of mortality strongly indicated that 
all cause and stroke mortality were reduced by treatment. It was less clear as to the 
effect on ischaemic heart disease. Age, male sex, blood pressure and the presence of 
secondary hypertension were associated with increased mortality. In addition, 
cigarette smoking, a history of myocardial infarction, angina pectoris or 
cerebrovascular accident, an increased concentration of serum urea and ECG 
abnormality were also associated with increased mortality. They were unable to 
study the effect of serum cholesterol due to lack of data. Another issue, brought out 
by the Glasgow mortality study, was the demonstration that, despite treatment, the 
mortality rates remained higher than for the 'normal' population, indicating that 
more than hypertension was implicated in the long term cardiovascular mortality of 
these individuals (Isles et al 1986).
This excess mortality was also identified in the hypertensive population 
attending a clinic in Dalby, Sweden. Lindholm and his colleagues have been 
following up this community based population since 1972. After 10 years of follow- 
up, they found that the relative odds (risk) of MI in male hypertensives was 3.8 in 
comparison to a normotensive population from the same community. The estimates 
calculated for smokers was 4.9 and non-smokers 2.2. This again supports the concept
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that more than hypertension needs to be addressed in caring for hypertensive 
populations. Both hypertensives and controls were re-examined in 1988-89. 
Assessment included glucose tolerance and cholesterol levels. There was a much 
higher prevalence of disturbed glucose metabolism in the hypertensive group which 
appeared to be related to some drug treatments. Those patients on a calcium 
antagonist or ACE inhibitor had levels similar to the control group (Lindholm,
1991).
1.3.1. Epidemiology of cardiovascular risk
Long term prospective epidemiological studies in 'normal' populations can 
shed further light on the relationships between cardiovascular risk factors. The 
following studies have involved more than blood pressure measurement. The blood 
pressure results from some of these studies have been previously cited in relation to 
the epidemiology of hypertension discussion (1.1.). The limitations of such, 
generally one off, examinations have also been cited.
Craig et al in 1989 reviewed 54 published studies to examine the relationship 
between smoking and serum lipoprotein concentrations in adults. In particular, this 
meta-analysis found that serum cholesterol concentrations were 3% higher in 
smokers compared with non-smokers, and high density lipoprotein cholesterol was 
5.7% lower (Craig et al 1989).
While excess weight and alcohol consumption are not identified in the 
following multiple risk factor surveys as relating independently to increased 
cardiovascular or coronary mortality, they have been shown to contribute to higher 
levels of hypertension, which is a strong independently linked risk factor. The 
Kaiser-Permanente study of 87,000 men and women, showed that blood pressure 
increased with alcohol consumption even when controlling for weight and tobacco 
use (Friedman et al 1982). A household survey of drinking patterns and blood 
pressure in 1,630 Americans, showed a significant increase in systolic blood pressure 
with increasing alcohol consumption. Those reporting 'less than weekly drinking'
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had lower blood pressures than abstainers (Russell et al 1991).
Sonne-Holm et al evaluated nearly 1,000 obese Danish men with Body Mass 
Index (BMI) > 3 1 ,  after first attending for a military physical examination, and a 
randomised control group of slightly over 1,000 men with BMI < 3 1 .  At initial 
examination, prevalence of hypertension (>160/95) was greater as BMI increased.
At a follow-up 4 - 4 0  years later, hypertension was more prevalent in those 
individuals whose weight had increased and less so for those whose weight had 
decreased from initial values regardless of starting levels of blood pressure (Sonne- 
Holm et al 1989).
One of the first prospective studies of a number of risk factors was undertaken 
in Goteborg, Sweden and published in 1973. Wilhelmsen et al followed 834, 50 year 
old men without signs of coronary heart disease, for 9 years. Of the 9 factors 
analysed by a multiple logistic model, high serum cholesterol, smoking, high systolic 
blood pressure, dyspnoea and registration by the Temperance Board were found to 
significantly increase the risk of experiencing events related to coronary heart disease 
(Wilhelmsen et al 1973).
In the Seven Countries Studies, 75 % of the coronary mortality variance was 
accounted for by differences in mean serum cholesterol and blood pressure. When 
looking at the risk for individuals in the countries, serum cholesterol, blood pressure 
and smoking were highly significant for coronary death in all regions except Japan 
(Keys et al 1984).
The Pooling Project and Framingham studies were the first large reviews to 
demonstrate the additive nature of cardiovascular risk factors in individuals. In the 
Pooling Project, the risk factors considered in addition to blood pressure, were serum 
cholesterol, desirable weight for height, smoking habits and ECG abnormalities other 
than myocardial infarction (MI) (evidence of previous MI was an exclusion criteria). 
Endpoints assessed after 10 years of follow-up in 5 year increments, included non- 
fatal and fatal MI, and sudden CHD death. For this population, it was found that the 
20% of the population at highest risk yielded 40% of all first coronary events. They
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concluded that the risk relationship of blood pressure, serum cholesterol and cigarette 
smoking to susceptibility to CHD was 'consistent, strong, graded and independent' 
and had 'predictive ability' (Pooling Project Research Group 1978).
In the ongoing Framingham Heart Study, smoking status, left ventricular 
hypertrophy on electrocardiogram, and from 1971-74 review, high density 
lipoprotein (HDL) cholesterol were assessed. Utilising a multiple logistic model to 
analyse risk, it was found that when cigarette smoking, increased systolic blood 
pressure and increased total cholesterol were present, the 6 year risk of coronary 
artery disease (CAD) was 40% greater in women and 100% greater in men than for 
individuals who were non-smokers, had normal systolic blood pressure and normal 
levels of cholesterol. The 6 year rates were calculated from 16 years of follow-up 
data available at that time (Wilson et al 1987).
The additive nature of cardiovascular risk factors has been confirmed in a 
number of other surveys. In the MRFIT screenees, death rates were analysed by 
quintile of blood pressure and cholesterol as well as by smoking/non-smoking status, 
and were cross tabulated for combinations of these risk factors. Again it was found 
that serum cholesterol, hypertension and smoking each independently contributed to 
coronary risk. In addition, there was a 'distinct escalation of risk noted for 
combinations of these risk factors' (Kannel et al 1986).
The British Regional Heart Study examined 7,735 40-59 year old men from 24 
towns in England, Wales and Scotland. After 8 years of follow-up, a number of 
factors were found by multivariate analysis to contribute to the risk of developing 
ischaemic heart disease. These were age, mean blood pressure (systolic blood 
pressure +  (2 x diastolic blood pressure)) -s-3), serum total cholesterol, years of 
cigarette smoking, and the presence or absence of the following: myocardial 
infarction or ischaemia on electrocardiogram, (definite or possible) angina, recall of 
a diagnosis of ischaemic heart disease or diabetes made by a doctor, and parental 
death from "heart disease" (Shaper et al 1986).
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The Renfrew and Paisley Survey demonstrated a somewhat different risk 
factor and mortality profile for women. In comparison with men, the women had a 
higher average plasma cholesterol (6.4 vs 5.9 mmol/1), fewer smoked (44.2% vs 
83.2%) more were obese (BMI >29), but they had a similar diastolic blood pressure 
to the men (85 vs 86 mmHg). The relative risk was similar between the sexes, but 
the overall absolute risk and attributable risk were less for women with similar risk 
levels to that of the men (Isles et al 1992).
To clarify further the relationships between risk factors and cardiovascular 
mortality, the MONICA project, co-ordinated by WHO, was started in 1982 to 
assess worldwide trends in myocardial infarctions, strokes and their determinants 
over the subsequent decade. Using a standardised protocol, data are being collected 
in 41 Collaborating Centres with 118 Reporting Units. One of the unique features of 
this collaborative venture is that each centre is self funding and allowed to investigate 
additional hypotheses as 'local options' as well as the 'core protocol'. Overall, it is 
anticipated that this study will provide the opportunity to compare results from 
centres and reporting units with contrasting profiles of risk factors and events as well 
as differing patterns of risk factor and mortality change (WHO MONICA Project 
Principal Investigators 1988).
The Scottish Heart Health Study, which includes the MONICA core protocol, 
investigated coronary risk factors and lifestyle in 10,359 men and women between 
the ages of 40-59 years in 22 districts in Scotland. Standardised mortality ratios for 
coronary heart disease in both sexes were obtained for these districts. The mean risk 
factor values for men from each district were entered into a predictive formula 
derived from the European cohort of the Seven Countries Study and the American 
Pooling Project. Cigarette smoking and blood pressure were able to explain a portion 
of the regional variation in mortality. Cholesterol did not, but it was generally high 
and varied less between the districts. Women's data were not entered into a 
predictive formula as 'data for prediction in women are much weaker' (Tunstall- 
Pedoe et al 1989).
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Several epidemiological surveys have demonstrated the 'clustering' effect of 
cardiovascular risk factors. That is, the major cardiovascular risk factors co-exist 
more often than would be expected by chance. In the Australian Risk Factor 
Prevalence Study of over 5,000 men and women, 40% of the untreated hypertensives 
and more than 50% of the treated hypertensives had total cholesterol > 6 . 5  mmol/1, 
while only 30% of those with normal blood pressure had cholesterol greater than this 
value (MacMahon et al 1985). The Lipid Research Clinics Program Prevalence 
Study showed similar profiles in over 4,000 men and nearly 4,000 women (Criqui et 
al 1986). The concept of 'clustering' could be considered a circular argument in that 
surveys such as the MRFIT screenees and the Framingham study have identified that 
when these factors are present together, there is an increased chance of that 
individual dying from cardiovascular disease, ie. that they are risk factors. The 
benefit of these two studies is to confirm that the apparent synergistic relationship 
between risk factors identified in the mortality studies, has a basis in the actual 
occurrence of these factors in a population.
1.3.2. Hypertension trials and cardiovascular risk factors
The management committee of the Australian National Blood Pressure Study 
reported on covariates which influenced ischaemic heart disease and cerebrovascular 
disease events in a study of mild hypertension. These factors were older age, male 
gender, cigarette smoking, and higher systolic blood pressure at screening.
Treatment was more beneficial in smokers with lower weight, and, in a preliminary 
analysis, in individuals with lower serum cholesterol (Management Committee of the 
Australian National Blood Pressure Study 1984).
In the MRC trial of treatment of mild hypertension in men and women, the 
entry characteristics of age, male sex and cigarette smoking were significantly related 
to stroke, coronary events, all cardiovascular events and all cause mortality by 
logistic regressions. Elevated serum cholesterol and an electrocardiogram showing an 
ischaemic pattern on entry, were significantly related to coronary events, all
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cardiovascular events and all cause mortality. BMI was only related to coronary 
events (MRC Working Party 1985).
The age and sex, history of cardiovascular disease, smoking and non-smoking 
sub-group analysis from the EWPHE trial demonstrated there was similar percentage 
reduction in events for those with a history of cardiovascular disease and over the 
age of 70 years as for those between the ages of 60-69 years. Little benefit was 
demonstrated for those over the age of 80 years. As in the MRC trial in mild 
hypertension, smoking did not influence diuretic treatment outcomes (Amery et al
1986).
In a sub-group analysis of 686 treated hypertensives participating in the 
Primary Prevention Trial in Goteborg, Samuelsson et al demonstrated a significant 
reduction in cardiovascular and coronary morbidity in individuals who were able to 
achieve a substantial reduction in both blood pressure and serum cholesterol 
(Samuelsson et al 1987).
1.3.3. Population cardiovascular risk factor epidemiology
There is some evidence that reductions in ischaemic heart disease (IHD) and 
cardiovascular rates parallel reductions in risk factor levels in general populations. 
Sigfusson et al compared trends in mortality and morbidity with observed levels of 
risk factors from population surveys conducted in Iceland between 1968 and 1988. 
They analysed smoking, total serum cholesterol and systolic blood pressure and 
assessed risk using Cox's proportional hazard model derived from data obtained from 
an unpublished study done in Reykjavik between 1968-1985. The decrease in 
mortality, predicted by the decrease in risk factor levels, coincided with the observed 
decrease in the population's cardiovascular mortality (Sigfusson et al 1991).
Nissinen and colleagues, using the first MONICA survey data collected in 
Finland, compared the risk factor levels in North Karelia, where a community based 
multiple risk factor intervention program had been going on for the previous ten 
years, with levels in their reference area. The community project focused on 
reducing smoking, promoting a cholesterol lowering diet and on systematic care for
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hypertension. Previous research had demonstrated higher levels of cardiovascular 
risk factors in North Karelia but this survey showed a general decrease to the levels 
seen in the reference area. There had also been a decline in cardiovascular disease 
mortality in North Karelia, which is attributed to the change in risk factor level 
(Nissinen et al 1987).
During the 1970's a community based multiple risk factor intervention 
programme entitled the Community Syndrome of Hypertension, Atherosclerosis and 
Diabetes (CHAD) programme was implemented by specially trained physician/nurse 
teams in four housing projects in Jerusalem. The aims of the programme were to 
reduce the prevalence of hypertension, hypercholesterolaemia, and overweight and to 
change dietary, smoking and exercise behaviours. The prevalence of risk factors 
after 5 years of the programme in 524 men and women, was compared with a control 
population of 1,512 men and women living in an adjacent neighbourhood who were 
screened and received routine medical care during the same time period. The 
prevalence of elevated blood pressure (>160/95 mmHg) was significantly reduced 
by 20%, hypercholesterolaemia (>250 mg/dl or 6.5 mmol/1) was significantly 
reduced by 23% when standardised for age and sex, smoking was significantly 
reduced by 11% and overweight (BMI> 28) was significantly reduced by 13% when 
compared with the differences observed in the control population (Abramson et al 
1981).
Unfortunately, other specific trials of population intervention have not had 
such positive results. The WHO European Trial of Multifactorial Prevention of 
Coronary Heart Disease studied 60,000 male factory workers in 4 European 
countries including the United Kingdom. The factors addressed were cholesterol, 
smoking, exercise, and systolic blood pressure > 1 6 0  mmHg. The interventions 
consisted of a low fat, increase in polyunsaturated fat, high fibre diet; stop smoking 
advice; exercise for the sedentary; and treatment for systolic blood pressure > 1 6 0  
mmHg. Risk factor changes were assessed by random sampling of approximately
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10% of their population. The reductions in CHD mortality in the total intervention 
group were not significantly different from the control group. However, it was 
found that the benefit of the interventions were significantly related to the extent of 
risk factor change (WHO European Collaborative Group 1986).
The results from the multifactor primary prevention trial in Goteborg were 
similarly disappointing. After 10 years of follow-up, risk factor levels changed 
substantially in the control groups as well as the intervention group. This was a 
population based study with 10,000 men in an intervention group and an equivalent 
number in 2 control groups. Random sampling was done to ascertain levels of risk 
factors in one of the control groups and in the intervention group at a 10 year final 
examination. The second control group was not examined or interviewed. One 
quarter of the intervention group did not participate. This subgroup experienced 
twice the total mortality of those who participated in the intervention group. Thus it 
was found that risk factor reduction, all cause mortality, stroke and coronary heart 
disease incidence was not significantly different between the groups in this study on 
an intention to treat basis (Wilhelmsen et al 1986).
Both of these studies suffer from methodological difficulties. The small 
random sampling technique, required due to the resource implications of attempting 
to test the entire study population, may have produced samples that were not truly 
representative. In addition, with the world-wide media coverage of cardiovascular 
health issues in the last two decades, it would have been impossible to prevent 
control populations from receiving and acting upon such information.
1.3.4. Multiple risk factor intervention studies
Due to the population size required, complexity of conducting and the 
difficulties in interpreting results, there have been few multiple risk factor 
intervention studies with mortality follow-up. The Oslo Study's interventions, in 40- 
49 year old men, consisted of a diet low in saturated fat, with some polyunsaturated 
fat and high in fibre; and stop smoking advice. The intervention and control group, 
each contained more than 600 participants and there was a significant decrease in
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MI, sudden death and CVA in the dietary intervention group. Overall mortality was 
decreased but not significantly in comparison with the control group (Hjermann et al
1981).
The Multiple Risk Factor Intervention Trial (MRFIT) randomised more than 
12,000 men to special intervention or usual care. In the special intervention group, 
blood pressure was lowered by drug treatment, smokers were advised to stop and a 
diet low in saturated fat, high in polyunsaturated fat which was low in calories for 
those who were overweight, was prescribed. There was no significant difference in 
cardiovascular disease mortality or all cause mortality after 10.5 years of follow-up 
between the special intervention or usual care groups (MRFIT Research Group 
1990b). However, post-hoc analysis of the 771 men in the special intervention group 
and 739 men in the usual care group, with entry diastolic blood pressure greater than 
100 mmHg and on no treatment, showed a significantly lower CHD and all cause 
mortality in the special intervention than the usual care group (MRFIT Research 
Group 1990a).
The Multifactorial Primary Prevention of Cardiovascular Diseases in Middle- 
aged Men Trial was conducted in 40 to 55 year old Finnish business executives 
between 1974 and 1980. There were 612 in the intervention group, 610 in a high risk 
control group and 540 in a low risk control group. The intervention group was given, 
as appropriate, dietary advice to decrease cholesterol and weight, drug treatment to 
lower blood pressure and cholesterol, stop smoking advice and a program to increase 
physical activity. The intervention group experienced a significant reduction in risk 
factor levels compared with control groups yet had an increase in the incidence of 
coronary events over the first 5 years of follow-up. This was not statistically 
significant (p=0.057). The authors relate this result to the drug treatments used to 
lower blood pressure (beta blockers) and cholesterol (clofibrate). The individuals 
treated with these agents had an associated increased incidence of coronary events 
compared with those who received other treatment or no treatment (Miettinen et al
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1985). Unfortunately, the 15 year mortality follow-up of this study was also negative, 
with continuing higher coronary rates in the intervention group. The authors 
discussed their findings in depth with no firm conclusions save 'research on the 
selection and (interactions of methods, including drugs and life-style changes 
currently in use for primary prevention, is still warranted' (Strandberg et al 1991).
Overall results of multiple risk factor intervention studies, either in community 
populations or high-risk groups have been generally very disappointing. It may well 
be that the reverse of the synergistic interaction of factors to increase risk does not 
operate in risk reduction. In addition, as has been previously stated, changes in the 
"control" groups have been impossible to prevent due to the wide-spread availability 
of health promotion and disease prevention information in the world.
1.4. Hypertension follow-up in the United Kingdom
Unfortunately, it has also been clear that the actual detection, and particularly 
the follow-up of identified hypertensives, has been less than adequate in the United 
Kingdom. The Renfrew Study showed that out of 422 patients, whose diastolic blood 
pressure was greater than 100 mmHg on a second reading, and whose health records 
were traced, 54.5% had not been previously identified as hypertensive (Hawthorne et 
al 1974).
Miall and Chinn, in their final Welsh survey, found that only 24% of men and 
45% of women with phase IV diastolic blood pressures >  110 mmHg had ever 
received treatment. For those who were receiving treatment, 27 % of the men and 
24% of the women had diastolic blood pressures >110 mmHg (Miall & Chinn
1974). Heller and Rose, in their companion papers in 1977, found only 12% of 
identified hypertensive patients in hospital and 38% of those in general practice were 
receiving treatment for their hypertension (Heller & Rose 1977a,b).
In a paper about patients who had regularly attended the Glasgow Blood 
Pressure Clinic during its first 10 years of operation, Johnston et al were able to 
report on only 16% of the 3500 patient enrolled who had visits recorded continuously 
over the three years following initial registration. Of these 562 patients, only 27.6%
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had systolic blood pressure <139 mmHg and 22.1% had diastolic blood pressure 
<89 mmHg after 3 years of attendance (Johnston et al 1980).
In a survey of the general practice records from 1968-1977 of 1000 men over 
the age of 20 living in the north east of Scotland, only 34% had a blood pressure 
recorded. Of those recorded 34% had levels > 160/100 but only 56% of those with 
elevated readings had a recorded follow-up reading (Ritchie & Currie 1983).
Kuiji and Haines in a review of records (1972-1982) in 18 practices in North 
West London found 53% of patients had at least one blood pressure measurement 
recorded, but 69% of the hypertensives had periods of more than 1 year between 
blood pressure recordings (Kuiji & Haines 1984). Michael found only 22% of 
patients from inner London practices and 43 % from outer London practices had a 
blood pressure recorded in their notes (Michael 1984).
Stem conducted a review of the management of hypertension in 12 
Oxfordshire general practices. Of the 2371 hypertensive patients on drug therapy, 
53% had last recorded systolic blood pressure < 155 mmHg and 40% had last 
recorded diastolic blood pressure <90 mmHg (Stern 1986).
In a follow-up to Hawthorne's Renfrew study, Smith et al evaluated the blood 
pressure status of the 10,000 participants in the Scottish Heart Health Study. There 
was virtually no change in the intervening years in the control of blood pressure. 
They found that 53% of men and 46% of women who were found to be hypertensive 
had previously been undiagnosed. Only 25% of the men and 42% of the women, 
identified as hypertensive, had satisfactorily controlled blood pressure (Smith et al 
1990).
The previous catalogue of under-identification and treatment is disappointing, 
particularly in the light of Hart's work which showed as early as 1970 that is was 
possible to screen (Hart 1970) and follow-up identified hypertensives in general 
practice (Hart 1974, Hart 1993).
1.5. Computer based patient information systems
It is acknowledged that computerised patient information can vastly assist the
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monitoring and assessment of any disease process. It can facilitate the standardisation 
of information recorded, its retrieval, and analysis (Slack et al 1966, Whiting- 
O'Keefe et al 1985, McDonald & Tierney 1988).
The Glasgow Blood Pressure Clinic and the DHSS Hypertension Care 
Computing Project gathered such data to monitor the long-term care of hypertensive 
patients since 1968 and 1971 respectively. This involved a number of hospital sites 
and clinicians (Glasgow Blood Pressure Clinic 1972, Beilin 1974).
Despite efforts to make the systems 'user friendly', both had multiple paged 
forms that required meticulous completion by an experienced clinician, data input by 
specialist computer personnel, a turn around time of at least a week before 
computerised records were added to the patient's notes, and the raw data were only 
accessible by experienced computer staff (Glasgow Blood Pressure Clinic 1972,
Beilin et al 1974).
Other centres also developed systems to deal with the follow-up of 
hypertensive patients using mainframe computers. One of the earliest reports came 
from the Bronx HDFP centre. They set up a system for use by the nurses in the 
study at each clinic visit. In addition, they met regularly with their physician 
supervisor to review summary reports from the system (Wassertheil-Smoller et al
1975). Another came from a group at Wayne State University where a system was 
developed in conjunction with the university's computing centre (Laurent et al 1980). 
The involvement of the nurses in both studies will be discussed in the next section.
A group at the Harvard Community Health Plan in Massachusetts, evaluated a 
surveillance and reminder system for the follow-up of patients with newly discovered 
elevated diastolic blood pressure. Of those in the experimental group with computer 
generated reminders, 98% had follow-up attempted or achieved after 6-24 months, 
compared to only 46% of the control group (Barnett et al 1983).
A computer assisted shared care scheme in hypertension was started in 
Aberdeen in 1980. Patients are assessed at the specialist clinic at Aberdeen Royal 
Infirmary, and, once blood pressure is stabilised, patients are transferred back to
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their general practitioner. Doctors and patients are reminded by the system to 
organise follow-up visits (Petrie et al 1985). Over 250 general practitioners 
participate, and over 3300 patients had been seen by 1989 (Petrie et al 1989).
In Toronto, a controlled trial of computer assisted management of hypertension 
in primary care showed that those patients whose general practitioner had feedback 
from the computer had lower average blood pressure, yet were seen for fewer visits. 
Also fewer dropped out of active treatment (McAlister 1986).
Several systems have been developed that not only monitor care but assist in 
medical decision making as an 'expert system1, ie. '..a  program that symbolically 
encodes concepts derived from experts in a field and uses that knowledge to provide 
the kind of problem analysis and advice that the expert might provide’ (Shortliffe
1987).
The ARTEMIS system for the management of hypertensive patients has been 
developing in Paris since 1975. By 1990, data from more than 22,000 patients with 
more than 70,000 outpatient and 20,000 inpatient visits were coded on the system. 
The knowledge base utilises dynamic reasoning which is expressed by means of more 
than 800 production rules. By integrating the clinical data and rules, it predicts for 
each patient, his/her cardiovascular risk, risk of dropping-out, risk of insufficient 
blood pressure control and probable blood pressure level. It was prospectively 
evaluated by comparison with expert specialists' assessment of 80 new referrals, and 
agreement with the specialists was achieved in 58% to 89% in regards to 
investigations proposed. These results are difficult to assess since the differences 
between the specialists was not reported, nor was a pre-set acceptable standard 
identified (Degoulet al 1990).
Hypertension-aid in physician treatment (HTN-APT) was developed at the 
Mayo Clinic to assist in the management of hypertension. It was developed to run on 
International Business Machines Corporation (IBM) personal computers and is a 
database system based more on clinical judgements of a panel of advisors than patient
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data, a simpler system than ARTEMIS. In a small evaluation, it was found to be in 
general agreement for choice of drug treatment by 8 family physicians who evaluated 
drug treatment choices for a set of 20 hypertensive patients (Siepmann & Bachman
1987).
1.6. Role of the nurse practitioner
Nurses began to extend their scope of practice into areas previously considered
the sphere of their medical colleagues in the 1960's and 1970's. Particularly in North
America, the role of the nurse practitioner developed in response to the limited
availability of medical care in rural and inner city areas (Stilwell 1982, Jones 1984).
The nurse practitioner role has been defined by Prescott and Driscoll as:
'a blending of medical or cure activities with the supportive and health 
promotion activities associated with the traditional nursing care function. It 
is this unique combination of care and cure functions that distinguishes the 
nurse practitioner from other primary care givers.'
(Prescott & Driscoll 1979)
In the UK, with the growing interest in nurses extending their roles, the 
Department of Health and Social Security published Health Circular HC(77) 22 in 
1977. The role included tasks previously done by physicians but now delegated by 
the physician, but with the responsibility for the patient and overall management of 
treatment remaining with the physician. With the advent of the United Kingdom 
Central Council for Nursing, Midwifery and Health Visiting, this advice has been 
superseded by the recent revision of their Code of Professional Practice (UKCC
1992) and Scope of Professional Practice (UKCC 1992). The emphasis has shifted 
from the delegation of tasks by physicians, to each nurse taking responsibility and 
being accountable for his/her own practice (UKCC 1992).
Sox reviewed 40 published studies presenting observations of patient care 
provided by nurse practitioners and/or physician assistants. Of these, 21 were direct 
comparisons with care given by physicians. A substantial proportion of these studies
(6) were in paediatrics. He concluded that in the ambulatory care settings in which it 
was evaluated, these studies showed nurse practitioner follow-up to be at least
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equivalent to the care provided by physicians (Sox 1979).
Nurses have been involved in screening for hypertension and caring for the 
individuals subsequently found to be hypertensive in a variety of settings, since the 
mid-1960's, although they had some involvement in hypertension research as far 
back as 1950 (Frant & Groen 1950). Unfortunately, many of these studies have small 
populations with scant data reported, were limited in duration and anecdotal in 
nature.
One of the earliest nurse clinics was set up at the University of Kansas Medical 
Center. In an evaluation of 66 chronically ill patients (1/3 were hypertensive) who 
were randomised to either nurse or routine medical follow-up for one year, the 33 
patients followed by the nurse expressed 'greater satisfaction' with their care. Within 
the nurse clinic there was better adherence to appointments, fewer complaints, and 
fewer calls upon physicians for minor ailments, in addition to lower overall costs 
(Lewis & Resnik 1967). Similar results were obtained by Schulman and Wood. They 
reviewed 110 general medical patients, 51 of whom were hypertensive, who were 
cared for by a nurse practitioner over 6 months (Schulman & Wood 1972).
Clark and Dunn reported on a study done in Kansas City, in which a nurse 
clinician followed 32 hypertensive patients with initial diastolic blood pressures 1 GO- 
125 mmHg for 15 weeks at fortnightly intervals. Care included blood pressure 
measurement, medication adjustment according to an agreed protocol, and 
monitoring of side effects. 20 of the 32 patients (62%) had diastolic blood pressure 
<  90 mmHg on two consecutive visits without notable side effects (Clark & Dunn
1976). This was a higher percentage than the 48.5% reported by Logan et al (Logan 
et al 1979).
At Wayne State University Medical School in Detroit, Michigan, a clinic was 
set up in 1975 to follow-up hypertensives using nurse specialists and a computer 
based patient information system. During the first and subsequent visits, each patient 
was seen by one of the nurses who obtained a medical history, measured height, 
weight, blood pressure and heart rate. They also counselled patients regarding the
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importance of compliance to treatment and the complications of hypertension. 
Physical examinations were completed by the clinic physician. By 1980, they had 
seen 1,030 new patients and conducted 5,873 follow-up visits (Laurent et al 1980).
Ramsay et al compared nurse practitioner versus medical follow-up over 15 
months in matched groups of 40 out-patients. Diastolic blood pressure was reduced 
on average by 12 mmHg compared to 7 mmHg, weight in obese patients decreased 
by 2.7 kg compared with 1.2 kg loss in obese patients in the physician treated group, 
and there was no difference between the groups for rates of attendance (Ramsay et al
1982). Watkins and Wagner also found no difference in the level of blood pressure 
control in their review comparing 3 groups of patients: 61 patients followed by 
physicians alone, 50 patients followed by nurse practitioners alone and 50 patients 
who were followed by both (Watkins & Wagner 1982).
One study with substantially more information was carried out by a team from 
Cornell University who set up a work site screening and follow-up program at 
Gimbels' department store in 1973. The nurses screened 1,674 men and women, 
assisted in the assessment of those found to be hypertensive, and followed-up patients 
at their work site under medical supervision. After 1 year, 97% (94 individuals) of 
those enrolled in the follow-up program were still participating. Systolic blood 
pressure decreased on average by 27 mmHg and diastolic pressure by 13 mmHg 
from initial values (Alderman & Schoenbaum 1975).
A very few studies have compared nurse practitioner follow-up with medical 
follow-up of hypertension. In a community based project in Memphis, Tennessee and 
the surrounding Shelby County, Runyan compared follow-up care received for 
diabetes, hypertension, cardiac disease or a combination of these provided by nurse 
practitioners in decentralised clinics near the patients' homes. This form of care for 
1,006 patients was compared with traditional hospital based follow-up for 498 
patients aged 40-79 years. Overall, there was less hospital utilisation by patients 
followed by the nurse practitioners. Diastolic blood pressure was significantly
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reduced when compared with starting values (8 mmHg) as well as in comparison 
with the change in the control group (8 vs. 0 mmHg) who were attending hospital 
(Runyan 1975).
Another work site study, carried out in Canada by Logan et al, randomised 
hypertensives to work site care by specially trained nurses or to management by the 
patient's family doctor. The referral letter to the family doctor included information 
on the evaluation, management and target blood pressure, and protocol to be 
followed by the nurse. The nurses measured blood pressure, reviewed drug 
treatment, and sent a summary of every visit to the family physician. The supervising 
physician dealt with difficult problems and reviewed patients' charts weekly. Nearly
22,000 were screened to find the 457 employees who were eligible and agreed to 
participate. After 6 months, more patients in the nurse group had reached their target 
blood pressure (48.5% vs 27.5%), more were prescribed treatment (95% vs 63%) 
and a tablet count showed 68% vs 49% were taking their medications as prescribed 
(Logan et al 1979).
In a follow-up study, Logan et al looked at the cost effectiveness of involving 
an occupational health nurse in the routine follow-up of hypertensives compared with 
a similar group receiving regular health care from their family physician. After 
screening, 97 employees were randomised to be seen by the nurses and 97 to receive 
his/her regular care. The nurses were to ensure that patients in their group saw their 
family physician and arrange further appointments if one was missed. They measured 
blood pressure, reviewed drug treatment and compliance to medication, and whether 
each was reviewed by his personal physician. After obtaining the approval of an 
employee's physician, the nurses were allowed to counsel the patient regarding 
compliance strategies. Due to this doubling-up of professional effort, without 
significant differences emerging between the groups, the costs of caring for the 
employees in the nurse group were significantly greater than those being cared for 
solely by their personal physician (Logan et al 1983).
Lindholm anecdotally reviewed the efficacy of district nurses following up
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hypertensive patients in the community at the nurses' surgeries, between yearly visits 
with the district physicians. He reviewed the records of 223 patients referred and 
followed for an average of approximately 16 months. Less than half continued 
follow-up, frequently due to having their blood pressure measured during visits to the 
district physicians for other chronic disease. For those who continued to attend, 86% 
maintained their treatment goal (Lindholm 1984).
Viskoper and Silverberg described the positive results obtained by family clinic 
nurse/physician teams in hypertension detection and follow-up in Israel. The nurses 
conducted hypertension screening in the community and at worksites, and followed 
up patients, after an initial medical examination. They measured blood pressure and 
weight, monitored compliance, offered health education, and tracked non-attenders. 
The results from a number of Israeli studies are summarised including those from the 
CHAD study presented above. In one study reported, 73-92% of patients had an 
average diastolic blood pressure < 95 mmHg after 2-4 years of follow-up. It is 
difficult to ascertain the contribution of nurse practitioner care as a number of other 
innovations were instituted over the same period (staff education, structured clinical 
notes including proformas, and hospital consultant visits to the family clinics) 
(Viskoper & Silverberg 1985). A review of the last two blood pressures recorded 
before the physician/nurse teams took over care, compared with the last two 
recordings 2 years after, in 4,255 patients, showed that 82.4% had diastolic blood 
pressure <  95 mmHg with physician/nurse care compared to only 42.1% under 
physician only care (Silverberg et al 1982).
While the majority of the above studies, except for the Israelis', looked at the 
effectiveness of nurses participating in routine care of relatively small numbers of 
individuals with hypertension, other studies have used nurses to evaluate the 
effectiveness of hypertension treatment under clinical trial conditions. In the United 
States, the Hypertension, Detection and Follow-up program depended on nursing and 
para-medical staff to screen for hypertension and offer the majority of the care in
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specialist clinics. The nurse practitioners followed the patients as a physician would, 
changing medication and providing health counselling. In addition, they were 
responsible for the training of paramedical assistants (Robinson 1974, Wassertheil- 
Smoller et al 1975). Nurses have continued in this role, and, for example, they 
managed the clinics in the recent SHEP study (SHEP Co-operative Research Group
1991).
The first large trial to use nurses extensively in the United Kingdom was the 
Medical Research Council's trial for mild hypertension which was begun in the 
1970's. The pilot study of 25 centres from a variety of health care screening and care 
settings demonstrated a number of problems. These included poor quality trial data 
attributable to lack of standardisation and inexperienced staff, and slow recruitment 
due to cumbersome screening procedures. It was found that the general practice 
centres that employed nurses were the most effective in carrying out the pilot study 
(MRC Working Party 1977). Barnes established the training and review methods 
(Barnes 1981) which continue to facilitate large scale research projects today in the 
MRC's 'general practice research framework', including the recently published 
Hypertension In the Elderly trial (MRC Working Party 1992).
In the original trial, after training, the nurses screened, recorded 
electrocardiograms, measured height and weight, and undertook urine testing.
During follow-up visits they continued to measure blood pressure using the 
standardised MRC method, titrated drug doses and generally reviewed each 
participant. Annually, the supervising physician conducted a review. Trial techniques 
were reviewed regularly under the trial's quality control scheme (Barnes 1981; MRC 
Working Party 1985).
It is now standard practice to use nurses to collect data in epidemiology survey 
work. These studies have included the British Regional Heart Study (Shaper et al 
1981), the Scottish Heart Health Study (Tunstall-Pedoe et al 1989), and the Nine 
Towns Study (Bruce et al 1993).
In the Goteberg hypertension clinic which cared for the hypertensive
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participants in their Primary Prevention Trial, the nurses conducted the first two 
clinic visits, where they measured blood pressure, obtained an ECG and blood for 
tests. During follow-up, the patients attended one of the clinic's physicians for annual 
review, but saw one of the nurses up to six times in the interim, to assess the control 
of blood pressure, advised smokers to stop, and those with cholesterol >  6.7 mmol/1 
to lower the saturated fat content of their diet (Samuelsson 1985).
In Coope and Warrender's randomised trial of treatment of hypertension in 
elderly patients in primary care, the trial nurses screened 10,718 patients in 13 
general practices to identify the 884 participants. They reviewed the medical records 
regularly of all participants, administered and assisted with the completion of the trial 
symptom questionnaires where necessary, carried out home visits, sent out 
appointment reminders and generally implemented the trial protocol with back-up of 
each patient's general practitioner (Coope & Warender 1986).
There have also been a number of initiatives by individual nurses or groups of 
nurses to establish screening and follow-up programmes in general practice in the 
United Kingdom (Antrobus 1983, Antrobus 1984, Carroll-Williams & Allen 1984, 
Hawke 1984, Bracey & Blythe 1985, Kenkre et al 1985, Jewell & Hope 1988, 
Hudson 1993).
Other initiatives have been developed by multi-disciplinary teams which have 
included nurses. At the Veterans' Administration Outpatient Clinic in New Bedford, 
Massachusetts, a multi-disciplinary small group educational program was set up by 
the clinic's nurse practitioners. The report followed up 66 participants up to 3 years 
after attending. Two thirds of the participants reported more positive health 
behaviours compared with an initial assessment. Least change occurred in the areas 
of smoking and weight reduction (Wyka-Fitzgerald et al 1984).
In the United Kingdom, the Oxford Prevention of Heart Attack and Stroke 
project used specially trained nurses to screen and counsel patients in 3 general 
practices in Oxford. One nurse acted as 'facilitator' to the project (Fullard et al 
1984). The nurses measured blood pressure and weight, checked diet, smoking and
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drinking habits, and assessed general well-being. They counselled patients regarding 
weight loss, smoking cessation, and monitored anti-hypertensive drug therapy 
(Anderson 1984, Fullard et al 1987).
The results of the Oxford study has lead to the employment of a number of 
'facilitators' by health boards in England and Wales. Their role is to support general 
practices in establishing nurse run prevention clinics (Holmes, 1986). A follow-up 
audit of hypertensive patients (>160/90 mmHg) identified at screening in the three 
original practices demonstrated improvement in blood pressure control. The 
percentage of patients with diastolic blood pressure >100 mmHg decreased from 
15.8% to 8.1% over 3 years. The changes in smoking habits and weight were very 
modest (Mant et al 1989).
Robson et al demonstrated the effectiveness of a health promotion nurse 
employed in general practice for the routine screening and recording of blood 
pressure, smoking status, family history of ischaemic heart disease and serum 
cholesterol. All 30-64 year old patients were randomised to nurse follow-up for 
health promotion or continued care by the general practitioners who were also 
engaged in preventive activities with their patients. The group cared for by the nurse 
had significantly more frequent blood pressure recordings and follow-up visits, 
smoking status identified and family history recorded (Robson et al 1989).
Two recent studies have reported on the effect of health promotion screening. 
and risk factor follow-up by practice nurses in general practice (OXCHECK Study 
Group 1994, Family Heart Study Group 1994). The Oxford group's study screened 
6,124 men and women, approximately one third were followed up by the nurses for 
one year and compared with a non-intervention control group. Results were very 
modest reductions in blood pressure (3/2 mmHg), total cholesterol (0.1 mmol/1) and 
smoking (0.5%) compared with controls (OXCHECK Study Group 1994).
The British Family Heart Study screened 12,472 men and women in 13 towns 
with an approximately 2/3 size internal comparison group and an external 
comparison group approximately 1/3 larger than the intervention group. On an
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intention to treat basis, an overall reduction of 12% in coronary risk was determined 
using the Dundee risk scoring system (Tunstall-Pedoe 1991). There were modest 
reductions in blood pressure (8/3 mmHg), total cholesterol (0.1 mmol/1) and smoking 
(3.5%) compared with external controls (Family Heart Study Group 1994). Blood 
pressure reductions are in keeping with a number of clinical trials that have also 
shown reductions in cardiovascular mortality (Management Committee 1980, MRC 
Working Party 1985).
While these last two studies call into question the effectiveness of health 
promotion and screening in the general population (Stott 1994), they have also been 
used to discredit the value of nurses working more independently within the general 
practice primary care team (Cassidy 1994). Yet, the conclusion drawn from the 
above review is that, in terms of hypertension research, screening and follow-up, 
nurses have played an effective role.
This role for nurses has been accepted by a number of experts in the field of 
hypertension research and care. As early as 1981, the proceedings of a symposium 
on hypertension was published in the Nursing Clinics of North America with 6 
papers by 13 nurse authors describing various aspects of hypertension detection and 
follow-up (Hill & McCombs 1981). By 1985, nurses were following up more than
100,000 hypertensive patients, as part of nurse/physician teams, in over 600 family 
clinics in Israel (Viskoper & Silverberg 1985). Beevers and MacGregor in their book 
'Hypertension in Practice' make many references to the role practice nurses can play 
in the long term care of hypertensive patients (Beevers & MacGregor 1987). In 
Laragh and Brenner's two volume textbook: Hypertension: Pathophysiology, 
Diagnosis and Management, a chapter is written by two nurses describing the 
'Nursing Management of the Hypertensive Patient' (Marion & Ryan 1990).
1.7. Scope of Thesis
In this chapter, the background and epidemiology of hypertension and other 
cardiovascular risk factors has been presented. The effects of pharmacological and
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non-pharmacological treatment have been outlined, the usefulness of computer based 
patient information systems and the role of the nurse practitioner in hypertension 
research and follow-up have been described.
This review has demonstrated that increased levels of blood pressure are 
associated with increased mortality, particularly due to cardiovascular causes 
(MacMahon et al 1990). In addition, the effectiveness of anti-hypertensive treatment 
is particularly significant in relation to cerebrovascular mortality (Collins et al 1990) 
and that the cardiovascular mortality reductions seen with anti-hypertensive drug 
treatment are greater in the elderly (SHEP 1991, Dahlof 1991, MRC Working Party
1992).
However, adequate long term follow-up of patients with hypertension is yet to 
be achieved, with less than half of the women and only a quarter of the men 
identified as hypertensive in the Scottish Heart Health Survey, found to have 
controlled diastolic blood pressure between 85-90 mmHg (Smith et al 1990).
The benefits of a computer based patient information system and how it can 
facilitate the collection, retrieval and analysis of data has been presented. Personal 
microcomputers provide the opportunity for further development of such systems 
(Lilford & Chard 1981).
The role nurses can play in the care of hypertensive patients has also been 
illuminated. Nurse practitioner follow-up in a number of outpatient settings has been 
judged to be at least equivalent to physician follow-up (Sox 1979).
Therefore, with the help of the Scottish Chest, Heart and Stroke Association, a 
clinic was set up in 1981 utilising a nurse practitioner and a microcomputer based 
patient information system to follow-up patients with hypertension. Data were 
collected for a period of 8 years with 1091 patients enrolled, and a total of 705 
continuing to attend at the end of 8 years. The aim of the work presented in 
subsequent chapters is to evaluate that follow-up care and related projects.
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Chapter 2. Methods
2.0. Summary
In this chapter, the structure and functioning of the blood pressure clinic are 
described. The data sets, their rationale, and description of the databases used, are 
included. Examples of computer output are shown. The statistical methods used for 
analysis are also presented.
2.1. Introduction
The nurse practitioner clinic with microcomputer patient information system, was 
inaugurated in September 1981 within the Department of Materia Medica at Stobhill 
General Hospital, Glasgow, G21 3UW. Funding was obtained from the Scottish 
Chest, Heart and Stroke Association for the first 2 years of operation. The original 
Commodore PET computer system was funded by the Greater Glasgow Health Board 
and was replaced by an Apricot system.
2.2. Aims
The primary aims of the clinic were to assess the effectiveness of:
1. offering standardised anti-hypertensive care by the same specialist nursing staff 
with expert physician backup.
2. using a computerised patient information system to facilitate the follow-up of 
individuals identified as having hypertension.
3. new pharmacological and non-pharmacological treatments to reduce 
cardiovascular risk in hypertension.
2.3. A nurse practitioner hypertension follow-up clinic.
2.3.1. Clinic staff
The nurse practitioner saw patients, organised and managed day-to-day activities, 
collated and analysed the data generated. In addition to the nurse practitioner, the 
dedicated clinic staff included a part-time receptionist, and eventually an additional 
part-time clerk. By the second year, an auxiliary nurse was assigned to the clinic 
from the outpatient department for the three sessions per week the clinic was held. 
During the third year of operation, a second nurse practitioner joined the clinic part-
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time due to the increasing patient population.
Medical staff were 'on call' to each clinic session with every effort made to 
have the same physician covering the clinic the same day each week. In this way 
patients generally were seen by the same nurse practitioner and physician for follow- 
up.
2.3.2. Patient population
Patients were recruited from the department's general medical clinics. Initial 
assessment occurred at these general medical clinics, to which patients had been 
referred by their general practitioner or other hospital consultant. Therefore, over the 
8 years of the clinic, 1091 patients entered the nurse practitioner clinic for long term 
follow-up.
2.3.3. Clinic Management
A protocol for the management of hypertension in the clinic was developed in 
consultation with the three senior physicians whose patients would be attending the 
clinic after initial outpatient assessment. The flow chart summarising the protocol is 
given in Figure 2.1 (Curzio 1983). The rationale for the target blood pressures is 
discussed in section 2.3.4.
An initial blood pressure data form (Figure 2.2) was completed either by one of 
the physicians or one of the nurse practitioners prior to the patient first attending the 
Hypertension Clinic for long term follow-up. The form changed with the introduction 
of the Apricot system which is described in detail in section 2.4.2 (Figure 2.3).
The initial data were then entered into the clinic database by the clinic 
secretary or one of the nurse practitioners. A first appointment letter was sent to the 
patient with directions on how to get to the clinic.
Each patient was issued with a specially designed Blood Pressure Information 
and Appointment Card. In addition to the date and time of the next appointment, 
there was space for supine and erect readings and current anti-hypertensive drug 
treatment. Staff names and the clinic telephone number were on the back of the
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Figure 2.1. Main follow-up protocol flowchart.
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Figure 2.2. Initial blood pressure data form for PET system.
B.P. DATA INITIAL
NAME ____________________________  GP NAME ____
ADDRESS ADDRESS
UNIT No
SEX: MALE = 1  __
FEMALE = 2 
DATE OF BIRTH (day, 
month, year)
HEIGHT _____  METRES
WEIGHT _____  kg
OBESITY NONE = 0 _____
MOD. = 1 
SEVERE = 2
SMOKING NEVER = 0  ___
PRESENT = 1 PIPE = 3
PAST = 2 CIGAR = 4
No CIG/DAY _____
ALCOHOL NONE = 0 ___
MOD = 1 
HEAVY = 2 
FAMILY HISTORY 
HYPERTENSION
YES = 1 NO = 0 ______
PERSONAL HISTORY OF: 
(YES = 1  NO = 0)
Myocardial Inf. _____
Angina _____
C.C.F. _____
C.V.A. _____
Per. Vase. Dis. _____
C.O.A. D. _____
PREVIOUS TREATMENT 
(Up to this visit)
YES = 1  NO = 0 _____
Details
PRESENT TREATMENT 
(On leaving the clinic)
Beta Blocker ____
NONE = 0
ATENOLOL = 1 
PROPRANOLOL = 
METOPROLOL = 
OXPRENOLOL =
OTHER
DOSE ____  mg
Diuretic 
NONE
THIAZIDE 
K SPARING 
LOOP
COMBINATION =
OTHER
DOSE ____  mg
Vasodilator 
NONE
PRAZOSIN 
HYDRALAZINE = 
ENDRALAZINE = 
CAPTOPRIL 
NIFEDIPINE =
DOSE ____  mg
Centrally Acting 
NONE = 0
METHYLDOPA = 1 
CLONIDINE = 2 
OTHER = 3
DOSE ____  mg
ADVERSE EFFECTS 
YES = 1  NO = 0 
Details
2
3
4
5
0
1
2
3
4
5
0
1
2
3
4
5
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Figure 2.2. Initial blood pressure data form for PET system (cont'd)
DETAILS AT INITIAL VISIT
Type of Hypertension ______
ESSENTIAL = 1 PREGNANCY = 4
ACCELERATED = 2 OTHER = 5
PILL = 3
SUPINE DATA
Sys. B.P. ______
Dias. B.P. ______
Heart Rate ______
ERECT DATA
Sys. B.P. ______
Dias. B.P. ______
Heart Rate ______
TARGET B.P. (Sys,Dias)
ARE BIOCHEMICAL DATA AVAILABLE?
YES = 1  NO = 0 ______
CHOLESTEROL ________  date of Biochem update
GLUCOSE________ ________  ______________________
URATE   (1 yr after last data obtained)
POTASSIUM______ ________
CREATININE_____ ________
GAMMA G.T.______ ________
URINE GLUCOSE ________
PRESENT = 1 ABSENT = 0
URINE PROTEIN ________
PRESENT = 1 ABSENT = 0
ECG LVH________ ________
PRESENT = 1 ABSENT = 0 
DATE OF NEXT APPOINTMENT 
(Day, month, year)
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Figure 2.3. Initial blood pressure data form for Apricot system.
Initial BP DATA - Apricot Microcomputer System
Patient Surname: _______________________________________
Forename: _______________________________________
Address - Street: _______________________________________
Town: _______________________________________
Post Code: ___________________
Tele: ___________________
Unit No: ___________________
GP Surname: ______________________________________
Forename: ______________________________________
Address-Health Centre: ______________________________________
Street: ______________________________________
Town: ______________________________________
Post Code: ___________________
Tele: ___________________
Sex ( M or F) :
Date of Birth: 7 /
Ht: ______  (M)
Current Wt: (Kg)
Smoking (cigs/day) : ________
Alcohol Intake (gm/wk) : ____ (1/2 pint or 1 gl wine or a sherry=10 gm)
Evidence of LVH on ECG: Y or N 
Family History of Hypertension:
Patients Risks Factors: eg. MI, CCF, COAD, CVA, ANGINA
Any Other Relevant Conditions:
Date of Next Visit: / J
Initial Data - Date: 7 7
Wt: ______  (Kg)
Type of Hypertension: ________________
Supine Data SBP:______ DBP:_______ HR:
Erect Data SBP:______ DBP:______  HR:
Target BP SBP:______  DBP:_______
Appt Cycle: ______
BP Control:
Date of Annual Review: ___/___ /___
Cholesterol:  ______
Glucose: ____________
Urate: ______________
Potassium: __________
Creatinine: ________
Gamma GT: ___________
Protein in Urine: Y or N
Glucose in Urine: Y or N
Current Treatment
Beta Blocker: _________________________
Diuretic: _____________________________
Vasodilator: __________________________
Centrally Active Drug: _______________
Other: ________________________________
Adverse Reactions:
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card to facilitate contact. In addition, there were explanatory notes to the patient and 
general practitioner (Figure 2.4). The card was updated at the end of each clinic visit 
and patients were encouraged to carry it.
An appointment was arranged with each patient at the end of the clinic visit 
based on the need for follow-up and personal preference for time and day of the 
week. If unable to attend, all patients were encouraged to telephone for another 
appointment. When a patient did not attend, two further appointments were arranged 
before a letter was sent to the general practitioner reporting the failure to attend, and 
stating that no further appointments would be made unless requested to do so.
A master name and address file with GP noted was kept in the clinic office for 
quick reference. This file was used frequently to determine if a patient was on the 
database, to obtain a patient's telephone number and to identify the patient's general 
practitioner. In addition, if a patient was no longer being followed up, the reason was 
noted on the bottom of the card with the date it was recorded.
2.3.4. Measurement of weight
At each visit the nurse practitioner or auxiliary nurse would weigh each patient 
in kilograms on an Avery balance scale, which was calibrated regularly. Height in 
metres was measured during the first clinic visit if it had not been previously 
recorded in the case notes.
A Body Mass Index (BMI) was determined for each patient. BMI is calculated 
by dividing an individual's weight in kilograms by the square of their height:
weight (kg)
height2(m)
Garrow demonstrated the correlation between BMI, first put forward by 
Quetelet in the 17th century, and overall mortality using insurance company data.
The gradings are as follows:
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Figure 2.4. Blood pressure information and appointment card.
To the patient:
1. Keep this card with you and bring it to  the  clinic.
2. Show it to  your family doctor w hen you attend 
his surgery.
3. If you have an accident or enter hospital, show 
th is card.
5. Bring your tab lets each visit.
6. If you are unable to  attend for an appointment, 
please telephone the nurse, Joan  Curzio 
(041-558-0111 Ext. 278) for another one.
7. If you have a question about your blood pressure 
th a t needs to  be answered before your next 
appointm ent please feel free to telephone.
To the doctor:
If the drug dose is changed, please write the 
new dose on the card in the appropriate 
column, together with any blood pressures 
recorded by you, on the line below the next 
appointment date.
Further information or assistance in 
management can be obtained from:
Prof. Reid, Dr. Rubin, Dr. Elliott or the 8A BP 
Clinic at Stobhill General Hospital 
(041 -558-0111  Ext. 278)
8 3 -3 8 6 -22
MEDICATION and DOSE
APPOINTMENT
DATE TIME
BLOOD PRESSURE 
This Visit
Lying Standing
8A Blood Pressure Clinic
Name of fam ily doctor 
Dr.
Stobhill General Hospital 
Blood Pressure Information and 
Appointment Card
N am e________________________
Address____________________
Hospital N o ._________________
Please carry this card with you
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BMI 20 - 24.9 Grade 0
BMI 25 - 29.9 Grade I
BMI >  30 <  40 Grade II
BMI >  40 Grade III
(Garrow 1981). This index has been validated in other populations (Goldourt & 
Medalie 1974, Bray 1978, Bray 1985). Thus those individuals with BMI >  30, 
being at greatest risk, were targeted for repeated counselling regarding weight 
reduction.
2.3.5. Measurement of blood pressure
Blood pressure was measured by the nurse practitioner using a Sentron semi­
automatic sphygmomanometer (C R Bard International, Penny well Industrial Estate, 
Sunderland, SR4 9EW). A semi-automatic device was chosen to maintain consistency 
of readings by a regularly calibrated device. Calibration procedures were carried out 
quarterly on both devices used in the clinic.
The Sentron measures blood pressure oscillometrically, by sensing the pulse 
waves through the cuff as the pressure is released. If the pulse sensations are outwith 
pre-set norms (possibly due to arm movement or a low heart rate, ie. less than 44 
beats per minute), the machine will re-inflate and begin the measurement again. The 
machine will zero if it is unable to obtain an acceptable reading after 3 re-inflations.
Small (22 cm x 10 cm), regular (31 x 12 cm) and large (39 cm x 16 cm) cuffs, 
with velcro fastenings, were available at all times in the clinic. An appropriate sized 
cuff, based on the cuff markings, was applied to the right upper arm of each patient 
to ensure the cuff bladder would encircle at least 80% of the circumference of the 
arm as recommended (Petrie et al 1986).
Since the Sentron re-sets itself after each reading, basing the pressure level of 
inflation for a reading on the level of the preceding measurement, two supine and 
two erect measurements were obtained after a short period of rest. The second 
measurement of each was recorded in the database.
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2.3.6. Target blood pressure
Thrget blood pressures were determined for all patients, and failure to reach 
these targets was the criterion for referral to medical staff for further treatment. The 
targets were globally based on age. For those individuals less than 60 years of age, 
the target blood pressure was less than 140/90, and for those over 60 it was less than 
160/90. However, targets were further individualised for a few patients, as required, 
so that if a patient had a problem such as polycystic kidneys the target would be 
lowered to 135/85, in order to protect renal function.
The use of target or goal blood pressures is now common. These levels are 
somewhat less than the 160/90 mmHg recently recommended by the British 
Hypertension Society (Sever et al 1993), but higher than the 120-130/80 mmHg for 
young patients and 140/90 mmHg for elderly patients recommended by the World 
Health Organisation and the International Society of Hypertension (WHO/ISH Mild 
Hypertension Liaison Committee 1993).
2.3.7. Patient interview
During the subsequent interview, patient well-being and compliance were 
assessed by the nurse practitioner. Poorly controlled blood pressure and possible 
drug side-effects, as well as other medical problems, were referred to the backup 
medical staff. Drug treatment changes were instituted only by medical staff.
2.3.8. Health education and counselling
Obese patients, particularly those with BMI > 30 were advised to lose weight. 
The protocol developed for weight reduction advice is given in Figure 2.5. Patients 
were given the option to see one of the hospital dietitians for specialist advice or to 
receive support only from the clinic nurse practitioner. In addition, patients were 
encouraged to take prescribed medication regularly and smokers to stop smoking. 
Health education material obtained from the Greater Glasgow Health Board and from 
the Dietetics Department of Stobhill Hospital were used to support these health 
education messages. In addition, several leaflets were prepared by clinic staff. A list 
of the various materials used is shown in Thble 2.1.
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Table 2.1. Health education materials.
Is it blood pressure 
British Heart Foundation
Do you understand these numbers?
Stobhill Hypertension Clinic
Dieting Advice
Stobhill Hypertension Clinic
Coming down lightly
Good Hearted Glasgow weight reduction leaflet
Giving up smoking: Let your body breathe 
Scottish Health Education Group
So you want to stop smoking 
Scottish Health Education Group
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Copies of several in-depth paperback books on hypertension were available on 
loan from the clinic. The clinic had two copies of 'High Blood Pressure: What it 
means for you and how to control it1 (O'Brien & O'Malley 1982) and 4 copies of 
'Churchill Livingstone Patient Handbook 7: High blood pressure'(Lewis 1981). 
These were made available to new patients and those who expressed an interest, to 
provide additional information about hypertension.
2.3.9. Annual review
Each year all patients underwent an 'Annual Review' in addition to the routine 
clinic assessment. The nurse practitioner obtained a blood sample for analysis by the 
hospital's Biochemistry and Haematology departments for the tests listed in Thble
2.2. A mid-stream specimen of urine was obtained for multi-stix dipstick assessment 
in the clinic, and culture and sensitivity assessment by the hospital's Bacteriology 
Department. Each patient's current address, general practitioner and smoking status 
were reviewed and updated. A 12-lead electrocardiogram (ECG) was done in the 
hospital's ECG Department.
The majority of the routine biochemistry tests were measured by an SMA-12. 
Total cholesterol was measured enzymatically on a Technicon RA1000. 
Haematological samples were auto-analysed. For the studies described in Chapters 5 
and 6, triglyceride was measured enzymatically on a Technicon RA1000, very low 
density lipoprotein cholesterol (VLDL) was isolated by ultracentrifugation and high 
density lipoprotein cholesterol (HDL) by precipitation using heparin/manganese.
The physician interviewed the patient and conducted a physical examination 
with particular reference to reviewing each patient's optic fundi and heart sounds. 
For those patients also entered onto the Glasgow Blood Pressure Clinic (GBPC) 
database (Glasgow Blood Pressure Clinic 1972), a GBPC Annual Review form was 
completed.
2.3.10. Drug treatment
Drug treatment choice and treatment changes were the province of the medical 
staff. 'Stepped Care' was the underlying principle of care in the early and
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Table 2.2. Annual review blood tests.
Biochemistry
Total cholesterol*
Random glucose*
Sodium
Potassium*
Chloride
Bicarbonate
Creatinine*
Urea
Calcium
Phosphate
Urate*
Total Protein
Albumin
Alkphosphatase
Bilirubin
AST
ALT
GammaGT*
* entered into database
Haematology
RBCs
WBCs
Haemoglobin
Haematocrit
MCV
MCH
MCHC
RDW
Platelets
Pet
MPV
PDW
Lymphocytes (percentage) 
Lymphocytes (number)
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mid-1980's. The efficacy of this approach had been validated in the Hypertension, 
Detection and Follow-up Program (HDFP Cooperative Group 1979). Newly 
diagnosed hypertensives without contraindications, were treated as described in Thble
2.3. The first choice was a beta blocker with the addition of a thiazide diuretic and 
then a vasodilator if blood pressure control was not obtained.
With the advent of angiotensin converting enzyme inhibitors and calcium 
channel blockers in the mid-1980's treatment choices shifted to these newer agents. 
The changes in drug treatment are highlighted in Chapter 3.
2.4. Microcomputer patient information system
2.4.1. Data
The data stored in the database for each patient were those which were 
identified by the senior medical staff, at the beginning of the project, as being the 
most relevant for the follow-up of hypertension. Storage space was particularly 
limited in the original system and therefore only 100 items of information were 
obtained for each patient (T&ble 2.4).
Information included weight, smoking, family history, drug treatment, 
biochemistry and blood pressure measurements. This data set facilitated the 
monitoring of each patient for the development of diabetes or renal disease, in 
addition to the review of blood pressure and anti-hypertensive treatment. Such 
monitoring is important since diabetes is an independent cardiovascular risk factor 
(Kannel & McGee 1979) and renal disease can make the control of blood pressure 
more difficult as well as influence the risk of developing malignant hypertension 
(Kincaid-Smith 1985).
2.4.2. Hardware and software development
Over the 8 years the clinic was held at Stobhill General Hospital, the computer 
database underwent several refinements due to the improvements in available 
computer hardware and programming software. However, the core data did not 
change.
Version 1.0 of the software was written in PET BASIC to run on a
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Table 2.3. Drug treatment regimen: 'Stepped Care1. 
Step 1 Beta blocker or thiazide diuretic
Step 2
Step 3
i
(if blood pressure were uncontrolled on Step 1 
medication)
the alternative drug not used in Step 1 added for 
a combination of beta blocker plus diuretic or 
diuretic plus beta blocker
(if blood pressure continues uncontrolled on Step 2 
medication)
add in a vasodilator which initially was 
hydralazine or prazosin and later a calcium 
antagonist (Nifedipine) or ACE inhibitor (Captopril 
or Enalapril)
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Table 2.4. Data identified for inclusion into the database.
Record Patient Details
1 Patient Number
2-5 Name
6-16 Address
20 Unit number
21 Sex (1 = male, 2 = female)
22 Date of birth
23 Age
24 Height (m)
25 Weight (kg)
Risk factors;
26 Obesity
(none, moderate, severe)
27 Smoking (yes/no)
28 No. of cigarettes/day
29 Alcohol use
(none,moderate,heavy)
History:
31 Family history of
hypertension
32 Patient's history
of: MI
33 angina
34 CCF
35 CVA
36 PVD
37 COAD
Previous treatment:
38 Any previous 
treatment (yes/no)
39 Details
Present treatment:
47 Beta blocker (none, atenolol, 
propranolol, metoprolol, 
oxprenolol, other)
48 Dose of beta blocker
49 Diuretic (none, thiazide,
k sparing, loop, combination, 
other)
50 Dose of diuretic
51 Vasodilator (none, prazosin, 
hydralazine, other)
52 Dose of vasodilator
53 Centrally acting drug (none, 
methyldopa, clonidine, other)
54 Dose of CA drug
Adverse effects:
55 Present (yes/no)
56 Details
Record1 Patient Details
Initial BP data:
63 Type of hypertension
(essential, accelerated, due to
contraceptive, first diagnosed
during pregnancy, other)
64 Supine systolic BP
65 Supine diastolic BP
66 Supine heart rate
67 Erect systolic BP
68 Erect diastolic BP
69 Erect heart rate
70 Target systolic BP
71 Target diastolic BP
Biochemical data:
72 Serum cholesterol
73 Serum glucose
74 Serum urate
75 Serum potassium
76 Serum creatinine
77 Serum t<jT
78 Presence of protein in
urine (yes/no)
30 Presence of glucose in
urine (yes/no)
2nd last visit:
82 Supine systolic BP
83 Supine diastolic BP
84 Supine heart rate
85 Erect systolic BP
86 Erect diastolic BP
87 Erect heart rate
Last visit:
88 Supine systolic BP
89 Supine diastolic BP
90 Supine heart rate
91 Erect systolic BP
92 Erect diastolic BP
93 Erect heart rate
Miscellaneous data:
79 ECG: Presence of left
ventricular hypertrophy
80 Most recent weight (kg)
81 Current treatment drug
94 Date for update of
biochemical data
95 Appointment cycle
96 Estimate of patient's
compliance
97 Estimate of BP control
98 Date file was last updated
99 Date of next clinic appointmei
100 Number of appointments
missed
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Commodore PET4040 and then a PET8000. It was capable of outputting a full 
summary (Figure 2.6), a partial summary of the data held on each patient (Figure 
2.7), as well as printing the entire database in total or by appointment date. The 
partial summary was updated at each clinic visit by the nurse practitioner. The 
database was then updated, and the hand-written updated partial summary filed in the 
patient’s case notes for future reference. Each 360,000 byte disk held data for 
approximately 250 patients. This set-up supported the patient information system for 
the first three years (Kelman et al 1982).
During the fourth year of operation, data were manually transferred into an 
enhanced Version 2.0 of the software written in dBasell (Ashton-Thte) designed to 
work on an 256K RAM Apricot PC. An added feature of this version was an option 
to output standard letters in batch mode, many of which had been generated 
individually using the Commodore's word processor. These included letters to 
patients regarding appointments (Figure 2.8), and letters to general practitioners 
about routine follow-up visits (Figure 2.9) or patients who failed to attend and who 
might have died or were known to be dead. The last letter was sent with a brief form 
for completion by the general practitioner (Figure 2.10).
The output used in the clinic now included all data held in the system for that 
individual (Figure 2.11). Each printout continued to be updated in the clinic with the 
updated data used to amend the database after the clinic session. The manually 
updated printout continued to be filed in the patient's case notes. Data from patients 
who were no longer attending or who had moved or died were transferred to either a 
'Lost-to-follow-up' file or 'dead' file, leaving data for patients currently attending in 
the active file.
Version 2.0 processed data more quickly, was able to handle a much larger 
data set per disk (900+ records) and allowed for the electronic transfer of data to 
other software packages and other hardware platforms for data analysis.
Finally, a local area network (LAN) was installed connecting a number of 
Apricot machines in the department to a 20 mega-byte hard disk file server. There
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Figure 2.6. Partial summary of data for each patient held in PET system.
(all data presented here are fictitious)
BLOOD PRESSURE CLINIC DATE 291181
PATIENT 124 IVOR PALSHIRE DATE OF APPT. 010983
8 GREEN STREET GLASGOW
UNIT NO. 123456
MOST RECENT WEIGHT 72 
CURRENT TREATMENT
BETA BLOCKER 1 160 
BLOOD PRESSURE DATA
INITIAL 2ND LAST VISIT LAST VISIT
SUP SYS.B .P . 178 154 146
DIAS.B.P. 98 92 84
HEART RATE 88 65 62
ERECT SYS.B.P. 180 168 142
DIAS.B.P. 106 100 86
HEART RATE 95 72 62
******** TARGET B.P. 150 /90 * * * * * * * *
BIOCHEM. DUE TO BE UPDATED ON 200682
APPOINTMENT CYCLE
COMPLIANCE
B.P. CONTROL
DATE OF NEXT APPOINTMENT
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Figure 2.7. Full summary of data for each patient held in PET system.
(all data presented here are fictitious)
BLOOD PRESSURE CLINIC DATE 291181
PATIENT NO. 124 UNIT NO. 123456 TYPE OF HYP.l
NAME IVOR PALSHIRE
ADDRESS 8 GREEN STREET GLASGOW
SEX 1 AGE 57 DATE OF BIRTH 030924
INITIAL WT(KG) 81 HEIGHT (M) 1.72
PRESENT WT(KG) 72
RISK FACTORS
OBESITY 0 SMOKING 1 ALCOHOL 0
40 CIGS/DAY
*********** FAMILY HISTORY OF HYPERTENSION ************ 
PATIENT'S HISTORY 
PER. VASC. DISEASE 
BLOOD PRESSURE DATA
INITIAL 2ND LAST VISIT LAST VISIT
SUP SYS.B.P. 178 154 146
DIAS.B.P. 98 92 84
HEART RATE 88 65 62
ERECT SYS.B.P. 180 168 142
DIAS.B.P. 106 100 86
HEART RATE 95 72 62
******** TARGET B.P. 150 /90 ********
BIOCHEMICAL DATA
CHOLESTEROL 4.7 GLUCOSE 6 URATE 0.44
POTASSIUM 4.2 CREATININE 101 GAMMA GT 26
BIOCHEM. DUE TO BE UPDATED ON 200682
PREVIOUS TREATMENT PROPRANOLOL
CURRENT TREATMENT
BETA BLOCKER 1 160
ASSESSMENT OF COMPLIANCE 3 
ASSESSMENT OF B.P. CONTROL 3 
APPOINTMENT CYCLE 8
NEXT APPOINTMENT 051282
NO. OF APPTS. MISSED 
FILE LAST UPDATED ON 291181
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Figure 2.8. First, follow-up, and missed appointment letters to patients, generated
by the Apricot system, (all data presented here are fictitious)
Ms Elizabeth Hogg 10/04/85
5 Kingsway 
KIRKINTILLOCH G66
Dear Ms Hogg
Your next appointment at the Blood Pressure Clinic in Ward 8A 
is at 11.00 am on 26/06/85.
Instead of going to the Outpatient Department, please come along to 
the Department of Materia Medica, Ward 8A. It is therefore not 
necessary for you to check in at the Appointments Desk, just come 
straight to this clinic.
A map is enclosed with this letter to help you find your way. 
Once inside the hospital you can follow the signs for Wards 9-14.
The Department of Materia Medica is in that part of the main 
corridor towards the front of the building complex.
If you are unable to come at this time, please telephone me, or 
the receptionist, Mrs Richardson, any morning at the above number, 
ext. 278. We can then make an appointment that is more convenient 
for you.
Yours sincerely,
Mrs Joan Curzio 
Research Nurse
10/07/85
Ms Elizabeth Hogg 
5 Kingsway 
KIRKINTILLOCH G66
Dear Ms Hogg
Your next appointment at the Blood Pressure Clinic in Ward 8A 
is at 11.00 am on 26/06/85.
If you are unable to come at this time, please telephone me, or 
the receptionist, Mrs Richardson, any morning at the above number, 
ext. 278. We can then make an appointment that is more convenient 
for you.
Yours sincerely,
Mrs Joan Curzio 
Research Nurse
10/07/85
Ms Elizabeth Hogg 
5 Kingsway 
KIRKINTILLOCH G66
Dear Ms Hogg
I am sorry that you were unable to come to your appointment at 
the Blood Pressure Clinic. Could you please come in at 10.30 on 
20/06/85.
If you are unable to come at this time, please telephone me, or 
the receptionist, Mrs Richardson, any morning at the above number, 
ext. 278. We can then make an appointment that is more convenient 
for you.
Yours sincerely,
Mrs Joan Curzio 
Research Nurse
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Figure 2.9. Letter sent to each patient's general practitioner after a visit.
(all data presented here are fictitious)
29/02/85
Dr J Yard 
Union Street 
KIRKINTILLOCH G66
Dear Dr Yard
re: Elizabeth Hogg, D.O.B. 04/07/26, Unit No. 008039 
5 Kingsway, KIRKINTILLOCH G66
Your patient was seen on 27/02/85 at the 8A Blood Pressure Clinic at 
Stobhill Hospital. Her blood pressure was 150/88 lying and 146/81 
standing. Heart rate was 86 beats per minute lying and 101 standing.
Her current treatment is
Bendrofluazide 5 mg 
Nifedipine Retard 20 mg b.d.
to be taken daily. I have asked her to continue on this regimen. A 
further visit has been arranged for 8 weeks.
Yours sincerely,
John L. Reid
Professor of Materia Medica
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Figure 2.10. Letter sent to each patient's general practitioner when patient has not
attended and might have died, (all data presented here are fictitious)
29/02/85
Dr J Yard 
Union Street 
KIRKINTILLOCH G66
Dear Dr Yard
re: Elizabeth Hogg, D.O.B. 04/07/26, Unit No. 008039 
5 Kingsway, KIRKINTILLOCH G66
The above named patient has been managed at the Hypertension Clinic 
at Stobhill Hospital and our records indicate that she has been 
under your care. She has failed to keep a recent appointment and I 
understand that she has died. I would be most grateful if you could 
please provide us with some information, not only to allow us to 
update our case records, but also to reduce the likelihood of 
distressing the family with enquiries or further appointments.
Yours sincerely,
John L. Reid
Professor of Materia Medica
Blood Pressure Patient Information
Patient's Name...........................  Case No............
Patient's Address...............................................
Please complete and delete as appropriate
1. This patient is not now under my care and I have no record of 
him.
2. I believe this patient has recently been under the care of 
Dr...........................  of................................
3. This patient is alive and wishes a further appointment.
4. I confirm that the patient died on ......................
5. The patient died at home
i n .......................... hospital
6. The cause of death was.........................................
7. Do you believe death was directly related to cardiovascular 
disease (myocardial infarction) (stroke)
(other.............................. )
8. A post mortem was/was not performed.
Signed Date. . . .
name and address of GP/Hospital Dr.
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Figure 2.11. Full summary of data held in Apricot system for each patient.
(all data presented here are fictitious)
— STOBHILL BLOOD PRESSURE CLINIC—
NAME
ADDRESS
TEL.
Elizabeth Hogg 
5 Kingsway 
KIRKINTILLOCH , G66 
776-55555 UNIT NO. 008039
G.P.
ADDRESS
TEL.
DR J. Yard
, Union Street 
KIRKINTILLOCH , G66 
041-776-1111
DATE OF 
DATE OF
SEX
DATE OF 
AGE
HEIGHT
WEIGHT
LAST APPT. 15/11/84 
NEXT APPT. 27/04/85
F
BIRTH 04/7/26 
59
(M) 1.51 
(KG) 55.1
RISK FACTORS
SMOKING (CIGS/DAY) 
ALCOHOL (GM/WK) 
OBESITY INDEX 
LVH
0
50
24.16
N
PATIENTS HISTORY
OTHER CONDITIONS Ex lung tumour 
FAMILY HISTORY
BLOOD PRESSURE DATA
INITIAL 2nd LAST VISIT LAST VISIT
SUPINE DATE 00/00/81 15/11/84 27/02/85
SBP 240 166 150
DBP 130 93 88
HR 100 93 86
ERECT SBP 220 167 146
DBP 122 93 81
HR 112 96 101
TARGET BLOOD PRESSURE 140/90
CURRENT TREATMENT
BETA BLOCKER
DIURETIC Bendrofluazide 5 mg
VASODILATOR Nifedipine Retard 20 mg b.d.
CENTRALLY ACTING DRUG 
OTHER THERAPY
ADVERSE EFFECTS RAYNAUD'S-ATENOLOL, REFLEX TACH-PRAZOSIN
APPOINTMENT CYCLE 8 WKS INITIAL WT. (KG) 52.2
NO. OF APPTS.MISSED 4 INITIAL OBESITY INDEX 22.89
BP CONTROL (SUBJ) S
DATE FOR ANNUAL REVIEW 00/08/85 TYPE OF HYPERTENSION - ESSENTIAL
BIOCHEMISTRY CHOLESTEROL 8.1 GLUCOSE 5.7 URATE 0.2
CREATININE 100 POTASSIUM 4.2 GAMMA GT 34
PROTEIN IN URINE N GLUCOSE IN URINE N
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were no further changes to the Hypertension clinic database structure or dedicated 
software, but the LAN allowed password protected access to the database from a 
number of stations and allowed for a larger database.
2.5. Clinical Audit
From the first year, pertinent data were tabulated annually as of 1 September 
and reported to the rest of the team. A complete copy of the database was obtained 
and archived for future analysis. Age, sex, weight, blood pressure ranges and drug 
treatment regimes were a particular focus. Serum cholesterol values were added to 
the review in the fourth year. In the fifth year, risk factor changes were assessed for 
the cohort of patients who had attended the clinic from its first year. An overview of 
these data can be found in Chapter 3.
2.6. Statistical analysis
During years 1-3 (1981-1984), data were analysed manually. Once the Apricot 
personal computer was available, data were analysed using LOTUS 123 version 1.0 
(Lotus Corporation) and dBase II (Ashton-Tate). It was also exported to the 
university's ICL 3980 mainframe computer for further analysis by MINITAB,
SPSSx, BMDP and RUMMAGE. Parametric and non-parametric tests, were applied 
as appropriate to the data.
Latterly, Quattro Pro version 3 (Borland) was used to edit and graph the data. 
In addition, MINITAB version 8 for the personal computer, was used to analyse 
additional audit data in Chapter 3. One way analysis of variance and chi-square tests 
were used.
The data from Chapter 4, the comparison with conventional hypertension care, 
were evaluated using SPSSx and MINITAB on the ICL 3980 mainframe. The 
mortality sub-routine of BMDP was used on the same system. The life-table analysis 
was generated according to the method described by Armitage (Armitage 1971) and 
was calculated without computer assistance.
Data were analysed for the Cholesterol Diet Study in Chapter 5, by repeated 
measures analysis of variance (ANOVA) and covariance (ANCOVA). For the
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ANCOVA, entry values were used as the covariates where appropriate. Bonferroni 
multiple comparisons and an overall confidence level of 95 % were also derived using 
RUMMAGE. Correlation analysis was undertaken as indicated using MINITAB.
Both of these statistical packages were run on the ICL 3980 mainframe.
The analysis of the guar study reported in Chapter 6, was carried out using 
MINITAB on the ICL 3980 mainframe and undertaken on an intention-to-treat basis. 
The changes in parameters were investigated by one way ANOVA. Power 
calculations were undertaken based on the method described by Day and Graham 
(Day & Graham 1989).
In Chapter 7, the evaluation of changing emphasis from hypertension follow-up 
to multiple cardiovascular risk factor intervention, data were analysed using the 
spreadsheet software Quattro Pro version 3 and version 4 as well as MINITAB 
version 8 for the personal computer. It is presented as mean +  standard deviation and 
percentages. One way analysis of variance, paired t-test and chi-squares were 
determined as appropriate.
Final spreadsheet analyses were undertaken and graphs generated using 
Quattro Pro for Windows version 5.0.
2.7. Ethical approval
All studies contained in this work have been passed by the local Stobhill 
Hospital/Northern District Research Ethical Committee.
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Chapter 3. Clinical Overview: 8 years of nurse practitioner care
3.0. Summary
A compilation of data from the 8 years of the nurse practitioner clinic is 
presented in this chapter. Results for the population continuing to attend at the end of 
each clinic year are included. Comparisons are made between those who entered the 
clinic each year.
3.1. Introduction
In 1981 when the Stobhill Clinic began, the clinic team realised the 
opportunity provided by having computer based clinical information. From the first 
year, regular annual compilations of sections of the data were carried out. It is now 
considered mandatory to review one's clinical practice, ie. audit.
The reviewing of clinical information has been a hallmark of medical practice 
for several millennia. Prior to the introduction of controlled clinical trials, it was one 
of the few ways in which advances in care were made. The regular systematic 
collection of information to compare against pre-set standards is a modem 
refinement. This form of review, now generally referred to as audit, was first 
seriously proposed by Donabedian in 1966 in the United States.
In an invited review of the methods for evaluating the quality of medical care 
research in the United States available at that time, Donabedian began talking about 
the need to identify the structure, process and outcome of care. The structure of care 
is the available resources that can be called upon to provide care, ie. educated 
nurses, specialist devices, etc. The process is how care is given. The outcome is the 
result. All three facets of care need to be evaluated in order to assess quality 
(Donabedian 1966).
Subsequent workers, particularly nurses in the United Kingdom, have taken up 
these concepts and have established a labour intensive, convoluted process of 
assessment called 'Standards of Care'. In this system specific standard statements are 
articulated with accompanying measurable structural, procedural and outcome
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measures delineated (Kitson 1989).
In the United Kingdom, medical audit came to prominence with the publication 
of the government white paper 'Working for Patients' in 1989 (Dept of Health 1989). 
In particular, the follow-up discussion document 'NHS Working Paper 6: Medical 
Audit', firmly threw down the gauntlet to medical practitioners. It outlined the 
requirement for the development of audit in each and every hospital with a locally 
appointed medical audit committee. There is also provision for audit committees to 
be set up at district and regional level and in general practice. It is interesting to note 
that it did not specify methods, it only demanded action (Dept of Health 1989).
It is important to be aware that recent thinking considers research and audit as 
two distinctly different activities with many aspects in common (Patterson 1986, 
Smith 1992). The impression in Donabedian's early work is that quality assessment is 
a form of research (Donabedian 1966).
Research can be defined as a:
"rigorous and systematic enquiry, conducted on a scale and using 
methods commensurate with the issue to be investigated, and designed to 
lead to generalisable contributions to knowledge."
(Strategy for Research in Nursing 1993)
Richard Smith in an editorial in the BMJ in 1992 reported on a meeting 
discussing the differences between research and audit (Ihble 3.1) as well as the 
similarities. Each ask questions, has a defined purpose, require logical thought and 
both use similar methods. A list of some of the more commonly used methods 
alluded to is given in Thble 3.2. (Smith 1992). Patterson came to much the same 
conclusion in an earlier discussion in the Journal of the Royal College of General 
Practitioners (Patterson 1986).
The current review of a multi-disciplinary project, utilises some of the 
techniques employed in medical audit as outlined above and does not utilise the 
nursing standards of care methodology advocated by Kitson (Kitson 1989). This 
research project has benefited from and been extended by the continuous internal
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Table 3.1. Differences between research and audit.
Research
discovers right thing to do 
one off
complex, specialist data 
controlled, limited 
can generalise from 
can assess audit methods
Audit
ensures the thing is done right
ongoing
routine data
covers everything done
limited to local results and circumstances
can provide background for research
(Smith 1992)
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Table 3.2. Similarities in research and audit techniques.
Peer Review 
Questionnaires/ surveys 
Direct observation 
Self recording by staff 
Statistical assessment 
Spot checks of data/records 
Trend analyses 
Comparative analyses
(Smith 1992)
78
audit carried out while it progressed.
This chapter presents an overview of the annual clinical review of data.
Further chapters deal with specific in-depth studies generated directly from the 
questions posed by the annual reviews.
3.2. Aims
The concern each year was to review the data to answer the question:
'Are we doing what we think we are doing?' 
which then extended itself to the questions:
1. Are we controlling blood pressure?
2. What drugs are being used?
3. How many patients are overweight and are they loosing weight?
4. Have the smokers attending the clinic stopped smoking?
5. Who are we seeing?
6. How many patients are we seeing and how often?
7. How many patients are lost to follow-up and why?
In 1985, an additional question was asked:
What is the range of biochemical indices in our population, particularly glucose and 
cholesterol?
3.3. Methods
A complete copy of the clinic database was obtained on floppy disk annually at 
the beginning of September. Blood pressure, weight, enrolment, and lost to follow- 
up, were analysed yearly. Data were also analysed by years of follow-up, ie. by 
years of attendance.
Blood pressure was reviewed by assessing the percentage of patients with 
systolic blood pressure (SBP) >180, >  150 & <180, and <  150 mmHg and 
diastolic blood pressure (DBP) >110, >90 & <  110, and < 90 mmHg. These 
distributions were determined for initial blood pressures as well as last blood 
pressure measured during each year for those patients continuing to attend but not 
involved in a clinical trial (<  10% of population any year). Population averages and
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standard deviations were also calculated.
Initial and end of first year of attendance blood pressures were compared for 
patients entering each year. The reductions in blood pressure achieved during their 
1-12 months in the clinic were calculated and compared.
Thrget blood pressures were set for each patient as described in Chapter 2. 
These generally were 160/90 for patients >60 years old and 140/90 for those < 60 
years of age. The percentages of the population within target, 10 and 15 mmHg of 
their systolic blood pressure targets and within target, 5 and 10 mmHg of diastolic 
pressure targets were calculated.
Drug treatment was reviewed at the end of the first (1981/82), fifth (1985/86) 
and eighth (1988/89) years. The types of drugs used as well as specific drugs were 
identified. The percentage of patients on mono, double and triple therapy was also 
noted. The drug treatment prescribed for those first attending these years has also 
been identified and compared.
Change in weight over time was investigated. The group of patients attending 
during the first 3 years had their first year's weights compared with their weights 
after three years of attendance. In Year 8 (1988/89), weights were assessed and 
compared to initial weights upon entry to the clinic. Initial and end of first year of 
attendance weights were compared for patients entering each year. The reductions in 
weight achieved by the end of their first clinic year, were calculated and compared.
Smoking was recorded at entry, and, from Year 4 (1984/85), current smoking 
habit was included as part of every annual review. The number of cigarettes smoked 
per day was recorded. Patients who reported smoking cigars or pipes were rated as 
smokers. The percentage of smokers of each sex entering the clinic each year was 
also noted.
Alcohol intake was initially rated as 'none', 'moderate' or 'heavy'. With the 
advent of version 2 of the database system, alcohol intake was recorded as grams of 
alcohol consumed per week (10 grams =  1 unit).
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Cholesterol and glucose values were measured at least annually from 1985 
onwards, with the first year values assessed retrospectively in 1985 by entering the 
data from an archived printout. Potassium, creatinine, urate and gamma-GT were 
also checked annually at annual review.
With the Commodore system, printouts of data were analysed manually for 
Years 1-3 (1981-1984). The Apricot system from Year 4 (1984/85) allowed most of 
the analysis to be carried out using dBase II then dBase III, once it was available, as 
well as LOTUS 123 version 1.0. Follow-up analysis was undertaken using Quattro 
Pro 3.0, Quattro Pro 5 for Windows and MINITAB version 8 for the personal 
computer. The partitioning method described by Siegel and Castellan was used for 
the chi-square post-hoc analysis to identify where the significant differences were in 
the contingency tables (Siegel & Castellan 1988). for those t-test analysis with 
differences in sample size, the method described by Snedecor and Cochran was used 
(Snedecor & Cochran 1967).
3.4. Results
3.4.1. Are we controlling blood pressure?
The assessment of blood pressure was the major focus of the clinic and it was 
summarised in several ways. Blood pressure distribution was assessed each year as 
an indication of control (Figures 3.1. and 3.2). There was no significant difference in 
the total population's initial systolic or diastolic blood pressure distribution over the 8 
years.
There were significant changes in the distribution between initial and last visit 
blood pressures each year by chi-square analysis for those patients continuing to 
attend (Ihble 3.3). The distributions of last visit blood pressures were significantly 
different between years for systolic (X1=24.94507, df=14, p<0.05) and diastolic 
blood pressure (Y2=30.69702, df=14, p<0.01). Partitioning revealed that Year 7 
last visit distribution was significantly different from Year 3 for systolic (Xz= 8.326, 
d f = l ,  p < 0.005) and diastolic blood pressure (X2—16.474, d f = l ,  p < 0.0005) and 
Year 6 was significantly different from Year 3 for diastolic blood pressure only
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Figure 3.1. Distribution of initial and last visit systolic blood pressures.
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Figure 3.2. Distribution of initial and last visit diastolic blood pressures.
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Table 3.3. Chi-square analysis results comparing initial with last visit blood 
pressure distributions each year for population continuing to attend.
df Chi-square p value
Systolic blood pressure
Year 1 1981/82 2 60.223 < 0.0005
Year 2 1982/83 2 115.084 < 0.0005
Year 3 1983/84 2 150.952 < 0.0005
Year 4 1984/85 2 193.315 < 0.0005
Year 5 1985/86 2 211.585 < 0.0005
Year 6 1986/87 2 225.606 < 0.0005
Year 7 1987/88 2 232.533 < 0.0005
Year 8 1988/89 2 264.286 < 0.0005
Diastolic blood pressure
Year 1 1981/82 2 230.381 < 0.0005
Year 2 1982/83 2 273.513 < 0.0005
Year 3 1983/84 2 230.381 < 0.0005
Year 4 1984/85 2 273.513 < 0.0005
Year 5 1985/86 2 273.692 < 0.0005
Year 6 1986/87 2 333.557 < 0.0005
Year 7 1987/88 2 370.938 < 0.0005
Year 8 1988/89 2 352.869 < 0.0005
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(X2=5.603, d f = l ,  p < 0.025). To evaluate these differences further, the blood 
pressures of those entering as new patients each year were also analysed.
Average initial blood pressures for those entering the clinic each year are 
plotted with the total population average initial blood pressure for that year, in Figure
3.3. One-way analysis of variance yielded significant differences between years for 
systolic blood pressure (p < 0.001) and diastolic blood pressure (p < 0.001). Tukey 
post hoc multiple comparisons (MINITAB 1991) showed that those entering Years 6 
and 7 had significantly lower systolic and diastolic blood pressures at entry compared 
to earlier years (Thble 3.4).
One-way analysis of variance of last visit systolic blood pressure for end of 
first year of attendance for those entering each year was non-significant. The end of 
first year of attendance diastolic blood pressure was statistically significant 
(p<0.05), but Tukey post hoc multiple comparisons failed to identify a significant 
difference between any two years, thus indicating that any between year differences 
in blood pressure control achieved within the first few months of attendance, are 
marginal.
Mean systolic and diastolic blood pressures compared with entry values are 
shown in Figure 3.4. As with the shift in blood pressure distribution, there is a 
significant difference between entry and last visit mean values each year (p<  0.001). 
There is a significant difference in mean last visit diastolic blood pressure between 
the Year 1 population of 191 and the Year 8 population of 700 patients (88 ±  10 vs 
84 ±10 mmHg) at p <  0.001 by unpaired t-test which was corrected for unequal 
sample size according to the method described by Snedecor and Cochran (Snedecor 
& Cochran 1967).
Blood pressure was also evaluated against the target blood pressure set for 
each patient and these are reported for Year 5 (1985/86) and Year 8 (1988/89) as a 
comparison (Table 3.5). 75% of patients were within 15 mmHg of their systolic 
targets for both years assessed, while 92% were within 10 mmHg of their diastolic 
target.
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Figure 3.3. New patient versus total population mean initial blood pressure.
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Figure 3.4. Blood pressure means and standard deviations.
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Table 3.5. Percentage of patients within 10 and 15 mmHg of systolic blood pressure 
target as well as within 5 and 10 mmHg of diastolic blood pressure target.
Year 5 Year 8 
(1985/86) (1988/89)
Systolic Blood Pressure
within target 44% 47%
within 10 mmHg 68% 71%
within 15 mmHg 76% 79%
Diastolic Blood Pressure
within target 71% 75%
within 5 mmHg 84% 87%
within 10 mmHg 92% 92%
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3.4.2. What drugs are being used?
Drug treatment strategies changed slowly over the years of the clinic. Initially, 
step-care was the advocated regimen. The percentage of patients receiving specific 
drugs and combinations is given in Thble 3.6. The use of beta blocking and diuretic 
agents has declined, whereas the use of calcium antagonists and angiotensin 
converting enzyme (ACE) inhibitors has increased. Centrally acting agents (e.g. 
methyldopa, clonidine, etc) were no longer being prescribed by Year 8 (1988/89). 
Despite its declining use, atenolol was still the most commonly prescribed medication 
for the treatment of high blood pressure in this clinic.
The choice of drugs used in combination also changed over time (Thble 3.7). 
The use of the beta blocker-diuretic combination was reduced to a third of its initial 
use by Year 8 (1988/89) when compared to Year 1 (1981/82), while the use of 
diuretics combined with vasodilators increased.
The percentage of patients who continued to attend the clinic on no treatment 
remained similar over time (Thble 3.8). The percentage of patients taking only a 
single agent increased from 25% to 40%, whereas the use of triple therapy declined 
by half (21 % to 10%). Despite these apparent major shifts in the number of drugs 
prescribed per patient to control blood pressure, there was no significant difference 
in the distribution by chi-square analysis.
3.4.3. How many patients are overweight and are they lojsing weight?
It was noted during the first year that many patients in the clinic were obese. 
The distribution of body mass indexes (BMI) did not change over the years for the 
clinic population as a whole (Figure 3.5), but it became apparent that some patients 
lost weight, while others gained. Changes in weight were investigated by comparing 
differences between Year 1 and Year 3 with differences between Initial and Year 8 
weights, by sex. The distribution of weight gain/loss changed significantly for men 
between the two assessments (Figure 3.6). Despite an increase of a more than half in 
the percentage of men losing greater than 2 kg over time (22% vs 36%), the 
percentage gaining more than 2 kg doubled (13% vs 27%) (X2= 17.332,
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Table 3.6. Changes in anti-hypertensive drug treatment over time.
Year 2 year 5 Year 8
Drug Treatment (1981/82) (1985/86) (1988/89)
Beta blockers 70% 57% 52%
Atenolol 64% 53% 49%
Propranolol 6% 2% 2%
Metoprolol 1 % 1 %
Other beta blockers 1 %
Diuretics 58% 46% 33%
Neo-Naclex 43% 16% 13%
Chlorthalidone 11% 22% 12%
Frusemide 3% 4% 6%
Modiuretic 1% 2% 1%
Other diuretics 2 % 1 %
Vasodilators 21% 44% 54%
Nifedipine Retard 4% 25% 27%
Verapamil 6% 6%
Diltiazem 3 %
Captopril 3% 1% 1%
Enalapril 10% 14%
Prazosin 4% 2% 1%
Doxazosin 1 %
Hydralazine 10% 4% 1%
Centrally Acting 3% 1%
(alone or in combination)
Other Drug Treatment
GTN 4%
Aspirin 4%
Dipyridamole 1 %
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Table 3.7. Changes in anti-hypertensive drug treatment combinations over time.
Year 1 Year 5 Year 8
Drug Treatment (1981/82) (1985/86) (1988/89)
Monotherapy
Beta blocker alone 19% 15% 20%
Diuretic alone 5 % 3 % 3 %
Vasodilator alone 13 % 17 %
Combinations
Beta blocker +  diuretic 51% 18% 10%
Atenolol +  bendrofluazide 15% 8% 3%
Atenolol +  chlorthalidone 36% 20% 6%
Beta blocker +  diuretic 19% 16% 9%
+ vasodilator
Beta blocker +  vasodilator 1% 7% 12%
Diuretic +  vasodilator 1 % 7 % 11 %
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Ikble 3.8. Changes in the number of drugs prescribed per patient over time.
Year 1 
(1981/82)
Year 5 
(1985/86)
Year 8 
(1988/89)
No treatment 17% 18% 15%
Single drug 25% 31% 40%
Two drugs 37% 32% 33%
Three drugs 21% 15% 10%
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Figure 3.5. Distribution of last visit body mass indexes over 8 years.
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Figure 3.6. Weight changes in men and women compared Year 1 with Year 3, and 
Initial with Year 8.
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df=2, p <  0.0005). This indicated, that by Year 8, the distribution of weight change 
in men was similar to that seen in women.
In addition, for those continuing to attend at the end of Years 5 and 8, changes 
in weight were compared by initial BMI gradings for all patients. There were no 
significant differences in the Year 5 population. In Year 8, patients with an initial 
BMI of 25.00 - 30.00, on average lost 1.0 kg in weight over their attendance in the 
clinic (3 months-8 years) compared to 0.2 kg gain for those with initially normal 
grade of 20.00 - 24.99 (p<0.05). Obese men with initial BMI > 30 lost 1.5 kg on 
average compared to a gain of 0.5 kg in males with initial BMI 20.00 - 24.99 
(p<0.05).
A similar analysis undertaken in new patients showed a 1.3 kg reduction in 
weight in those with initial BMI > 30 of during their first year of attendance. One­
way analysis of variance showed that this was a significant reduction in weight in 
comparison to those with BMI 20-24.99 who had gained 0.4 kg by the end of their 
first year of attendance (p<  0.001). Thus, the average weight changes identified 
between initial and Year 8 weights occurred during the first year and were 
maintained over time.
3.4.4. Have the smokers attending the clinic stopped smoking?
The percentage of patients who reported that they smoked generally declined 
over time apart from a slight increase in Year 4 (1984/85) when there was a change 
over in computing systems. All smoking data were entered prospectively as patients 
attended that year, so that at the time of the end of year audit, 21 % of patients had 
not had their smoking status updated (Thble 3.9). The changes in smoking over time, 
excluding Year 4 data, were not significant by chi-square analysis. There was no 
significant difference in the proportion of men and women smoking.
The number of cigarettes reported to be smoked each day by smokers declined 
over the years. In Year 1 (1981/82), 20% of smokers smoked more than 20 
cigarettes per day, while by Year 8 (1988/89) 7% reported smoking more than 20 
cigarettes per day. Those reporting smoking 10 or fewer cigarettes per day increased
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Table 3.9. Percentage of patients reporting smoking at the end of each year 
compared with percentage of new patients that year who reported 
smoking.
Percentage Percentage 
YEAR Total Without Smoking Percentage
Population Information New Patients
1 1981/82 39.1% 3.1% 40.3%
2 1982/83 34.1% 2.0% 26.5%
3 1983/84 35.0% 4.3% 36.6%
4 1984/85 36.1% 21.0% 32.4%
5 1985/86 32.6% 7.4% 26.3%
6 1986/87 31.3% 4.3% 31.8%
7 1987/88 28.4% 1% 22.6%
8 1988/89 27.8% <1% 30.7%
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from 44% to 57%. These shifts in the number of cigarettes smoked were significant 
over time by chi-square analysis, again excluding Year 4 data (Y2=25.840, df=12, 
p <  0.025).
At the end of Year 3, smoking levels were compared with entry levels for all 
reported smokers (31.1% vs 29.3%), males (30.2% vs 26.3%) and females (33.3% 
vs 31.8%), thus showing very modest reductions during attendance at the clinic (1 
month - 3 years). Smoking rates by sex in the clinic are plotted against the Scottish 
national averages (Information & Statistic Division 1990) for the same year in Figure
3.7. The rates for the 1986 MONICA survey in North Glasgow are also noted in the 
figure (Smith et al 1988). The percentage of clinic patients of each sex who smoke 
was consistently less than that for the general Scottish population and for the North 
of Glasgow. While the percentage of female smokers in the general population 
increased slightly with time, in the clinic, the percentage decreased.
Changes in smoking were analysed at the Year 5 (1984/85) annual review by 
comparing current status to the previous year's status for each patient, thus 
identifying more activity in attempts to change smoking habits than the stop smoking 
rate indicated (Table 3.10). Unfortunately, the 3.1% (11) patients who reported that 
they had stopped smoking, was offset by the 0.8% (3) who admitted that they had 
resumed, as was the 5.3% (19) who reported a decrease in the number of cigarettes 
smoked per day, by the 2.8% (10) who admitted smoking an increased number of 
cigarettes per day, from the previous year.
3.4.5. Who are we seeing? - Age/sex distribution
Initially, there was a relatively equal distribution of males and females in the 
clinic (48% vs 52%). However, latterly the men were outnumbered by the women 
(43% vs 57%), but the change in distribution between Years 1 and 8, was not 
significant by chi-square analysis (Table 3.11). There was no significant difference 
in the sex ratio of new patients that entered each year.
A summary of the percentage of each sex by age group over the 8 years of the 
clinic is given in Thble 3.12. During the early years of the clinic, there were more
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Figure 3 .7 . Smoking levels compared with Scottish percentages by sex including 
results from the North Glasgow cohort of the MONICA project.
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Table 3.10. Changes in reported smoking status between Year 4 (1984/85) and 
Year 5 (1985/86) for patients with smoking data both years.
Number
Smoking 119
Stopped smoking 11
Decreased number 19
smoked
Resumed smoking 3
Increased number 10
smoked
Percentage of 
Population with Smoking 
Data both years
33.1%
3.1%
5.3%
0 . 8%
2 .8 %
100
Table 3.11. Percentage of males and females continuing to attend each year.
1 1981/82
2 1982/83
3 1983/84
4 1984/85
5 1985/86
6 1986/87
7 1987/88
8 1988/89
Males
48% (101) 
49% (155) 
46% (187) 
47% (233) 
45% (239) 
44% (276) 
42% (274) 
43% (302)
Females
52% (108) 
51% (160) 
54% (216) 
53% (261) 
55% (294) 
56% (350) 
58% (371) 
57% (403)
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younger women and older men. Initially 22% of the women versus 12% of the men 
were 40 years old or younger, while 37% of the men versus 22% of the women were 
over 60 years of age. The percentage of younger women declined and the percentage 
of older women increased. By Year 8 (1988/89) 16% of the women were 40 years 
old or younger and 33% were over 60 years. These shifts in distribution were non­
significant by chi-square analysis and represent an aging clinic population continuing 
to attend.
3.4.6. How many are we seeing and how often? - Enrolment and attendance
There were 247 patients enrolled from the outpatient clinics during the first
year of operation. In subsequent years enrolment of new patients to the clinic 
averaged about 125 per year. Non-attendance rates averaged about 10% per year as 
did cancellations. The population continuing to attend grew yearly by approximately 
100 patients per years. Annual totals are given in Thble 3.13.
The number of years of attendance is given in Thble 3.14. Nearly half of those 
who enrolled during the first year of operation had last visit data in Year 8.
3.4.7. How many were lost to follow-up?
Those patients no longer attending were tracked and the reasons noted. A 
summary by year is given in Thble 3.15. It can be seen that relatively few patients 
were lost to follow-up through non-attendance. The general practitioners of those 
who failed to attend were notified, to give them the opportunity to 'recapture' their 
patient's care.
The 146 who failed to attend over the 8 years included 13 patients who were 
repeat attenders. One lady re-entered the clinic 4 times after failing to attend for 
three appointments each time. In total, only 123 individuals (11%) out of the 1091 
referred were lost due to non-attendance. The other major reasons for patients not 
attending were (a) returning to their general practitioner for care either at their own 
request or that of their general practitioner (9%), and (b) death (8%).
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Table 3.13. Number of patients enrolled each year and continuing to attend.
Number Number Currently
Enrolled Attending
Year 1 1981/82 247 209
Year 2 1982/83 129 315
Year 3 1983/84 120 403
Year 4 1984/85 121 494
Year 5 1985/86 95 533
Year 6 1986/87 134 626
Year 7 1987/88 137 645
Year 8 1988/89 108 705
Total 1091
Table 3.14. Years of attendance.
Number of Number of
Years of Attendance Patients Attending
8 112
7 86
6 98
5 83
4 105
3 140
2 177
1 251
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3.4.8. What happened to biochemical indices, particularly cholesterol and 
glucose?
The mean and standard deviations for all biochemical indices each year are 
given in Thble 3.16. Total cholesterol decreased significantly between Year 6 
(1986/87) and Year 7 (1987/88) at p <  0.001 by unpaired t-test. The changes in 
cholesterol will be presented in detail in Chapters 5 and 7. There was a non­
significant rise in blood glucose between Year 1 (1981/82) and Year 4 (1984/85).
The standard deviation for GammaGT was greater than the mean due to a small 
number of patients who had quite elevated levels due to admitted excessive alcohol 
intake.
3.5. Discussion
The annual review of clinic data has shown the impact of nurse practitioner 
care in the population continuing to attend at the end of each year. First and 
foremost, blood pressure rapidly came under control, and control was maintained 
over time for the majority of patients. In addition, drug treatment regimens were 
simplified, with more patients taking less drug therapy without loss of blood pressure 
control. This level of control is in sharp contrast to that which has been previously 
reported in general practice in Scotland (Hawthorne et al 1974, Ritchie & Currie 
1983, Smith et al 1990). The level of diastolic blood pressure achieved is in keeping 
with that obtained within clinical trials such as the HDFP (HDFP Cooperative Group 
1979).
Despite differences observed between years in the initial systolic blood 
pressures of new patients, by the end of their first year of attendance there were no 
significant differences in last visit pressure. Bulpitt et al demonstrated, using the 
DHSS computing project data, that achieved blood pressure predicted outcome far 
better than initial or entry measurements (Bulpitt et al 1988).
Body mass index did not change. Very modest (1.3 kg), but significant, 
reductions were noted in those with BMI > 30 within their first year of attendance.
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Similar reductions were observed when comparing initial weight with last visit 
weight for those continuing to attend at the end of Year 8. Therefore, the average 
reduction in weight observed during the first year in the nurse practitioner clinic 
were present over time. These changes are similar to other reports of long term 
weight reduction in an outpatient hypertension clinic (Straznicky et al 1991).
Reported levels of smoking declined over the years and were much reduced 
compared to Scottish averages (Figure 3.7). Reporting bias cannot be ruled out, but 
it would appear that a number of these patients had stopped smoking prior to their 
attending, so that those who continued to smoke were likely to be individuals who 
found it difficult to stop. Yet, a few more managed to stop each year.
Continued attendance in this clinic has been shown to be high, with only 11 % 
of those enrolled lost due to non-attendance, and 65 % continuing to attend at the end 
of 8 years. This result is in marked contrast to a report from the Glasgow Blood 
Pressure Clinic which was only able to report on the 16% of its enrolled population 
who had 3 years of continuous data (Johnston et al 1980).
It is unlikely that the participation in clinical trials of patients attending the 
nurse practitioner clinic has affected these results as patients may or may not have 
had uncontrolled blood pressure at the time of their recruitment, and no more than 
10% of the population participated any year. In addition, if a patient was in a clinical 
trial at the time of the annual audit, their data were withheld from the analysis.
A vast quantity of routine clinical data have been generated over the course of 
this project. The regular annual reviews and other analyses have stimulated the 
development of a number of projects which are presented in subsequent chapters of 
this thesis.
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Chapter 4. Comparison of nurse practitioner care with conventional 
hypertension clinics
4.0. Summary
In this chapter, the nurse practitioner clinic (NPC) is compared with a 
conventional hypertension clinic (CHC). Clinical care of patients enrolled in both 
clinics between 1 September 1981 and 1 September 1982 is compared initially at 
entry, and after 1 and 4 years of follow-up. Mortality over 6 years is reported and 
discussed.
4.1. Introduction
Nurses, working in a variety of settings, have been involved in screening for 
hypertension and caring for the individuals subsequently found to be hypertensive 
since the mid-1960's as described in detail in Chapter 1. Much of this original work 
was carried out in North America. In addition to traditional outpatient clinics and 
community clinics, the care settings have included department stores (Alderman & 
Scholenbaum 1975), and other worksites (Logan et al 1979, Logan et al 1983).
One of the few comparisons reported was Runyan's community care study 
which compared follow-up care received for diabetes, hypertension, cardiac disease 
or a combination of these provided by nurse practitioners in decentralised clinics near 
their homes. Overall there was less hospital utilisation by patients followed by the 
nurse practitioners. Diastolic blood pressure was also significantly reduced (Runyan 
1975).
In a Canadian study, Ramsay et al compared nurse practitioner versus medical 
follow-up in matched groups of 40 out-patients over 15 months. Diastolic blood 
pressure was reduced and weight decreased in obese patients cared for by the nurse 
practitioner. There was no difference between the groups for levels of attendance 
(Ramsay et al 1982).
An Israeli comparison study which followed 5,541 hypertensive patients 
attending community family health clinics, demonstrated improvements in the 
percentage of patients with controlled diastolic blood pressure. During care by a
110
physician alone, only 42.1% had an average diastolic blood pressure < 95 mmHg
over 2 visits, while 2 years after commencing care by nurse/physician teams, 84.6%
had diastolic blood pressures at these levels (Viskoper & Silverberg 1985).
Unfortunately, of the studies reported above and in Chapter 1, only Ramsay's
compared the care provided by nurses/nurse practitioners in a hospital outpatient
clinic with traditional medical hospital outpatient follow-up (Ramsay et al 1982).
Most of these report on short term follow up of less than two years except for the
/
controlled clinical trials. In addition, only the controlled clinical trials looked at 
mortality over time as well as degrees of blood pressure control.
In order to assess the impact of our nurse practitioner clinic method of follow- 
up care, a study was devised to compare patients enrolled during the first year of 
operation with a group who had been seen in conventional hypertension clinics in two 
other teaching hospitals within the Greater Glasgow Health Board. They first 
attended during the same year, and their information was collected prospectively and 
incorporated into the Glasgow Blood Pressure Clinic (GBPC) database (Glasgow 
Blood Pressure Clinic 1972). Clinical data were compared initially, and after one 
year and 4 years. Mortality was analysed over 6 years of follow-up.
4.2. Methods
4.2.1. Referral sources
Referrals to all three hospitals for the management of hypertension came from 
general practitioners (secondary referral) or hospital specialists (tertiary referral). 
Patients at each clinic were initially seen by a physician, and it was the agreed policy 
of all the clinics to continue hospital based care for these patients.
4.2.2. Nurse Practitioner Clinic (NPC)
The NPC patients were seen by one of two experienced nurse practitioners for 
follow-up. The NPC is explained in detail in Chapter 2, but briefly the nurse 
practitioners measured blood pressure, body weight, and assessed general wellbeing. 
Patients were counselled regarding weight, smoking and compliance with drug and
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diet therapy. They were referred to medical staff for assessment of possible drug side 
effects or for poorly controlled blood pressure. Annually, patients were seen by a 
clinic physician and given a physical examination. Urinalysis and 12-lead 
electrocardiogram were carried out, and a venous blood sample was taken for 
biochemical analysis, including non-fasting glucose and total cholesterol.
Drug treatment in the NPC was based upon a step care approach as 
recommended by the United States National Committee on Detection, Evaluation and 
Treatment of High Blood Pressure (Joint Committee 1977). A beta blocker was first 
choice with the addition of a diuretic and vasodilator added, as required, to achieve 
target blood pressure. Treatment decisions were taken by medical staff. Thrget blood 
pressures were set according to age, with those patients under 60 years of age having 
a target of <  150/90 mmHg and those over 60 years a target of <  165/95 mmHg.
4.2.3. Conventional Hypertension Clinics (CHC)
In the CHC, patients were seen regularly by senior or junior medical staff. 
Several papers have described the functioning of these clinics (Ramsay et al 
1978,Isles et al 1986). Blood pressure and weight were measured at each visit and 
drug treatment recorded. An annual review, similar to that undertaken in the NPC, 
was part of the routine follow-up. Drug treatment was broadly similar, but less 
formalised, them the NPC's step care.
4.2.4. Data compared
NPC data were stored as previously described on a succession of 
microcomputers using software developed in house (Kelman et al 1982). The CHC 
data were stored on the Greater Glasgow Health Board's ICL mainframe computer 
using the GBPC's 'SWITCH' system (Kennedy 1968). The subset of data for those 
patients enrolled between 1 September 1981 and 31 August 1982 from the other two 
teaching hospitals contributing data to this system was obtained on a micro-floppy 
disc compatible with the NPC's microcomputer system. Thus both sets of data were 
collected prospectively.
Due to a substantial lack of data beyond four years in the CHC group, analysis
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was limited to attendance levels, supine blood pressure, weight, drug treatment, and 
routine biochemistry at the end of the first and fourth years of attendance. In 
addition, an assessment of the six year mortality in both populations was performed.
In order to obtain mortality data, all patients were traced up to 1 September 
1987. Patients enrolled onto the GBPC's 'SWITCH' system are recorded with the 
Registrar General’s office in Edinburgh, so that notification is given within 6 months 
if these individuals die. A copy of the death certificate is sent to and stored in the 
'SWITCH' office.
The NPC, when notified of a death, sent a letter to the patient's general 
practitioner asking for the cause of death. This information was used for analysis 
unless the patient had been enrolled onto 'SWITCH', in which case the death 
certificate cause of death was utilised. All NPC patients not enrolled onto 
'SWITCH', and no longer attending, were traced via correspondence with their 
general practitioner. The cause of death was noted for those who had died since 
leaving the NPC.
4.2.5. Data analysis
Data were analysed using either LOTUS 1-2-3 (Version 1A) on the 
microcomputer, or SPSSx, MINITAB and BMDP on the Glasgow University ICL 
3980 mainframe computer. Results are presented as means for initial, first year and 
fourth year data. Parametric and non-parametric tests were undertaken as 
appropriate. Life table analysis was done according to the method described 
Armitage (Armitage 1971) and without computer assistance.
4.3. Results
4.3.1. Results - All patients
There were 247 patients enrolled in the NPC clinic and 229 enrolled in the 
CHC clinics from 1 September 1981 to 31 August 1982. A summary of initial data 
for each group is presented in Thble 4.1. The patients attending the NPC were older 
(51 vs 48 yrs) than patients attending the CHC (p<0.02), starting blood pressures 
were not different but almost reach significance with p <  0.06 for supine systolic
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Table 4.1. Initial profile of all patients (Mean ±s.d. or percentage).
Age (years)
Sex (M/F)
Body Mass 
Index
% Smokers
Supine Systolic 
Blood Pressure
% with SBP
< = 150 mmHg
Supine Diastolic 
Blood Pressure
% with DBP
< = 90 mmHg
Cholesterol
(mmol/1)
Glucose
(mmol/1)
Potassium
(mmol/1)
Urate
(mmol/1)
Creatinine
(/xmol/1)
Gamma GT 
(iu/1)
NURSE CONVENTIONAL
PRACTITIONER HYPERTENSION
CLINIC CLINIC SIGNIFICANCE
51 48 p <  0.02
±13 ±14
119/128 112/117
27.21 26.90
±4.54 ±4.56
41% 47%
175 169 p <  0.06
±31 ±30
28% 29%
103 101 p < 0.08
±16 ±14
23% 25%
6.3 6.2
±1.4 ±1.7
5.9 5.3 p <  0.10
±2.1 ± 1.8
4.0 3.9
±0.5 ±0.7
0.38 0.34
±0.12 ±0.10
100 97
±45 ±69
41 33 p <0.10
±33 ±42
blood pressure and p < 0.08 for supine diastolic blood pressure.
Follow up attendance differed markedly between the clinics over the four years 
(Thble 4.2). By four years, 70% of the NPC patients but only 33% of CHC were 
continuing to attend. There were also profound differences in favour of the NPC in 
the number of patients who had routine follow-up biochemistry data available at four 
years (Thble 4.3). While the NPC had values obtained in 91-100% of the patients 
attending, for each of the 6 biochemistry indices under consideration, only 13%-75% 
of the patients in the CHC had values for each of these biochemistry results.
Blood pressure control improved from initial values in both clinics during the 
four years of follow-up care (Figure 4.1). At the end of the first year, the average 
decrease in diastolic blood pressure of 15 mmHg in the NPC was statistically 
significantly greater than the 9 mmHg decrease in the CHC (p<  0.005).
Diastolic blood pressure was also statistically significantly lower in the NPC at 
four years (p < 0.005), with average diastolic blood pressure 85 +9 mmHg in the 
NPC and 89 ± 9  mmHg in the CHC. There were no statistically significant 
differences in systolic blood pressure between the groups at any of the time points.
Drug treatment initially and at the end of the first year are shown in Thble 4.4. 
Drug treatment regimens approximated 'step care' by the end of the first year. 
However, there were more patients receiving no treatment in the CHC initially and at 
the end of the first year.
Thus, preliminary data analysis revealed statistically significant age and 
diastolic blood pressure differences as well as minor differences in sex distribution 
between the groups. Further analysis was undertaken, as these differences might 
have influenced drug treatment choices and acceptability of blood pressure levels. 
This further analysis controlled for age and sex.
4.3.2. Results - Age and sex matched groups
Patients were matched retrospectively for sex and age (within 5 years), and 
198 patient pairs were obtained from the original NPC and CHC cohorts. A 
summary of the initial data for these matched groups from each clinic is given in
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Table 4.2. Attendance over 4 years in all patients.
Initial
Enrolment
At One Year
At Four Years
NURSE
PRACTITIONER
CLINIC
247 (100%)
191 (77%)
173 (70%)
CONVENTIONAL
HYPERTENSION
CLINIC
229 (100%)
167(73% )
76 (33%)
SIGNIFICANCE
n.s.
p < 0.001*
* Chi-square Y2= 64.692, df = 1
Table 4.3. Biochemistry results after 4 years of follow-up in all patients.
NURSE 
PRACTITIONER 
CLINIC 
(N = 173/247)
CONVENTIONAL 
HYPERTENSION 
CLINIC 
(N = 76/229)
Cholesterol 158 6.6 35 6.3
(mmol/1) ±1.3 ±1.7
Glucose 164 6.1 10 5.9
(mmol/1) ±2.3 ±1.1
Potassium 172 4.0 57 4.2
(mmol/1) ±0.4 ±0.5
Urate 172 0.38 45 0.39
(mmol/1) ±0.09 ±0.10
Creatinine 173 98 57 101
(jLimol/1) ±27 ±50
Gamma GT 173 35 51 37
(iu/1) ±32 ±46
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Figure 4 .L  Systolic and diastolic blood pressures for all patients.
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Thble 4.5. There were no significant differences in obesity, supine systolic blood 
pressure, supine diastolic blood pressure, percentage of regular to heavy drinkers, 
percentage of patients diagnosed as having essential hypertension or most 
biochemical indices. Gammaglutamyltransferase (Gamma GT) and urate were higher 
in the NPC, fewer patients were untreated and there were fewer reported smokers in 
that group.
Out of the 198 age and sex matched patients from each clinic, 160 in the NPC 
clinic and 147 in the CHC clinic were still attending at the end of the first year, but 
at the end of the fourth year there were 136 patients continuing in the NPC and only 
70 in the CHC. Even after one year there was a greater loss to follow-up (26%) in 
the CHC compared to the NPC (19%). By the end of four years, 65% of the CHC 
were not attending for follow-up while only 31 % of the NPC were no longer 
attending (p<  0.001). The disposition of those patients no longer attending after 4 
years is presented in Table 4.6.
As can be seen in Thble 4.5, there were no significant differences between the 
NPC or CHC groups in mean starting supine systolic or diastolic blood pressure. 
Supine blood pressures for the first and fourth years and their average differences 
from initial values are given in Thble 4.7. The percentages of patients with controlled 
blood pressure for their age at the end of one and four years compared with initial 
levels are in Figure 4.2. First year systolic blood pressure for the 114 remaining age 
and sex matched pairs was significantly different (p<0.05) by paired t-test. Overall, 
the NPC group achieved a greater reduction in both systolic and diastolic blood 
pressure over the first year of attendance, and had a higher percentage of patients 
with blood pressures less than or equal to the predetermined target. The difference in 
diastolic blood pressure extended into the fourth year for those patients continuing to 
attend.
Obesity was assessed in both groups using Body Mass Index (BMI) (WT/HT2). 
There was no difference in starting BMIs between the groups, or in weight change at 
the end of the first year. By the end of the fourth year there was no difference in
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Table 4.5. Initial profile of age and sex matched groups (Mean ±s.d. or 
percentage).
NURSE CONVENTIONAL
PRACTITIONER HYPERTENSION 
CLINIC CLINIC
Age (years) 50 49
±13 ±13
Sex M 92 M 92
F 106 F 106
Obesity Index 26.95 27.08
±4.30 ±5.12
% Smokers 37% 46%
% Regular to Heavy 29% 26%
Drinkers
Supine Systolic 173 171
Blood Pressure ±32 ±30
% Controlled SBP 30% 27%
(<.150 mmHg)
Supine Diastolic 102 101
Blood Pressure ±15 ±14
% Controlled DBP 24 % 25 %
(< 9 0  mmHg)
% Untreated 22% 32%
% Essential 87% 80%
Hypertension
Cholesterol 6.4 6.3
(mmol/1) ±1.3 ±1.5
Glucose 5.9 5.3
(mmol/1) ±2.3 ±1.8
Urate 0.38 0.35
(mmol/1) ±0.12 ±0.09
Potassium 4.0 3.9
(mmol/1) ±0.5 ±0.5
Creatinine 102 98
(umol/1) ±50 ±74
Gamma GT 40 28
(IU/1) ±33 ±31
SIGNIFICANCE
p< 0.05
p< 0.05
p<0.01
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Table 4.6. Disposition of age and sex matched groups no longer attending after 4 
years. +
NURSE
PRACTITIONER
CLINIC
Moved 8 ( 4 % )
To Other Medical Care 21 (11%)
(other clinics,
hospital admission, GPs)
Discharged 1
Died (during first 18(9%)
4 years of attending)
Non-attendance/ 15 (8%)
Lost to Follow-up
+  adjusted X2=54.1,df=4,p<0.001
CONVENTIONAL
HYPERTENSION
CLINIC
0
12 ( 6 %)
30 (15%) 
17(9%)
68 (34%)
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Table 4.7. First and fourth year supine systolic and diastolic blood pressures and 
differences from initial blood pressure values in age and sex matched 
groups.
Systolic 
Blood Pressure
Diastolic 
Blood Pressure
NURSE
PRACTITIONER
CLINIC
CONVENTIONAL
HYPERTENSION
CLINIC
X/s.d. X/s.d. 95 % Confidence Interval
Year 1 152
+24
156
+32
Difference 
Year 1-Initial
-24
+33
-16
+30
-14.5, -0.4+
Year 4 150 
+  18
147
+20
Difference
Year4-Initial
-24
+30
-26
±29
-5.9, 11.1
Year 1 88 
+10
92
±13
Difference 
Year 1-Initial
-15
±18
-9 
+  15
-9.9, -2.5*
Year 4 85
±9
89
+ 8
Difference
Year4-Initial
-18
±16
-13
±16
-9.5, -0.4+
+ p  <  .05
*p <  .005 by unpaired t-test
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Figure 4.2. Percentage of patients whose blood pressures were considered to be 
'controlled' adequately ( <  150/90 mmHg for age <  60 years and 
<  160/95 mmHg for age >  60 years) in the age and sex matched 
analysis.
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the mean change in weight from initial values for either group (0.3 kg vs. 0.9 kg). 
However, in severely obese patients with initial BMIs > 30 in both groups, the 
NPC patients had a mean loss of 2.8 kg versus a 0.5 kg loss in the CHC (Figure
4.3).
Initial drug treatment did differ between the groups. By the end of the first 
year there were fewer NPC patients on no drug treatment, more on a beta-blocker 
alone, and more on triple therapy with a beta-blocker, diuretic and a vasodilator. 
(The vasodilator category included hydralazine or prazosin in early years, and 
calcium antagonists, or ACE inhibitors in later years.) At the end of four years there 
were more NPC patients on no drug treatment, and the treatment regimens in the 
clinics were similar for those continuing to attend (Thble 4.8). The number of drugs 
prescribed in each clinic was highly significantly different initially and continued to 
be significantly different at 4 years (Thble 4.9).
More NPC patients had initial and follow-up biochemistry undertaken, and, 
thus, more results recorded and available for analysis. There was no difference by 
unpaired t-test between the groups for cholesterol, glucose, or creatinine, initially or 
at the end of the first or fourth years (Thble 4.10). Gamma GT was initially 
significantly different (p<0.01) as was urate (p<0.05), but there was no difference 
at the end of the first and fourth years. Potassium was significantly different at the 
end of four years (p<0.05), but levels were within the clinically acceptable range.
The disparity in the size of the groups at four years precluded further analysis, 
but emphasised the superiority of the NPC in collecting clinical information. 
Measurement of cholesterol and glucose in all patients at annual review was the 
agreed policy at both clinics as was continued hospital based follow-up.
The total number of deaths in each group over the four year study was similar 
(Thble 4.6) and the collection of mortality data was extended for a further 2 years in 
order to compare the rates with those previously measured in the Glasgow Blood 
Pressure Clinic (Isles et al 1986). At six years, the number of deaths in each group 
was not significantly different, with 25 in the NPC and 29 in the CHC. The
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Figure 4.3. Mean and 95% confidence intervals for weight change after 4 years in 
patients with initial BMI >  30.
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Table 4.8. Drug treatment initially and at the end of 4 years in age and sex matched
groups.
Initially +  Fourth Year +  +
NURSE
PRACTITIONER
CLINIC
(N=198)
CONVENTIONAL
HYPERTENSION
CLINIC
(N=198)
NURSE
PRACTITIONER
CLINIC
(N=136)
CONVENTIONAL
HYPERTENSION
CLINIC
(N = 70)
No drug 
treatment 43 (22%) 63 (32%) 21 (15%) 6 ( 9 % )
Beta-blocker
alone 40 (20%) 25 (13%) 25 (18%) 7 (10%)
Diuretic alone 8 ( 4 %) 15 (8%) 6 ( 4 % ) 4 (6%)
Vasodilator*
alone 0 1 8 (6%) 1 ( 1 %)
Beta-blocker 
and diuretic 53 (27%) 53 (27%) 34 (25%) 20 (29%)
Beta-blocker 
and vasodilator 7 ( 4 %) 6 ( 3 %) 12 (9%) 3 ( 4 % )
Diuretic and 
vasodilator 0 5 ( 3 %) 7 ( 5 % ) 4 (6%)
Diuretic and 
Methyldopa 0 11 (6%) 0 1 ( 1 %)
Beta blocker and 
diuretic and 
vasodilator 41 (21%) 9 ( 5 %) 23 (17%) 21 (30%)
Other treatment 6 ( 3 %) 10(5%) 0 3 ( 4 % )
* Vasodilator= alpha blocker or calcium antagonist or ACE inhibitor or direct 
vasodilator such as hydralazine
+  adjusted X2=30.221, df=6, p <0.0005 (cells with <  5 not included in analysis) 
+  +  n.s.
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Table 4.9. Number of drugs prescribed initially and at the end of 4 years in age and
sex matched groups.
Initially+ Fourth Year+ +
NURSE CONVENTIONAL 
PRACTITIONER HYPERTENSION
No drug 
treatment
One Drug
Two Drugs
Three Drugs
CLINIC 
(N=198)
43
48
60
41
CLINIC
(N=198)
63
41
75
9
NURSE
PRACTITIONER
CLINIC
(N=136)
21
39
53
23
CONVENTIONAL
HYPERTENSION
CLINIC
(N = 70)
6
12
28
21
+  X2=26.432, df=3, p<0.0005 
+  +  X>= 7.893, df=3, p<0.05
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Table 4.10. Fourth year biochemistry results in age and sex matched groups.
NURSE
PRACTITIONER
CLINIC
(n=136)
% X/s.d.
Cholesterol 93 6.7
(mmol/1) ±1.3
Glucose 96 6.0
(mmol/1) ±2.3
Urate 99 0.31
(mmol/1) ± . 10
Potassium 99 4.0
(mmol/1) ±0.4
Creatinine 100 98
(umol/1) ±28
Gamma GT 99 34
(IU/1) ±31
+  p< 0.05
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CONVENTIONAL
HYPERTENSION
CLINIC
(n= 70)
% X/s.d.
44 6.5
±1.4
14 5.9
± 1.2
57 0.39 
±.11
77 4.2 +
± 0.6
77 101
±52
66 37
±49
percentage of cardiovascular deaths was higher in the CHC at 79% (n=23) of deaths 
compared with 68% (n =  17) in the NPC, but it was not statistically significant. Life 
table analysis showed that the cumulative probability of surviving 6 years was 87 % 
in the NPC and 85% in the CHC (Thble 4.11). Mortality in both clinics in the early 
1980's appeared to be better than that reported for the Glasgow Blood Pressure 
Clinic in earlier years (Isles et al 1986).
4.4. Discussion
It has been demonstrated that a clinic utilising nurse practitioners with a 
microcomputer patient information system and physician back-up is effective (Rubin 
1984). Similar approaches involving nurses have been developed in a number of 
countries for the long term management of hypertension. These nurses have worked 
successfully in occupational health settings (Alderman & Scholenbaum 1975, Logan 
et al 1979, Logan et al 1983), hospital outpatient clinics (Lewis & Resnik 1967,
Clark & Dunn 1976, Laurent et al 1980, Wyka-Fitzgerald et al 1984), the 
community (Lindholm 1982), and in general practice (Mant et al 1989). However, 
all of the above mentioned studies looked at these clinical efforts alone and not in 
comparison with other forms of outpatient hypertension follow-up care.
Runyan compared follow-up care received for diabetes, hypertension, cardiac 
disease or a combination of these conditions provided by nurse practitioners in 
decentralised clinics near to their homes. This form of care was compared with 
traditional hospital based follow-up. Overall, there was less hospital utilisation by 
patients being followed by the nurse practitioners. Diastolic blood pressure was 
statistically significantly reduced in the nurse practitioner patients when compared 
with starting values for the group, as well as in comparison with the change in 
diastolic blood pressure of the control group (Runyan 1975). However, since this 
study compared care in the community with hospital follow-up, it is difficult to know 
how much the nurse practitioner affected outcome versus the switch to care in the 
community.
A more comparable study to the current one, was carried out by Ramsay
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et al in 1982 which investigated the care provided in a hospital outpatient setting by a 
nurse practitioner, and compared it with medical follow-up. The groups were small 
(40 patients) and follow-up was limited to 15 months. Blood pressure, weight and 
attendance were the only variables studied. For those continuing to attend, the nurse 
practitioner clinic had statistically significantly better blood pressure control and 
weight loss, but there was no difference in attendance or dropout rate (Ramsay et al 
1982).
Therefore, the current study is important since it does compare data collected 
prospectively from two very different forms of hospital outpatient care in groups of 
198 patients over an extended period of time. The results demonstrate that nurse 
practitioner follow-up is more effective than conventional medical clinics for the long 
term management of hypertension. The groups were well matched, with only three of 
sixteen initial variables being different (Table 4.5). By the end of the first year, the 
major difference between the two groups was the degree of blood pressure control. 
The NPC group had a greater reduction in both supine systolic and diastolic blood 
pressure. This trend continued and the NPC still had a greater percentage of patients 
with controlled systolic and diastolic blood pressure at the end of the fourth year 
(Figure 4.2). This is statistically significant and clinically relevant since the major 
aim of both clinics is the control of blood pressure.
The average decrease in first year blood pressure from initial values in the 
NPC group of 15 mmHg is similar to the 16 mmHg decrease found by Alderman and 
Schoenbaum's 1975 study of nurses following up hypertensive department store 
employees, but greater than the 12 mmHg decrease reported by Ramsay et al in their 
nurse practitioner group in 1982 after 15 months of follow-up (Ramsay et al 1982).
Thrget blood pressures were achieved after 4 years in 85 % of the NPC 
patients. This compares favourably to several Israeli studies which revealed 84.6% 
control in 5,541 patients after 2 years of follow-up and 73% control in 1,283 patients 
followed for 4 years (Viskoper & Silverberg 1985).
Analysis at the end of four years of follow-up was hampered by the differences
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in numbers of patients continuing to attend each clinic (136 at NPC vs. 70 at CHC in 
the age-sex matched groups). This observation alone was of considerable importance 
as the declared aim of both clinics was to provide long term hospital based care and 
supervision. The modest but greater reduction in weight in those who were obese at 
presentation in the NPC group reflected a particular emphasis on weight reduction 
and other dietary advice. It was consistent with earlier findings (Curzio 1987) and 
with the work of Israeli nurse/physician teams (Viskoper & Silverberg 1985).
The lack of biochemical data in the CHC after 4 years of follow-up (Table
4.3), precluded the identification in that population of individuals with developing 
diabetes, gout, renal failure, liver failure, hypokalaemia, and adverse changes in 
total cholesterol. Adverse effects on total cholesterol identified in the nurse 
practitioner clinic population stimulated changes in treatment strategies and the 
development of several projects to evaluate these changes (Chapter 5 and Chapter 7).
Mortality between the age-sex matched groups over 6 years was not 
significantly different, but fewer deaths were attributed to cardiovascular disease in 
the NPC. However, the groups are small, and 6 years is a relatively short time to 
evaluate the impact of a strategy of care on mortality, but no other clinically based 
study has assessed mortality in groups receiving alternative forms of follow-up.
4.5. Conclusions
A follow-up clinic, which utilises nurse practitioners for the management of 
hypertension, has shown better blood pressure control in a greater proportion of 
patients, maintained contact with a greater percentage of patients and collected data 
more reliably over the years on the risk factors needed to assess the effectiveness of 
care in the long term.
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Chapter 5. Effect of intensive lipid lowering dietary advice on 
hypercholesterolaemia in treated hypertensives
5.0. Summary
The introduction of regular, consistent lipid lowering advice in the clinic came 
in the form of a clinical trial to evaluate the effectiveness of intensive dietary 
intervention by dietitians over a 6 month period, which is reported in this chapter.
5.1. Introduction
It is well recognised that patients with both hypertension and 
hypercholesterolaemia are at greater risk of cardiovascular disease, regardless of 
their sex, than individuals with only one of these risk factors. Kannel and Dawber 
demonstrated this in the Framingham cohort (Kannel & Dawber 1974) as did The 
Renfrew and Paisley Survey (Isles et al 1992).
These major cardiovascular risk factors have been found to co-exist more than 
would be expected by chance. This 'clustering' of risk factors has been reported 
from Australia (MacMahon et al 1985) and the United States in the Lipid Research 
Clinics Program Prevalence Study (Criqui et al 1986). Such clustering was also noted 
in the Stobhill Hypertension Clinic, with 45 % of the patients having total cholesterol 
> 6 . 5  mmol/1 in 1987.
In addition, it has been postulated that the lack of efficacy of anti-hypertensive 
drug treatment regarding the reductions in coronary heart disease and cardiovascular 
disease may be due to lack of attention paid to co-existing risk factors (Reid 1988). 
Therefore, it has been suggested that, in addition to reduction of blood pressure, 
these patients may well require lipid lowering interventions.
5.1.1. Dietary intervention for hypercholesterolaemia
The first line of treatment advocated for hypercholesterolaemia is dietary 
modification. This recommendation comes from the European Atherosclerosis 
Society (Study Group, European Atherosclerosis Society 1987) and British 
Hyperlipidaemia Association (Shepherd et al 1987). The American Heart Association 
1988 Consensus Conference also identified it as the 'first logical step of treatment',
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but this group also admitted that its efficacy has not been proven (Gotto 1989).
Despite the obvious need for dietary intervention studies, there have been 
surprisingly few carried out, and only a minority investigated dietary changes alone 
in high risk individuals.
5.1.2. Studies in normolipidaemic individuals free of cardiovascular disease
There have been studies that have assessed the impact of diet on lipid levels in
healthy normolipidaemic individuals free of cardiovascular disease. Lewis and 
colleagues assessed a variety of diets, each lasting 5 weeks, in a group of 12 
normolipid monks, and found that there was a significant reduction with the intake of 
a fat-modified, fibre rich diet (Lewis et al 1981).
Weintraub et al assessed chronic and acute effects of different types of dietary 
fat in 8 normolipidaemic males under hospital conditions. Each diet was taken for 25 
days, and the greatest reduction in total cholesterol occurred on the diet high in w-3 
polyunsaturated fatty acids which are found in fish (Weintraub et al 1988).
Mensink and Katan assessed the impact of diets high in monounsaturated and 
polyunsaturated fats for 36 days in a group of 83 healthy men and women students 
after 17 days on a high saturated fat diet. They concluded that both diets were 
equally effective in lowering low density lipoprotein cholesterol (Mensink & Katan
1989).
All of these studies which were carried out in small numbers of normolipid 
individuals for relatively short periods of time, and only investigated the efficacy of 
diet in lowering cholesterol and lipoproteins. None assessed the long term impact of 
diet on mortality.
5.1.3. Studies in institutionalised individuals
Other investigators have manipulated the diets of institutionalised individuals 
with a range of lipid levels and whose diet can be more readily controlled. In the 
landmark Los Angeles Veterans Administration study, men living at the VA hostel 
were randomised to one of two dining rooms. In one dining room, the diet served
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had polyunsaturated fat substituted for saturated fat, and the cholesterol content was 
decreased. Over 6-8 years, the morbidity and mortality of the 424 men eating in this 
dining room were compared with that of 422 men eating the usual diet offered in the 
other dining room. Cardiovascular mortality was statistically significantly less in the 
intervention group, but there was no difference between the groups for all cause 
mortality (Dayton et al 1969).
In the Finnish Mental Hospital Study, men from 1 of 2 hospitals were given a 
diet in which polyunsaturated fat was substituted for saturated fat and the cholesterol 
content was reduced, while the men in the other hospital consumed a usual diet. 
After 6 years, the subjects in each hospital changed to the alternative diet for a 
further 6 years. Coronary heart disease (CHD) and all cause mortality was assessed 
in the approximately 4000 participants. For those consuming the modified fat diet, 
CHD mortality was significantly reduced, and all cause mortality was decreased, but 
not significantly, over the time the participants partook of the intervention diet 
(Turpeinen 1979).
Keys et al studied the effects of a variety of diets in groups of 24-38 mentally 
retarded residents of a state hospital and school to assess the variability in individual 
serum cholesterol response to changes in diet. The studies lasted from 3 to 10 weeks 
and the authors found a lack of consistency in responsiveness to dietary change in 
individuals between experiments (Jacobs et al 1983)
The Minnesota Coronary Survey was conducted in 4,393 men and 4,664 
women patients in 6 state mental hospitals and one nursing home in the late 1960's 
and early 1970's. This study used a diet low in saturated fat, high in polyunsaturated 
fat and low in cholesterol content. Most of the participants were on the diet for less 
than 2 years, but mortality was tracked for five years with no significant differences 
noted between the groups (Frantz et al 1989).
5.1.4. Diet studies in high risk groups
Several studies have investigated diet in post-myocardial infarction (MI) 
patients. Researchers from a group of London hospitals, assessed a 'fat modified'
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diet (decreased amount of saturated fat only) compared to usual diet in a group of 
post-MI men. In total, 264 subjects were randomised to either diet. There was no 
difference in relapse rate, ie. further MI or death due to MI, between the groups 
(Research Committee 1965). The Diet and Reinfarction Trial (DART) randomised 
2033 post-MI males to one of three diets for two years. The diets were 1) low in 
saturated fat, high in polyunsaturated fat, 2) at least 2 weekly portions of fatty fish, 
and 3) high in fibre. There was no significant reduction of total cholesterol in the fish 
or high fibre diet groups, and only a modest reduction of 3.6% in the low fat diet 
group. However, there was a 29% reduction in all cause mortality in the fish diet 
group (Burr et al 1989).
The Leiden Intervention Trial looked at angiographically assessed coronary 
artery lesion progression in 35 men and 4 women with angina who consumed a 
vegetarian diet for 2 years. Lesion progression correlated with total/HDL cholesterol 
ratio. Progression was significant in patients with higher values of the ratio (8.1 
±1 .7  vs 5.8 ±1.2). No progression was observed in patients either with lower ratios 
or who had initial high values which were significantly lowered by the intervention 
(Amtzenius et al 1985).
The St Thomas' Atherosclerosis Regression Study (STARS) used a low fat 
diet, high in omega-3 and omega-6 polyunsaturated fat and high in fibre, particularly 
soluble fibre in the form of pectin. This study demonstrated an increase in the 
frequency of luminal widening and fewer cardiac events in the diet only group of 26 
middle aged men with history of angina or MI compared to 23 untreated controls on 
their usual diet. Another group who received cholstyramine in addition to diet also 
showed an increased mean coronary diameter (Watts et al 1992).
5.1.5. Multiple risk factor studies
A number of the multiple risk factor studies have used diet as their sole 
intervention for hyperlipidaemia. The Oslo, MRFIT and European Trial of 
Multifactorial Prevention of Coronary Heart Disease studies have been described in
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detail in Chapter 1. In the Oslo Study a diet low in saturated fat, having some 
polyunsaturated fat and high in fibre was used (Hjermann et al 1981). The diet in 
MRFIT was low in saturated fat, high in polyunsaturated fat and low in calories for 
those who were overweight (MRFIT Research Group, 1990). The World Health 
Organisation European Trial of Multifactorial Prevention of Coronary Heart Disease 
dietary advice consisted of a cholesterol lowering diet that was low in fat, had an 
increase in polyunsaturated fat, and was high in fibre (WHO European Collaborative 
Group 1986).
The Toledo Exercise and Diet Study assessed whether exercise was additive to 
diet in a group consisting predominantly of women (49 of 66), with hyperlipidaemia, 
moderate to low fitness and a high fat, high cholesterol diet. Greatest reductions in 
total cholesterol were observed after 8 weeks of diet with no further reductions by 6 
months. There was no difference between the groups at the end of 26 weeks 
(Leighton et al 1990).
The Lifestyle Heart Trial instituted a low fat vegetarian diet, stop smoking 
counselling, stress management training and moderate exercise in 28 patients, and 
compared them with a group of 20 in a usual care group. All participants had 
angiographically documented coronary artery disease. After 1 year, intervention 
group subjects' average percentage stenosis was less while it was increased in the 
control group. The intervention group also reported reduced frequency, severity and 
duration of angina (Ornish et al 1990).
There is some difficulty in assessing the absolute impact of a single component 
of a multiple risk intervention. This is particularly so as the above studies were 
designed to investigate the effect of the combination of interventions.
5.1.6. Summary of diet studies
The majority of the studies presented above (10 of 15) were conducted in men. 
The Mensink and Martin study, DART, Leiden Intervention Trial, and Toledo 
Exercise and Diet Study together, involved a total of 89 women. Only the Minnesota 
Coronary Survey involved a substantial number of women (4,000), but this study is
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weak in that it reports 5 year mortality after less than a year of dietary intervention 
which occurred only when the patients were hospitalised.
The decreases in total cholesterol reported in the intervention groups of these 
studies range from 3.6% in the DART study (Burr et al 1989) to 29% reported by 
Lewis (Lewis et al 1981). This is a wide range of effectiveness, and it is interesting 
to note that the smallest percentage decrease in total cholesterol occurred in high risk 
angina patients.
5.1.7. Discussion of the impact of dietary intervention
The true magnitude of the cholesterol reduction induced by dietary 
modification, and its independent impact on coronary heart disease (CHD), was 
unclear until recently. The epidemiological evidence from around the world that 
people with lower levels of cholesterol have significantly lower mortality due to 
cardiovascular disease is impressive. The Seven Countries Study (Keys et al 1984), 
the Donolo-Tel Aviv Prospective Coronary Artery Disease Study (Brunner et al 
1987) the MRFIT screening cohort (Martin et al 1986) and the more recent Whitehall 
Study (Smith et al 1992) have shown this relationship.
In addition, studies that have looked at diet consumed and cardiovascular 
disease, have found that groups with higher intakes of saturated fat have higher CHD 
mortality. The Western Electric Study scored dietary intake according to fat intake 
and found a positive association, prospectively, between the mean base-line diet 
score and the 19 year CHD risk (Shekelle et al 1981). A similar scoring was used in 
the Ireland-Boston Diet-Heart Study with similar CHD mortality correlations to fat 
intake, but with additional decreased risk associated with higher fibre intake (Kushi 
et al 1985). Keys et al also found this relationship when looking at the 15 year 
mortality in the Seven Countries Study, as well as an inverse relationship between 
the intake of mono-unsaturated fatty acids and CHD (Keys et al 1986).
However, the evidence from individual clinical trials that lowering total 
cholesterol by dietary means decreases cardiovascular, coronary heart disease or all
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cause death rates is conflicting. As previously presented, the Finnish Mental Hospital 
Study (Turpeinen 1979) and the Veterans' Hospital Study (Dayton et al 1969) 
showed reductions in CHD (but not overall mortality), while the Minnesota Coronary 
Survey (Frantz et al 1989) and the Middlesex post-MI study (Research Committee 
1965) showed no significant effect.
There has been, and there continues to be, a controversy with respect to the 
impact of primary and secondary prevention trials on total mortality. Three major 
reviews were published in 1990 considering a number of the studies reviewed above 
as well as lipid lowering drug trials. Other experts have followed, and a further set, 
known as the 'Cholesterol Papers', were published in the British Medical Journal in 
1994 (Law et al 1994a, Law et al 1994b, Law et al 1994c).
Muldoon, Manuck and Matthews looked at 6 randomised primary prevention 
trials. They concluded that the association between reduced cholesterol levels and 
non-cardiovascular deaths warrants further investigation. In addition, the apparent 
lack of effect of cholesterol lowering on all cause mortality 'justifies a more cautious 
appraisal of the probable benefits of reducing cholesterol concentrations in the 
general population' (Muldoon et al 1990).
Rossouw, Lewis and Rifkind reviewed 7 secondary prevention trials and 
concluded that if 'gains are achieved in cardiac morbidity alone and not overall 
mortality this remains a net gain'. They argued that longer term follow-up of up to 
15 years may be required to demonstrate positive effects on mortality (Rossouw et al
1990).
Holme reviewed 19 studies including primary and secondary prevention trials 
which used single or multiple risk interventions. This review concluded that for each 
1 % reduction in total cholesterol there results an estimated 2.5% reduction in CHD 
incidence. However, it was briefly pointed out that what was gained by CHD 
reduction was lost on other fatal end points (Holme 1990).
It is interesting to observe that the concerns expressed by Muldoon, Manuck, 
and Matthews regarding non-cardiovascular deaths is 'downplayed' by not only
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Rossouw, Lewis and Rifkind but by Holme as well. Muldoon and Rossouw 
continued their discussions in an exchange of letters in a subsequent issue of the New 
England Journal of Medicine (Muldoon et al 1991; Rossouw et al 1991). Others have 
taken up the concerns expressed by Muldoon et al, Smith and Pekkanen called for a 
moratorium on the use of lipid lowering drugs (Smith & Pekkanen 1992) and Oliver, 
in a BMJ editorial, agreed except in the case of high risk individuals (Oliver 1992).
Smith et al confirmed this concept of the value of lowering cholesterol in high 
risk individuals in a meta-analysis of 35 single factor dietary or drug treatment trials. 
Trials were stratified by the low, medium and high risk of coronary heart disease 
experienced in each trial's control population. Benefit of treatment in terms of total 
mortality as well as coronary heart disease mortality, was only seen in those at high 
risk, with no benefit for those at medium risk, and adverse effects noted in those at 
low risk. In addition, the adverse effects on total mortality appeared to be confined to 
the drug treatment trials and not the dietary trials, indicating that cholesterol 
lowering itself doesn't increase the risk of non-coronary death (Smith et al 1993).
Law et al in the 'Cholesterol Papers' noted a systematic underestimation of the 
association between cholesterol concentration and ischaemic heart disease due to 
regression dilution bias, and a surrogate dilution effect. Using data from 21,515 
males aged 35-64 years from the British United Provident Association (BUPA) 
physical examinations, they demonstrated that the relationship between the two is 
stronger than previously shown and is age related, decreasing with increasing age. 
They estimated that a 10% reduction in cholesterol in a man aged 60 years is 
associated with a 30% reduction in ischaemic heart disease, and not 20% as 
previously thought (Law et al 1994a).
In a companion paper, Law et al conducted a meta-analysis of 10 prospective 
cohort studies, 3 international studies in different communities and 28 randomised 
controlled trials with mortality data. They concluded that the full effect of the 
reduction in risk is achieved within 5 years (Law et al 1994b).
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Thus the 'consensus' view is that lipid-lowering interventions are a means of 
reducing cardiovascular mortality and morbidity, particularly in individuals at high 
risk of coronary heart disease. Diet is invariably the first choice lipid-lowering 
intervention. Most of the previously cited diet efficacy studies were carried out in 
normolipidic individuals for relatively short periods of time, so that, additional 
longer assessment of lipid lowering diet alone in high risk individuals of both sexes is 
warranted.
5.2. Study aims
This study was designed to assess the impact of dietary advice for serum 
cholesterol reduction, over a 6 month period, in treated male and female 
hypertensives who were at additional cardiovascular risk with cholesterol levels 
greater than 6.5 mmol/1, the level above which both the British Hyperlipidaemia 
Association (Shepherd et al 1987) and the European Atherosclerosis Society (Study 
Group 1987) recommend 'action'.
5.3. Methods
5.3.1. Patients, anti-hypertensive drug treatment and stratification
A total of 141 well controlled hypertensive patients from the nurse practitioner 
Blood Pressure Clinic at Stobhill (described in Chapter 2) and who were found at 
annual clinical review to also have hypercholesterolaemia (defined as a serum total 
cholesterol > 6 . 5  mmol/1), entered this controlled trial. These patients had been 
attending the clinic regularly 1-3 times per year for from 2 months to 6 V2 years prior 
to recruitment and were invited to participate after being informed of their 
cholesterol levels.
Of the original 141 patients, 116 completed the study and an additional 8 
patients attended all but the 6 month visit. Of the remaining 17 patients: 7 defaulted, 
4 formally withdrew and the other 6 dropped out for various incidental reasons. The 
results therefore relate to the 124 patients who completed at least 3 months of the 
study.
Anti-hypertensive drug treatment was not changed over the course of the study
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(Tkble 5.1). Enrolled patients were stratified by anti-hypertensive drug treatment 
and then randomly assigned to one of 2 groups: Group \ ,-Advice Group received 
intensive and specific dietary advice for cholesterol reduction from a specialist 
dietitian and Group 2,-No Advice Group, attended the same sequence of clinic visits, 
but did not consult with the dietitian and received no specific dietary advice.
5.3.2. Other risk factor interventions
Patients had previously been given advice to stop smoking if a smoker and a 
weight reducing diet if obese (body mass index > 30). It had not been clinic policy 
at that time to routinely give detailed advice about cholesterol lowering diets or 
sodium intake. Patients received no additional advice over the 6 months of the study 
for these risk factors.
5.3.3. Visit schedule and measurement techniques
Following recruitment, patients reported after an overnight fast for an initial 
entry (baseline) visit, and then at 1, 3 and 6 months for further measurements of 
weight, blood pressure, serum total cholesterol, triglyceride and high density 
lipoprotein (HDL) cholesterol. At entry to the study and at 6 months, low-density 
lipoprotein (LDL) cholesterol and very low-density lipoprotein (VLDL) cholesterol 
were also measured.
Blood pressure measurement, weight measurement, and laboratory lipid 
analysis were carried out as described in Chapter 2.
5.3.4. Dietary advice and diet questionnaire
Patients in the Advice Group were seen by a hospital dietitian at each visit for 
diet history and specific individualised dietary advice. Diet I (Figure 5.1) was the 
basis for advice with those patients who had not been following a low 
cholesterol/high polyunsaturated fat/high fibre diet and whose previous cholesterol 
was > 6 . 5  but < 8 . 0  mmol/1. This diet followed the guidelines of the National 
Advisory Committee on Nutrition Education (NACNE) and the Committee on 
Medical Aspects of Food Policy (COMA) who recommend a reduction in fat to 30%
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Table 5.1. Anti-hypertensive drug treatment of patients studied.
DIETARY NO DIETARY
ADVICE ADVICE
N=61 N =63
No treatment 7% 13%
Beta blocker alone 18 % 17 %
Diuretic alone 3 % 3 %
Calcium antagonist alone 13% 3%
ACE inhibitor alone 3 % 5 %
Beta blocker +  diuretic 21% 22%
Beta blocker +  calcium 11% 6%
antagonist
Diuretic +  calcium 2% 3%
antagonist
Diuretic +  ACE inhibitor 7 % 5 %
Beta blocker +  diuretic +  10% 14%
calcium antagonist
Other drug treatment 5% 8%
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Figure 5.1. Diet I. (Front of sheet is at bottom, and inside on top of figure).
Diet 1
Diet For Those With 
High Blood Fat 
Levels (Cholesterol)
1) Eat Less Dairy Produce.
2) Reduce the amount of 
Cheese eaten, try 
Cottage Cheese 
instead.
3) Use Skimmed or Semi- 
Skimmed Milk (Do not 
take cream in any 
form).
4) Restrict Eggs to 2 - 3 
per week.
5) Eat less Meat and cut 
off visible fat, include 
more Fish & Poultry in 
your diet.
6) Avoid Pies, Pastries 
etc., as these are a 
high source of fat.
7) Use Polyunsaturated 
Margarine e.g..Flora or 
Low Fat Spread.
8) Corn Oil, Sunflower Oil 
(Flora, Mazola, etc.,) to 
be used for Cooking, 
Oils labelled simply 
"Vegetable Oil" are not 
suitable. Food should 
be grilled.
9) "Low Fat" products are 
a better choice to 
make.
10) Eat plenty fresh 
Fruit, Vegetables and 
Salads. Use only oil 
free salad dressing.
11) If overweight a 
Low Calorie Diet is 
advised.
12) Increase the fibre 
content of your diet by 
choosing Brown Bread, 
High Fibre Cereals, 
Wholewheat Pasta 
and Brown Rice.
TO LOSE WEIGHT
1) Cut Out Sugar In all Forms. 
(No Lemonade, Squash, 
Sweets, Cakes, Jam, 
Marmalade, Ice Cream).
2) Use Margarine/Oil 
sparingly (Avoid 
Fried Foods) 
including oils.
3) Take average helpings of 
Meat, Fish, Poultry, Eggs 
(3/week) and Cheese 
(1 /4  lb/week). If
taken in excess 
these foods can 
prevent weight loss.
4) Reduce the amount of 
Bread and Potatoes you eat.
5) Eat plenty Vegetables, 
Salads and Fresh Fruit.
6) Alcoholic drinks are a high 
source of calories and 
should be restricted.
7) Care should be taken with 
foods labelled "low calorie" 
they often have a significant 
calorie value.
Check Your Weight Against 
the Chart Below
MEN WOMEN
Height Weight Height Weight
6 '3" 
6*4* 
6 ' 6 " 
6 ' 6 " 
6 '7" 
6 ' 8 " B'S" 
6 ’ 10 ’ 
6 '1 11 0’
6 ’1 ’  e'2"
6'3"
9st 8lb 4 ' 
9*t 101b 6' 
10st 11b 6' 
10st 4lb 6' 
10st 8lb 6' 
10 s tl 1 lb 6' 
11st 21b 6' 
11st 61b B' 
11 s tl  11b 6' 
12st2lb 6 
12st7lb 6 
12st1 llbB 
13st1 lb 6 6
11 "8st 3 lb 
8 s t Bib 
1’8st 7lb 
2 '8 s t  Sib 
3 ’8st12lb 
4 "9st 11b 
6 '9 s t  Bib 
6"9st 81b 
7"9st111b 
8 '1 0 st2 lb  
9"10st6lb 
10"10st10lb 
1 1 'H s t  
11st4lb
STOBHILL GENERAL HOSPITAL
(Dietetic Department)
Healthy Eating Can Help 
Prevent Heart Disease,
A Few Simple Dietary Changes 
Can Be Beneficial
1) EAT LESS FAT
2) EAT LESS SUGAR
3) EAT MORE FIBRE 
(Wholemeal Bread, Fruit 
and Vegetables)
4) DO NOT ADD SALT AT TABLE
5) AVOID BEING OVERWEIGHT
DO NOT SMOKE
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of total energy intake, an increase in fibre to approximately 30 g, a reduction in the 
amount of refined sugar consumed and restriction to no more than 3 eggs per week 
(National Advisory Committee on Nutrition Education 1983, Committee on Medical 
Aspects of Food Policy 1984).
Diet II (Figure 5.2) was used for patients who had previously been following 
a relatively low cholesterol/high polyunsaturated fat/high fibre diet, or whose 
previous cholesterol values were > 8 . 0  mmol/1. This diet incorporated Diet I, but 
cholesterol intake was restricted to less than 250 mg daily by a reduction in the 
consumption of meat, and the restriction to 1 egg per week.
In addition, all overweight patients were also given weight reduction dietary 
advice (smaller portions, lower calorie food choices, etc).
A food frequency questionnaire was devised by the study dietitians to assess 
the dietary intake of saturated fat, polyunsaturated fat and fibre (Figure 5.3a and 
Figure 5.3b). All patients completed this questionnaire at entry and at the end of the 
study to measure the reported change in diet.
The study dietitians rated the contribution of each food frequency to a low 
cholesterol, high polyunsaturated fat, high fibre diet (Figure 5.4). A negative score 
indicated a diet high in saturated fat, low in polyunsaturated fat and low in fibre, 
while a high positive score indicated a diet low in saturated fat, high in 
polyunsaturated fat and high in fibre. The potential impact of each reported dietary 
change on an individual's total cholesterol was also rated. Changes in food frequency 
were identified by comparison of diet questionnaire responses at 6 months with entry 
responses (Figure 5.5). A positive change score indicated an 'improved' diet while a 
negative score indicated the individual's diet was higher in saturated fat, lower in 
polyunsaturated fat or fibre than previously reported.
5.3.5. Data analysis
Data were analysed by repeated measures analysis of variance (ANOVA) and 
covariance (ANCOVA). For the ANCOVA, entry values were used as the covariates 
where appropriate. Bonferroni multiple comparisons and an overall confidence level
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Figure 5.2. Diet II.
Stobhill Hospital 
LOW CHOLESTEROL DIET TYPE H
FAT Total fat intake should be reduced.
Modify fat by using fats of plant origin in place of fats 
of animal origin, e.g.,
Polyunsaturated margarine instead of butter (1/2 lb. per 
week) Com or sunflower oil instead of cooking fat or 
vegetable oil.
CHOLESTEROL Foods with a high cholesterol, high saturated fat content 
must not be taken (see list below).
must be very lean and taken no more than once per day.
Include more chicken, turkey and fish in your diet.
should be restricted to one per week.
has a very high cholesterol/high fat content and only low fat cottage cheese should 
be taken.
Increase the fibre in your diet by using wholemeal bread, 
bran cereal (All Bran, Weetabix, etc.) Fruit, Vegetables and Pulses (Peas, Beans, 
Lentils).
It is important you achieve and maintain your ideal weight. If overweight, omit 
sugar and all foods containing sugar. Eat small helpings, and reduce alcohol 
consumption.
Meat
Eggs
Cheese
FIBRE
WEIGHT
HIGH CHOLESTEROL/SATURATED 
FAT FOODS
Milk, "St. Ivel 5 Pints", Semi-skimmed 
milk, Evaporated Milk, Condensed Milk, 
Coffee mate, "Compliment", Dream 
Topping
Cheese - all varieties except Low Fat 
Cottage Cheese 
Egg Yolk
Butter, ordinary Margarine, St. Ivel 
Gold,Vegetable Oil, Lard, Suet 
Olive oil, Mayonnaise, Salad Dressing 
Lemon Curd
Fatty Meat, Sausages, Bacon, Liver, 
Kidney, Tripe, Sweetbreads, Spam,Pate, 
Meat Paste, Black Pudding 
Shellfish, Fish Roe
Cakes, Biscuits, Pastry unless made with 
Com Oil 
Crisps, Chips
Puddings containing egg or fat 
Cream Soups, Kidney Soup 
Chocolate, Ice Cream
LOW
CHOLESTEROL/POLYUNSATURATED 
FAT FOODS
Fresh Skimmed Milk, Skimmed Milk 
Powder, e.g., Marvel.
Low Fat Yogurt 
Low Fat Cottage Cheese 
Egg White
Flora or Polyunsaturated Margarine 
Mazola, Com Oil, Sunflower Oil, Flora Oil 
or White Flora 
Sugar, Jam, Marmalade 
Lean Meat - no oftener than once/day. 
Turkey, Chicken, Chicken Roll, White Fish, 
Smoked Fish, Herring, Kippers, Salmon, 
Tuna, Pilchards and Sardines (drain off oil) 
Bread Rolls, Oatcakes, Ryvita, Plain 
Biscuits, Breakfast Cereal, Porridge, 
Potatoes, Rice, Pasta, Beans, Skimmed Milk 
Puddings, Jellies.
Fruit, Vegetables
Broth, Lentil, Vegetable and Potato Soup 
Boiled Sweets, Pastilles, Gums 
Lemonade, Squash
147
Figure 5.3a. Food frequency questionnaire - front.
8A BLOOD PRESSURE CLINIC
Cholesterol Study Questionnaire
Please answer these questions as best as you can... 
(underlining or circling your answer where applicable)
1. Bread: How many slices of bread or rolls do you eat 
on average each day?
What type of bread or rolls do you normally 
eat?
White Brown Wholemeal High fibre
2. a. What would you normally spread on the bread or roll?
Nothing Block margarine Polyunsaturated margarine
Butter Low fat spread Other ___________________
(please give)
b. Do you like it thick or thin?
c. Can you name the brand you normally use? ____________
3. Milk: What kind of milk do you use?
Skim Semi skim Low fat Ordinary Pasteurised 
How much milk do you use every day?
None Only in tea or coffee
1/2 pint every day 1 pint every day
4. Meat Products (Underline or circle which you eat
regularly, every week)
Meat (beef,including mince), lamb, pork, bacon and 
ham (not sausages)
Chicken and poultry
Tinned meat and made up meats-Corned beef, Pies, 
Bridies, Sausage rolls, Burgers, Haggis,
Black pudding, Sausage, Sausages
Fish
How often do you eat cheese or cheese dishes (such as 
macaroni cheese)?
Never Every day Twice per week
How many eggs do you eat per week?
(please turn over and answer questions on back of sheet)
148
Figure 5.3b. Food frequency questionnaire - back.
5. Which of the following foods would you normally fry? 
Chops Steaks Sausages Bacon Fish Burgers
6. With what do you fry foods?
Lard Dripping Vegetable oil Corn oil Sunflower oil
7. How often do you take chips or crisps each week?
Never Every day 4 times per week once weekly
8. How often do you have rice or pasta (such as spaghetti) 
each week?
9. Do you use sugar in tea or coffee? Yes No
If yes, how much?
10. Do you have fizzy soft drinks? (like lemonade, cola,etc.)
Never Up to 1/2 bottle/week 1 bottle/week More
11. Do you regularly eat...?
Cakes Never Daily Weekly
Biscuits Never Daily Weekly
Sweets Never Daily Weekly
12. Approximately how much alcohol do you drink each week?
None  Pub measures of whisky, vodka,
or other spirits
 Pints of beer  Glasses of wine or sherry
Thank you for completing this questionnaire, your cooperation is 
appreciated.
8A Blood Pressure Clinic Staff
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Figure 5.4. Initial diet scoring system.
Number of slices & type of 
bread
2 slices brown = 1.0 
1 slice brown = 0.5 
white+brown = 0 
2 slices white =-1.0 
1 slice white =-0.5
Amount of cheese
Daily =-3.5 
x4/ week =-2.0 
x3/ week =-1.5 
x2/ week =-1.0 
xl/ week =-0.5 
seldom = 1.75 
none = 3.5
Spread Type
polyunsaturated = 1.0 
low fat spread = 1.0 
low fat/polyun- 
saturated+butter = 0 
block margarine =-0.5 
butter/lard =-1.0
Thick/thin
thick butter =-0.5 
thick block =-0.25 
(if using polyunsaturated 
or lowfat spread-no score)
Kind of Milk
1 pint =-1.0 
(except skimmed milk) 
1/2 pint =-0.5 
(except skimmed milk) 
in coffee/tea =-0.25 
(except skimmed)
no milk = 2.0
Meats eaten regularly 
2 meats =-1.0
Chicken, poultry
Chicken = 1.0
Number of Eggs
2 eggs =-1.0 
(over 1/wk)
1 egg only = 1.0 
no eggs = 2.0
Fried Foods
2 foods =-1.0 
no fried foods = 1.0
Types of fat
lard/dripping =-1.0 
vegetable oil =-0.5 
cheapest =-0.5 
vegetable + 
polyunsaturated = 0.5 
polyunsaturated = 1.0
Freguencv of Chips/Crisps
daily =-3.5
x4/wk =-2.0
x2/wk =-1.0
xl/wk =-0.5
rarely,seldom =-0.25
never = 1.0
Freguencv of Pasta/Rice
2 servings/wk= 1.0 
serving/wk = 0.5 
no servings =-1.0
Prepared meats eaten Frequency of Cakes
regularly
2 meats
Fish
Fish
daily =-1.5 
weekly =-0.5 
seldom = 0.5 
never = 1.5
daily =-1.5
=-1.0 weekly =-0.5
seldom = 0.5 
never = 1.5
= i.o Freguencv of biscuits
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Figure 5.5. Change in diet, scoring system.
Bread type 
white to brown combo= 1. 
white to white+brown
combo= 0. 
white+brown combo
to brown combo= 0.
Spread type
saturated to poly­
unsaturated/low fat = 1. 
block margarine 
to polyunsaturated = 0. 
saturated+lowfat
to lowfat = 0. 
saturated to 
lowfat+saturated = 0. 
saturated to block = 0.
Thick/thin
thick to thin = 1. 
average to thin = 0. 
thin to 0 = 0.
Kind of Milk
whole to 
semi-skimmed/low fat = 1. 
semi-skimmed/low fat
to skimmed = 1. 
whole to skimmed = 2.
Amount of milk
1 pint to 1/2 pint = 1. 
1 pint to 
tea/coffee only = 1. 
1 pint to none = 2. 
1/2 pint to 
tea/coffee only = 0. 
1/2 pint to none = 1. 
more than 1 pint
to 1/2 pint = 1. 
tea/coffee to 1 pint =-1. 
tea/coffee only to
more than 1 pint - - 2 .
Meats eaten regularly
decrease by 2 = 1.
Chicken, poultry 
not eating regularly 
to eating regularly = 1.
Prepared meats eaten 
regularly
decrease by 2 = 1.
Fish
not eating regularly 
to eating regularly = 1.
Amount of cheese
daily to x4/wk = 1.5 
daily to x3/wk = 2.0 
daily to x2/wk = 2.5 
daily to xl/wk = 3.0 
daily to none = 3.5 
daily to seldom = 3.25 
x3/wk to xl/wk = 1.0 
x2/wk to xl/wk = 0 . 5  
x2/wk to seldom = 0.75 
x2/wk to none = 1.0 
xl/wk to none = 0.5
Number of Eggs
decrease of
2 eggs/wk = 1.0
Fried Foods
decrease of 2 = 1.0 
decrease of 1 = 0.5
Types of fat
lard/dripping to
vegetable oil = 0.5 
lard/dripping to 
polyunsaturated oil
(corn/sunflower) = 1.0 
vegetable oil to 
polyunsaturated oil
(corn/sunflower) = 0.5
Freguencv of Chips/crisps 
every day to x4/wk = 1.0 
every day to xl/wk = 2.0 
every day to none = 2.5 
x4/wk to xl/wk = 1.0 
xl/wk to never = 0.5 
rarely,seldom
to never = 0.25
Freguencv of Pasta/rice 
increased 
servings by 2 = 1.0 
0 to 1 serving = 0.5
Freguencv of cakes
daily to weekly = 1.0 
daily to never = 1.5 
daily to seldom = 1.25 
weekly to never = 0.5 
seldom to never = 0.25
Freguencv of biscuits 
daily to weekly = 1.0 
daily to never = 1.5 
daily to seldom = 1.25 
weekly to never = 0.5 
seldom to never = 0.25
0
5
5
0
5
5
5
5
0
5
5
0
0
0
0
5
0
5
0
5
5
0
0
0
0
0
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of 95 % were also derived using RUMMAGE. Correlation analysis was undertaken 
as indicated using MINITAB. Both of these statistical packages were run on the 
University's ICL 3980 mainframe computer.
5.4. Results
5.4.1. Group demographics
The groups were well matched for age, sex, reported cigarette and alcohol 
consumption, blood pressure, last clinic cholesterol and length of time followed in 
the clinic (Thble 5.2). The groups were balanced for the types of anti-hypertensive 
drugs in accord with the study design (Table 5.1). There were minor differences in 
the percentage of patients taking a calcium antagonist alone, and those taking a beta 
blocker with a calcium antagonist, but these differences were not significant by chi- 
square analysis. The significant differences between the groups at entry were in 
regards to body weight (Table 5.2), HDL and HDL/LDL ratio (Thble 5.3).
Blood pressure in both groups at all visits is plotted in Figure 5.6. There was 
a significant decrease in blood pressure in the No Advice Group over the 6 months of 
the study (p<  0.05) by ANOVA, with blood pressures similar in both groups until 
the 6 month visit. There was no correlation between changes in blood pressure and 
changes in weight for either group.
5.4.2. Weight
Since weight differed between the groups at entry, the change in weight in 
each group over the 6 months of the study was compared by ANCOVA, which 
accounts for the entry difference. Weight decreased in the Advice Group by an 
average of 2.6 kg, but by only 0.5 kg in the No Advice Group (Figure 5.7), and this 
difference in weight reduction between the groups was significant (p<0.01). 
Confidence intervals for weight change in each group are given in Table 5.4.
5.4.3. Total cholesterol and lipoproteins
Both groups showed decreases between the fasting cholesterol measured at 
entry to the study and previous random cholesterol values obtained in the clinic at 
routine annual review for several years previously (Figure 5.8). On average, total
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Table 5.2. Demographic features of patients studied.
Sex (M/F)
Age (years)
Age Range (years)
Weight (kg)
Smokers
Alcohol use 
>  200 gm/week
Last clinic cholesterol 
(mmol/1)
Systolic Blood Pressure 
(mmHg)
Diastolic Blood Pressure 
(mmHg)
Average length of 
follow-up (months)
Range of follow-up 
(months)
Number followed 
for <  6 months
**p<0.01
DIETARY
ADVICE
N=61
27/34 
57 ±9 
37-77
71.7 ±12 
30%
11%
7.7 ±0.8 
150 ±17
85 ±9 
37 ±22 
1-72 
3
NO DIETARY 
ADVICE 
N=63
34/29 
56 ±8  
32-72
76.2 ±16 ** 
33%
8%
7.5 ±0.8
149 ±15
86 ±9
41 ±25
2-78
6
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Table 5.3. Triglyceride and lipoproteins (Mean ±s.d.) at entry and after 6 
months.
ENTRY
DIETARY NO DIETARY 
ADVICE ADVICE
Triglyceride 2.0 ±1.1 2.2 ±1.0
mmol/1
Cholesterol 7.1 ±0.8 7.1 ±0.8
mmol/1
VLDL
mmol/1
LDL
mmol/1
HDL
mmol/1
0.7 ±0.4 0.8 ±0.4
5.0 ±0.8 5.1 ±0.7
1.4 +0.4 1.3 + 0 .3 ’
HDL/LDL 0.30 ±0.11 0.26 ±0.07* 
Ratio
HDL/ 0.21 ±0.06 0.19 ±0.05*
Cholesterol
Ratio
6 MONTHS
DIETARY NO DIETARY 
ADVICE ADVICE
1.9+ 1 .1  2 .0 + 0 .8
6.8 +0.9 6.9 +0.8
0.6 +0.4 0.7 +0.4
4.7 +0.8 4.9 +0.8
1.4 +0.4 1.3 +0.3*
0.32 +0.13 0.27 +0.07* +
0.22 ±0.08 0.19 ±0.04*
*p <  0.05 for between group differences at each time 
+ p  <  0.05 by ANCOVA for between groups
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Figure 5.6. Supine systolic and diastolic blood pressure in both groups over 
course of study.
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,85
75
65
p<0.05
ENTRY 1 MONTH 3 MONTHS 6 MONTHS
VISITS
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Figure 5.7. Weight (kg) in both groups over course of study.
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Table 5.4. Change in weight between the groups (kg).
DIETARY NO DIETARY
ADVICE ADVICE
Weight Difference -2.6 ±3.0  -0.5 ±2.4*
(Mean ±s.d .)
Confidence Interval (-3.14,-1.8) (-1.2,0.2)
Significance within p < 0.001 p =  0.15
*significant difference between the groups for change in weight (p<  0.01)
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Figure 5.8. Average cholesterol at annual review for previous 3 years compared to 
entry values for each group.
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cholesterol had decreased by 0.5 ±0.6 mmol/1 in the Advice Group and 0.4 ±0.7  
mmol/1 in the No Advice Group between last annual review and entry to the study.
During the study period, the average decrease in total cholesterol was 0.33 
±0.65 mmol/1 in the Advice Group (p<0.05) and 0.27 ±0.72 mmol/1 in the No 
Advice Group (n.s.). Using ANCOVA, a statistically significant group effect was 
observed (p<0.05) at 1 month (Figure 5.9), but there was no difference between 
the groups at 6 months. The change in total cholesterol ranged from -31 % to +12% 
of baseline (mean -4%) in the Advice Group, and from -26% to +16% (mean -3%) 
in the No Advice Group.
The changes from previous annual review levels to entry represented a 
decrease of 7% in the Advice Group, and 5% in the No Advice Group and these 
were at least as great as the reductions induced by formal dietary advice. Further 
reductions during the dietary study resulted in cumulative reductions in the order of 
12% and 7%.
The lipoprotein results are shown in Thble 5.3. Small changes were observed 
in both groups over the course of the study. Only the HDL/LDL ratio showed a 
statistically significant difference between the groups (p<0.05) by ANCOVA, with 
the Advice Group's mean ratio increasing from 0.30 to 0.32 and the No Advice 
Group from 0.26 to 0.27.
5.4.4. Changes in weight and cholesterol
There was no significant correlation between the change in weight and the 
change in cholesterol for all participants (r=0.1) (Figure 5.10). Furthermore, the 
changes in weight and cholesterol analysed by anti-hypertensive drug treatment using 
ANOVA, showed no statistical significant differences between drug treatments 
(Table 5.5).
5.4.5. Diet and diet scores
The diets reported by each group were similar at entry. In the Advice Group 
41 % were prescribed Diet I and 59% Diet II at entry. At three months 10 of the 25 
patients on Diet I were prescribed Diet II as total cholesterol in these individuals had
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Figure 5.9. Total cholesterol (mmol/1) for each group over course of study.
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Table 5.5. Change in total cholesterol (mmol/1) in groups by drug treatment between 
entry and 6 month visits.
Lipid Neutral+  
or no treatment
Beta blocker 
alone
Beta blocker 
and diuretic
Beta blocker, 
diuretic and 
calcium antagonist
Other@
Dietary 
Advice 
N (mmol/1)
15 -0.6 ±0.8
10 0.1 ±0.4
10 -0.4 ±0.6
6 -0.6 ± 0.6
13 -0.1 +0.5
N
11
11
12
8
No Dietary 
Advice 
(mmol/1)
0.0 ±0.7  
-0.3 ±0.7 
-0.4 ±0.6  
-0.1 + 0.8
13 -0.5 +0.8
+  monotherapy or combination of calcium antagonist and ACE inhibitors as 
well as no treatment
©diuretic with calcium antagonist or ACE inhibitor, or triple 
therapy including hydralazine
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not fallen below 6.5 mmol/1. In total, during the last three months of the study, 75% 
of the Advice Group were prescribed Diet II.
The end of study questionnaire results showed that those in the Advice Group 
who reported a decrease in the frequency of eating foods high in saturated fat, and an 
increase in the frequency of eating foods high in polyunsaturated fat and fibre. The 
No Advice Group reported little change in diet over the course of the study (Thble 
5.6).
Both groups' entry diets were negatively rated, indicating that on average both 
groups were generally consuming diets high in saturated fat, low in polyunsaturated 
fat and low in fibre. The Advice Group's average score was -3.3 ±6 .0  and the No 
Advice Group's average score was -1.4 ±5.6. Despite the Advice Group's 'worse 
diet' as indicated by the more negative score, there was no statistically significant 
difference between the average scores at entry.
With specific individualised dietary advice, the Advice Group scored an 
average change of 4.6 ±3.2 while the No Advice Group changed little with an 
average change of only 0.4 ±2.3. This was a statistically significant difference 
between the groups (p <0.05). Yet, 50% or less of the Advice Group reported 
having instituted the majority of the dietary changes listed in Thble 5.6. Only a 
decrease in the quantity of eggs eaten, was reported by 68% of the Advice Group.
The change in diet score is plotted against the change in total cholesterol for 
each group in Figure 5.11. It is apparent that most individuals in the Advice Group 
reported some positive dietary changes and had a corresponding decrease in total 
cholesterol. However, it is also interesting to note the sub-group who reported 
substantial dietary changes with little impact on their total cholesterol levels (blue 
rectangles in upper right quadrant) as well as those in the No Advice Group who 
indicated they were eating a 'worse diet' at 6 months but still lowered their 
cholesterol (red triangles in lower left quadrant). These results call in to question the 
assumption that dietary intervention lowers cholesterol.
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5.5. Discussion
This study is important since it attempted to intervene in a high risk group of 
hypertensive hyperlipidaemics of both sexes using diet alone. The significant 
reduction in blood pressure of 7/4 mmHg at 6 months compared to entry values in 
the No Advice Group, compared with little change (2/1 mmHg) in the Advice 
Group, might be explained by the extra attention paid to this group's blood pressure 
by the increased frequency of clinic visits required of the study. However, both 
groups average blood pressures were virtually the same up to and including the 3 
month visit (Figure 5.6). Differences in blood pressure only emerged at the 6 month 
visit when the No Advice Group's mean decreased (4/3 mmHg) and the Advice 
Group's mean blood pressure increased (3/2 mmHg) compared to 3 month visit 
means.
The significant reduction in weight in the Advice Group reflected the intensive 
dietary therapy which included weight reduction advice for the obese. The change in 
weight did not correlate with changes in cholesterol (Figure 5.9) or blood pressure. 
The lack of correlation between weight and blood pressure reduction is at odds with 
studies which have shown that lowering weight lowers blood pressure (Staessen J et 
al 1985).
The explanation for the fall in total cholesterol in both groups after 
identification for entry to the study is not clear (Figure 5.8). Many of the patients 
have had stable consistent measurements of high cholesterol over many years. It 
could be a result of self-induced diet changes following 'labelling' as hyperlipidaemic 
as the informed consent obtained for the clinical trial made all patients aware that 
their blood cholesterols were elevated. In addition, while the study was underway a 
major public health programme 'Good Hearted Glasgow' was initiated in the city. Its 
publicity may have contributed to an increased awareness of cardiovascular risk 
factors and lipids and diet in particular.
Food frequency questionnaires have been shown to be as adequate an 
assessment of intake as diet diaries (Salvini et al 1989) or diet recall (Suitor et al
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1989). Deriving a score for the potential impact on total cholesterol of a particular 
change in eating habit has facilitated a quantification of changes in diet and allowed 
for the plotting of the reported change in diet with change in weight (Figure 5.10) and 
total cholesterol (Figure 5.11).
From both plots it is apparent that for some people, the change in weight and 
reported dietary changes, were reflected by a change in cholesterol. However, 
particularly for cholesterol, it was evident that for about a third of the Advice Group 
who reported substantial changes in their diet (Change Score >5), their total 
cholesterols actually increased over the time of the study. 'Responders' and 'non- 
responders' to diet have been identified in the past (Jacobs et al 1983). However, 
there is no explanation for those few individuals in the No Advice Group who 
indicated they were eating a higher fat, higher cholesterol diet lower in fibre at the 
end of the study, yet had a decrease in total cholesterol (Figure 5.11).
Ramsay et al compared the preliminary results from this study with a number 
of the dietary intervention trials in a variety of settings. The percentage change in 
cholesterol was assessed to be the reduction in the intervention group minus the 
change in the control group in each trial. Thus in this study, net reduction was 2% 
from entry and 5 % from last annual review. With such limited results they 
questioned the efficacy of dietary treatment and the cost benefits due to the 
investment in professional staff time required for its implementation (Ramsay et al 
1991). This is a valid concern with ever shrinking health care resources, and in 
addition, it raises the concern as to why dietary intervention appears to be less 
effective in high risk groups.
Despite statistical significance in some parameters, all of the changes seen in 
this study were modest in clinical terms. At the end of the study, 56% of patients in 
the Advice Group and 57% in the No Advice Group still had total cholesterol > 6 . 5  
mmol/1.
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5.6. Conclusions
This study has shown that intensive dietary intervention may not significantly 
improve on the impact of merely telling individuals they are hyperlipidaemic, as 
nearly 50% in both groups managed to lower their cholesterols to below 6.5 mmol/1. 
This has cost implications as the cost of telling an individual they are 
hypercholesterolaemic is far less than intensive individualised dietary counselling by 
highly trained dietitians.
It has also shown that diet can only be the first course of treatment. Additional 
lipid lowering strategies will be required in many of those remaining individuals with 
elevated lipids.
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Chapter 6. A placebo controlled study of guar gum in hyperlipidemia and/or 
obese essential hypertension
6.0. Summary
In this chapter, a study which evaluated the effect of guar gum (guar) on 
weight, blood pressure and lipids after 6 months of active treatment in a placebo 
controlled, double blind study is reported.
6.1. Introduction
As previously noted, it has been shown that the major cardiovascular risk 
factors occur more frequently together in individuals than would be expected by mere 
chance (Criqui et al 1980, Criqui et al 1986).
By 1986 in the Stobhill Clinic, there were 526 patients continuing to attend, 
with a mean blood pressure of 151 ±19/86 +10 mmHg. 31% of patients had 
systolic blood pressures more than 10 mmHg above their target levels, and 16% of 
patients had diastolic blood pressures more than 5 mmHg above their target levels. 
44% had total plasma cholesterol values > 6.5 mmol/1, 23% had a BMI >  30 and 
33% continued to report that they smoked.
There was no difference in the distribution of obesity or smoking in the subset 
of hyperlipidaemic hypertensives from the total hypertensive population. The 
multiple risk of many of these patients warrants attempts to find a single therapeutic 
intervention that would be able to address more than one risk factor.
6.1.1. Role of fibre in cardiovascular disease
Epidemiological surveys of international diets have highlighted correlations 
between dietary fibre intake and rates of cardiovascular disease, and a Californian 
study indicated that this relationship may well be independent of the relationships 
identified with saturated fat and cholesterol intake.
Morris et al from the department of Community Health, London School of 
Hygiene and Tropical Medicine, in 1977 reviewed the CHD rates among 337 healthy 
middle-aged working men from London who had participated in seven-day individual
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weighed dietary surveys 10-20 years before. The data were re-analysed, correlating 
various dietary factors with CHD incidence. Correlations were observed with 
increasing levels of the known risk factors of systolic blood pressure, total 
cholesterol and smoking in 270 in whom this information was available for analysis. 
The dietary factors identified with decreased CHD incidence were increasing levels 
of calorie and fibre intake, and multiple regression analysis showed that the effect of 
each was independent. There was no association between blood pressure and the 
nutrient factors studied (Morris et al 1977).
The Ireland-Boston Diet-Heart Study followed 563 men of Irish descendent, 
between the ages of 30 and 69 who lived in the Boston area for at least 10 years, and 
572 brothers of the Boston men who were still living in Ireland. A third group of 373 
men who were bom in the Boston area but whose parents had emigrated from Ireland 
were also followed up for 20 years. Dietary intake was assessed at baseline as was 
blood pressure, 12-lead ECG, smoking habits, serum cholesterol level, triceps and 
subscapular skin-fold thicknesses, height and weight. 20 year mortality for CHD did 
not differ significantly between the three groups. However, for the entire population 
of 1001 men, initial analysis showed increased CHD mortality with lower vegetable 
food score which included a fibre intake sub-score (p<0.02). Unfortunately, this 
inverse association with fibre became non-significant (p=0.05) with adjustment for 
other risk factors (Kushi et al 1985).
Khaw and Barrett-Connor recorded 12 year ischaemic heart disease mortality 
prospectively in a group of 859 Californian men and women after obtaining a 
baseline survey of 24 hour dietary fibre intake. They also obtained data on the levels 
of known cardiovascular risk factors. Overall mean fibre intake was approximately 
12g/24 hours. Mortality was assessed for < 16 g/24 hours and > 1 6  g/24 hours 
intakes. Relative risk of ischaemic heart disease in the higher fibre group was .33 
(C.I. =  0.14-0.77) with p value of 0.01 in the males and .37 (C .I.=  0.11-1.24) with 
p value of 0.16 in the females. Dietary fibre correlated negatively at marginal levels
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of significance in men only for diastolic blood pressure, body mass index and plasma 
cholesterol. There was no relationship with smoking in either sex. Multi-variate 
analysis adjusting for age, systolic blood pressure or diastolic blood pressure, plasma 
cholesterol, fasting plasma glucose, obesity and smoking habit continued to 
demonstrate a significant inverse association between dietary fibre intake and 
ischaemic heart disease mortality in both sexes (Khaw & Barrett-Connor 1987).
Turning from the prospective surveys to intervention trials reveals mixed 
results of diets rich in fibre when used alone or more frequently in conjunction with 
other risk factor interventions, as reviewed in the introduction of Chapter 5. In the 
Diet and Reinfarction Trial (DART) in post MI males there was no significant 
difference in cholesterol levels or mortality in the high fibre group (Burr et al 1989), 
and in the Leiden Intervention Trial angiographically assessed coronary artery lesion 
progression was not observed in those who had high total/HDL cholesterol which 
was significantly lowered by the intervention (Amtzenius et al 1985).
Several of the multiple risk factor intervention studies have used high fibre as 
an added component to a high polyunsaturated, low saturated fat diet. These include 
the Oslo Study (Hjermann et al 1981), and the WHO European Trial of 
Multifactorial Prevention of Coronary Heart Disease study (WHO European 
Collaborative Group 1986). Unfortunately, since high fibre content was only a 
component of these diets, it is impossible to differentiate the effect of fibre from the 
effect of other dietary constituents.
6.1.2. Effect of adding fibre to the diet
Several multi-faceted diet studies have included an increased fibre intake as a 
component, while other researchers have investigated the effects of only increasing 
the dietary fibre content. Physiological parameters such as plasma or serum lipids, 
blood pressure, weight, blood glucose and insulin levels have been used as endpoints. 
The studies investigating the effects on blood pressure have been reviewed in 
Chapter 1.
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In a review of the effects of vegetarian diet on blood pressure, Rouse and 
Beilin identified a number of important methodological issues in interpreting dietary 
studies, including the measurement of blood pressure, assessment of dietary intake, 
confounding nutrient interactions and statistical methods. A factor analysis conducted 
on data from their controlled vegetarian studies showed that blood pressure changes 
significantly correlated to the factor representing increased intake of polyunsaturated 
fat, fibre, vitamin C, Vitamin E, calcium, magnesium and a fall in the intake of 
protein. They do not address the contribution which fibre has to this factor. They 
conclude that despite the lack of good data with respect to the effects of 'dietary 
fibre', what data there are suggest that this nutrient may be important (Rouse & 
Beilin 1984).
Jenkins et al compared 36 g/day doses of wheat bran, pectin and guar in young 
healthy normolipid males. In those individuals who completed each course, those 
taking the guar (7 volunteers) had a significant reduction (16%) in their serum 
cholesterols (Jenkins et al 1975).
In the Netherlands, Stasse-Wolthuis et al divided 62 healthy normotensive 
volunteers with cholesterol values < 5 . 1 7  mmol/1 and diastolic blood pressure < 90 
mmHg, into 4 groups after an initial 2.5 week period of a low-fibre diet. One group 
continued on the low fibre diet (18g/day), the second group were given a diet rich in 
vegetables and fruit (43 g/day of fibre), the third group was supplemented with citrus 
pectin (28g/day of fibre) and the fourth group was supplemented with wheat bran 
(37g/day of fibre). All other food, except 100 kcal/day, was also provided. There 
was a significant decrease in cholesterol in the pectin group, but no changes in HDL 
cholesterol. Fecal output was generally increased in the pectin and bran groups. Not 
surprisingly, there was no change in blood pressure in these normotensive subjects 
(Stasse-Wolthuis et al 1980).
Haskell et al conducted a series of experiments with various forms of water- 
soluble dietary fibre (WSDF). They demonstrated acacia gum had little lipid
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lowering effect, while guar alone or in combination with other WSDF did 
significantly lower lipids. A month long dose ranging study with a placebo, 5, 10 and 
15 g/day dose of guar in groups of 12 or 13 showed increasing reductions in total 
and LDL cholesterol with increasing dose. There was no gender effect nor were 
there significant weight changes in any of the groups (Haskell et al 1992).
Jenkins et al investigated the effect of 4 months of treatment with soluble or 
insoluble fibre in 43 hyperlipidaemics (15 men, 20 women) who had been on a low 
cholesterol diet for at least 2 months in an open study. Total cholesterol, LDL 
cholesterol and HDL cholesterol were significantly reduced by an additional 5 %, 5 % 
and 3% respectively during treatment with the soluble fibre compared with the 
reduction during insoluble fibre treatment (Jenkins et al 1993).
6.1.3. Role of guar in addressing single cardiovascular risk factors
Guar is a soluble fibre obtained from the cluster bean plant Cyamopsis 
tetragonoloba also called Cyamopsis psoraloides. It has been used for a number of 
years to treat diabetes by retarding glucose absorption from the gut. Jenkins et al 
assessed the effect of various fibres in groups of 4-6 individuals who underwent a 50 
g. glucose tolerance test. Guar significantly reduced hyperglycemia by 50% 
(p<0.01). The viscosity of the various fibre preparations correlated with the 
reduction in maximum rise in blood glucose concentration (Jenkins et al 1978) and 
the continued effect has been demonstrated after 1 year of treatment in 11 diabetics 
(Jenkins et al 1980a).
Blackburn et al investigated possible mechanisms of action of guar in the gut 
by assessing gastric emptying time, intestinal absorption and the 'unstirred water 
layer' in the small intestine. Guar was shown to decrease glucose tolerance, delay 
gastric emptying and decrease glucose absorption from the intestine. However, there 
was no correlation between change in gastric emptying and the peak increase in 
blood glucose concentration (Blackburn et al 1984).
Jenkins et al have carried out a series of small uncontrolled studies which have
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shown significant reductions in total cholesterol compared with pectin and wheat 
fibre (Jenkins et al 1975), after 2 weeks of treatment in 10 hyperlipidaemics (Jenkins 
et al 1979), and after 6 months of treatment in 8 normolipidaemic diabetics (Jenkins 
1980a). They also compared either guar crispbread, hydrated guar, semi-hydrated 
guar or cholestyramine with small groups of hyperlipidaemic patients, and found the 
guar crispbread to be more acceptable to patients. Weight was also significantly 
reduced by 1.5 kg on average in the 7 patients who completed the 8 week course of 
crispbread (Jenkins et al 1980b).
A 12 month study of active guar (6 g tds), following a 4 week placebo period, 
was conducted in 19 hypercholesterolaemic ( > 6 . 5  mmol/1) Australians. 2 patients 
withdrew due to severe diarrhoea initially, another 4 withdrew after 3 months. Guar 
was taken in a flavoured guar formulation mixed with 170 ml of water, half taken 
before and the rest during each meal. It contained an inhibitor of gelation which 
prevented the guar jelling until it reached the acidic contents of the stomach. Of the 
13 who completed 12 months of treatment, a significant reduction in serum 
cholesterol and LDL cholesterol was observed by analysis of variance (p<  0.001) 
(Simons et al 1982).
Kirsten et al assessed the influence of 4 g guar dissolved in 200 ml of water 
taken 3 times per day, on serum lipids in 13 hyperlipidaemic patients over a 60 day 
period. Values were compared with pre and post study assessments. There was a 
significant reduction in total cholesterol (13%) and LDL cholesterol (0.64 ±0.52 
mmol/1). However, HDL cholesterol was significantly decreased at 30 days, but 
returned to pre-treatment levels after 60 days of treatment (Kirsten et al 1990).
A few studies have been conducted with a more rigorous study design. Khan et 
al published the results of a double-blind placebo controlled study using 600mg 
capsules of guar and matching glucose capsules. 18 men and 6 women were 
randomised to take 5 capsules 3 times per day, ie. a total of 9.0 g. of guar or 
placebo, for a 4 week period. There was no change in body weight, but total
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cholesterol decreased by 16.6% (p<0.05) and LDL cholesterol by 25.6% (p<0.05) 
in the guar group. There were no significant lipid changes in the control group (Khan 
et al 1981).
A Scandinavian study showed guar to have a significant effect on weight in 
hypercholesterolaemic females after 4 months of treatment. Tuomilehto et al 
randomised 33 hypercholesterolaemic females (cholesterol > 7 . 6  mmol/1) to 3 
groups. Group 1 received 5 g of guar granules 3 times per day mixed with a small 
amount of food or drink, group 2 received placebo (5 g wheat flour without fibre 3 
times per day) and group 3 received no treatment. Mean weight was statistically 
significantly decreased by 2.5 kg in the guar group (p < 0.0005), but there was no 
change in total serum cholesterol in any of the groups (Tuomilehto et al 1980).
Subsequently, these investigators conducted a double-blind cross over study 
using the same treatment regimen and placebo in 10 obese hypercholesterolaemic 
patients who were receiving long term anti-hypertensive treatment. Each phase lasted 
for 3 months. Serum cholesterol statistically significantly decreased during the guar 
phase of treatment (p< 0.001) by ANCOVA, controlling for change in body mass 
index, since weight had significantly decreased during the trial 'run-in' phase. No 
significant weight change was observed in the 'active treatment' phase of this study 
(TXiomilehto et al 1983).
A guar containing 'snack' type bar was developed by Mclvor et al in 
Baltimore. The first study, in 1985, with 5 type 2 diabetics, failed to show any 
significant reduction in cholesterol, glucose or weight over a 16 week period, despite 
the subjects taking 4-6 bars per day (approximately 26-40 mg/day) (Mclvor et al
1985). In a second study reported the following year, they had equally negative 
results. They randomised 16 type 2 diabetics to either guar or placebo bars for 6 
months. LDL cholesterol was significantly reduced only in males on guar compared 
to males on placebo. All other parameters were unchanged (Mclvor et al 1986).
Lalor et al used a double blind, double dummy method to compare the
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effectiveness of guar, metformin and placebo on fasting glucose and lipid levels, and 
body weight in 19 obese type 2 diabetics. Each treatment period lasted 12 weeks. 
Both the guar and metformin were equally effective in lowering blood glucose, while 
cholesterol was only reduced in a sub-group of 6 hyperlipidaemics (cholesterol >
6.5 mmol/1). There was no change in body weight over the course of the entire study 
(Lalor et al 1990).
Another double blind, placebo controlled study was carried out in Finland with 
17 mildly hypercholesterolaemic (>5.7  mmol/1), insulin-dependent diabetics. The 
guar group (N=9) received 5 g. granulated guar, and the control group (N=8) 
received a wheat flour placebo, each four times per day before meals for 6 weeks. 
Weight was unchanged. Glycosylated haemoglobin and plasma glucose concentration 
did decrease significantly in the guar group, but the changes were not significantly 
different from those in the wheat flour group. Serum total cholesterol decreased 
significantly in the guar group when compared with the change in the wheat flour 
group (-1.0 mmol/1 vs. +0.1 mmol/1). Three guar patients reduced their insulin 
doses over the course of the study (Vuorinen-Markkola et al 1992).
A study, from Sweden, evaluated the effect of guar on glucose and lipid 
metabolism, blood pressure and fibrinolysis in a double-blind, placebo controlled 
cross-over study. 25 healthy, non-obese middle-aged men taking no medication were 
recruited from a normal population. 10 g of guar or granulated jelling starch in a 
glass of water was given 3 times per day before meals for 6 weeks after a 2 week 
run-in period without treatment. The second 6 week period on the opposite treatment 
was completed after a 2 week wash-out period. There was no change in body weight, 
fibrinogen concentration, renin activity or plasma aldosterone. Systolic and diastolic 
blood pressures decreased significantly compared to entry values (6 ±9/3 ±2  
m m H g,p<0.001), and both returned to pre-treatment values post-study. Blood 
glucose decreased significantly (0.3 ±0.2 mmol/1,p< 0.001) but insulin did not. 
Glucose disposal, as measured by the euglycemic-clamp, significantly increased
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(p < 0.001). Cholesterol and triglycerides decreased significantly by 0.6 ±0.3  mmol/1 
(p < 0.001) and 0.2 ±0 .6  mmol/1 (p<0.05). Basal glucose uptake by abdominal fat 
cells increased (p<  0.001) and maximally stimulated glucose uptake increased as well 
(p<0.01) (Landin et al 1992).
A study undertaken locally suggested that guar was an efficacious adjunct to 
diet therapy in the grossly obese (personal communication, A. Lakhdar).
6.1.4. Discussion of the role of fibre
There is more than the average amount of difficulty when trying to interpret 
dietary studies. In the epidemiological surveys carried out in Boston/Ireland (Kushi et 
al 1985) and California (Khaw et al 1987) the 20 and 12 year mortality results were 
correlated only with an initial survey of food recall. This fails to address the issues of 
dietary intake affected by seasons and changing cultural habits over time. 
Unfortunately, the Seven Countries study which actually had subsamples of 
participants weigh their dietary intakes over a set period of time, with duplicate 
samples of food chemically analysed for nutrient content, with this being repeated at 
5 yearly intervals, did not report on fresh fruit/vegetable or fibre intake (Keys et al 
1986).
In particular when evaluating the studies involving guar, the difficulties are 
best summed up by Todd et al in 1990 when they reviewed the use of guar as a 
dietary adjunct in hypercholesterolaemia. Difficulties identified in interpreting the 
results of completed studies include the differences in type of formulation used (ie. 
powder, granules, coated), dosages administered, whether taken hydrated with water 
or unhydrated with food, the problems with blinding due to the high frequency of 
side effects in the guar groups and the limited power of most studies due to small 
population size (Todd et al 1990).
Nearly half of the studies reported above did not have a control group nor 
were they blinded. Most studies lasted 4-6 weeks. In only 3 studies did the guar 
treatment period last for more than 3 months. Tuomilehto's study in obese women
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was 4 months long (Tuomilehto et al 1980), Simons' study from Australia was 12 
months (Simons et al 1982), and Mclvor's second study was 6 months (Mclvor et al
1986).
Therefore, with the accumulated evidence that increased dietary fibre had been 
associated with lowering blood pressure, and guar appeared to have an effect in 
lowering weight and lipids in some studies, a study was devised to investigate further 
these potential benefits in patients attending the nurse practitioner follow-up clinic.
6.2. Study aims
The aims of this double blind, placebo controlled study were to evaluate the 
effect of guar on:
1. lipids in hyperlipidaemic hypertensive patients with cholesterol >  6.5 mmol/1,
2. weight in obese hypertensive patients with body mass index >  30,
3. blood pressure in essential hypertensives.
6.3. Methods
6.3.1. Outline of Study
In total, 36 patients of either sex between the ages of 18 and 70 years with a 
last clinic blood pressure < 180/100, were to be recruited. For analysis purposes:
- 12 patients were to have BMI > 30 and total cholesterol <  6.5 mmol/1,
- 12 were to have BMI > 30 and total cholesterol > 6.5 mmol/1, and
- 12 were to have BMI between 20 and 25 and total cholesterol >  6.5 mmol/1.
Power calculations indicated with this group size the study had 92% power to 
detect 1 mmol/1 change in total cholesterol, 97% power to detect a standard deviation 
change in weight, systolic and diastolic blood pressure by the method described by 
Day and Graham (Day & Graham 1989).
Patients were excluded if their last clinic blood pressures were >  180/100 
mmHg, they were pregnant or lactating women, or of child bearing potential and not 
using a reliable form of contraception, had a history of hiatus hernia or gastro­
intestinal disease or were currently taking a thiazide diuretic. Patients were to be
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withdrawn if an adverse drug reaction occurred such as excessive flatulence or 
diarrhoea, as well as if they expressed a desire to withdraw.
Attempts were made, when selecting participants, to control for: age, sex, 
smoking status, and drug treatment. Drug treatment, including anti-hypertensive 
therapy, were to be kept constant throughout the study period. Patients taking a 
thiazide diuretic would have it withdrawn 6 weeks prior to entry to the study and 
were included only if after 6 weeks with no thiazide therapy they continued to meet 
the other entry criteria.
Hypercholesterolaemic patients were asked to continue their low 
cholesterol/high polyunsaturated fat, high fibre diets and overweight patients were 
encouraged to attempt to modify their caloric intakes.
Patients attended over a 7 month period with entry, 1 month, 2 month, 4 
month and 7 month visits according to the schedule of visits outlined in Table 6.1. 
This allowed for the initiation of the bran control in an increasing dose in all patients 
during a month prior to the start of the 6 month active treatment phase.
Dropouts due to drug side effects were to be recalled for a 6 month (from start 
of active treatment) visit for an assessment so that their data could be included in an 
intention-to-treat analysis. Dropouts due to other reasons were to be replaced to 
maintain the proposed group sizes.
Informed written consent was obtained prior to entry to the study, and patients 
were provided with a Patient Information Sheet which they could keep for reference 
(Figure 6.1).
6.3.2. Study Measurements
Supine and erect blood pressures were measured using a Sentron semi­
automatic sphygmomanometer as described in Chapter 2, using an appropriate size 
cuff depending upon the individual's upper arm circumference, and the cuff size 
remained standard for each patient throughout the course of the study. A series of 5
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Table 6.1. Visit and assessment schedule.
Visit Month Assessments
0 0 Height and weight, supine and erect blood pressure with heart rate
Start placebo before meals: 1 sachet per day first week
2 sachets per day second week
3 sachets per day third week 
continue t.d.s. until next visit
1 Weight, supine and erect blood pressure with heart rate
Fasting total cholesterol,LDL cholesterol,HDL cholesterol,triglycerides 
Compliance check
Start double blinded active treatment phase (guar 5g. t.d.s. or bran 
control t.d.s.) as per Visit 0:1 sachet per day first week
2 sachets per day second week
3 sachets per day third week 
continue t.d.s. until next visit
Weight, supine and erect blood pressure with heart rate 
Compliance check
Maintain guar/control dose.
Weight, supine and erect blood pressure with heart rate 
Compliance check
Maintain guar/control dose
4 7 Weight, supine and erect blood pressure with heart rate
Fasting total cholesterol,LDL cholesterol,HDL cholesterol,triglycerides 
Compliance check
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Figure 6.1. Patient Information Sheet given to all participants.
Patient Information Sheet
Study: To examine the effect of guar gum in overweight
patients and patients with elevated cholesterol, who 
also are hypertensive (have high blood pressure).
Guar gum is a plant fibre in a concentrated form. It 
has been shown to lower cholesterol and to help overweight 
people loose weight. We wish to assess these effects in 
people with high blood pressure.
We wish to treat you with guar gum for up to 6 months
to examine its effect on either your weight or cholesterol, 
or both if you have both health problems. We also wish to 
compare the effects with an inactive treatment. At some time 
during the study you will be taking inactive sachets.
You will be required to attend the Blood Pressure 
Clinic monthly for 2 months, then at 2 and 3 months. We will 
ask you to come fasting at the first monthly visit and at 
your last visit of the study for a blood sample to check 
your cholesterol and other blood fat levels.
You should continue your routine blood pressure
medication throughout the period of the study. Your blood 
pressure will be monitored at each visit as well as your 
general well being. No serious side effects are expected but 
you may experience an increase in flatulence ("wind") and an 
increased frequency of bowel motions during the first week 
or so of treatment.
If you have any questions about this study now or in 
the future, please ask Mrs Curzio, Dr Lees or Professor Reid 
at the Blood Pressure Clinic, Stobhill Hospital (041-558- 
0111 Ext 278). In an emergency contact Mrs Curzio (Bishopton 
862061).
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supine and then 5 erect blood pressure measurements were obtained at one minute 
intervals after 5 minutes resting. The mean of these supine and erect readings was 
determined and used for data analysis.
Venous blood samples were obtained for total cholesterol, triglycerides, HDL 
cholesterol, LDL cholesterol and VLDL cholesterol at Visits 1 (just prior to starting 
the active treatment phase, after 1 month bran control) and visit 4 (after 6 months in 
the active treatment phase). Patients were asked to fast from 10 pm the evening 
before each sample. These samples were assayed in the Stobhill Biochemistry 
Laboratory as described in Chapter 2.
6.3.3. Randomisation and drug dosage
Guar 5 g. was packaged in plain white, unmarked sachets, as was the wheat 
bran control. A statistician not directly involved in the study, randomised an equal 
number of participants in each of the three categories within the study, (overweight 
with normal lipids, overweight with hyperlipidaemia, normal weight with 
hyperlipidaemia) to each treatment.
At entry during Visit 0, all patients were asked to start one sachet per day of 
the wheat bran control preparation for the first week, then to increase the dose to two 
sachets per day the second week and to three sachets per day the third week, in order 
to build a tolerance to the high fibre load. They were asked to continue three sachets 
per day until the next visit.
At visit 1, a month after Visit 0, all patients were informed that they were now 
to receive a 'higher dose' and would therefore need to acclimatise their bodies to this 
higher dose by following the same increasing dosing schedule as they had done after 
Visit 0. In this way, the participants who were randomised to the active guar 
treatment would be able to develop tolerance to the high soluble fibre load.
6.3.4. Statistical analysis
It was originally proposed to analyse the change in weight, cholesterol, 
triglycerides, HDL cholesterol, LDL cholesterol, VLDL cholesterol, supine and
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erect blood pressure and heart rate between baseline (Visit 1, after 1 month of bran 
control) and after 6 months of the active treatment phase (Visit 4). The analysis 
would utilise an analysis of covariance (ANCOVA) such that weight would be the 
covariate for the cholesterol analysis, cholesterol would be the covariate for the 
weight analysis and cholesterol plus weight would be the covariates for the blood 
pressure analysis. Power calculations were carried out according to the method 
described by Day and Graham (Day & Graham 1989).
Analysis was undertaken on an intention to treat basis. Unfortunately, the 
analysis of co-variance could not be carried out as the main treatment groups were 
not homogeneous. One way analysis of variance (ANOVA) using MINITAB on the 
ICL 3980 mainframe computer, was carried out on the change in weight, cholesterol, 
triglycerides, HDL cholesterol, LDL cholesterol, VLDL cholesterol, supine and 
erect blood pressure and heart rate between baseline (visit 1) and after 6 months of 
the active treatment phase (visit 4) for all patients with data obtained on an intention- 
to-treat basis.
Further one way analysis of variance analysis was undertaken by partitioning 
the data into 2 sub-groups of:
1) those patients who were obese with and without hyperlipidemia
2) those who were hyperlipidaemic with and without obesity.
Factors were then analysed accordingly.
6.4. Results
6.4.1. Details of patients studied
As previously stated, the protocol sought to recruit 36 hypertensive patients 
from the Blood Pressure Clinic. In total, 39 patients, 16 males and 23 females, were 
recruited to the study (Thble 6.2). Withdrawals from the study were in excess of 
those anticipated, however, with half of the early withdrawals being due to 
intolerance of the bran control preparation. Thus 31 patients commenced active 
treatment. On an intention to treat basis, data were obtained for 29 patients, 12 males
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Table 6.2. Patient recruitment.
Men Women
Entered into placebo phase 16 23
Entered active treatment 13 18
Withdrew from active
treatment 1 5
Continued study visits,
but stopped treatment 3 1
Completed study 9 12
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and 17 females. One of the patients who withdrew from active treatment is not 
included as he failed to attend his clinic appointments. The other withdrawal from 
active treatment for whom intention to treat data were not obtained, had been started 
on a thiazide diuretic by her general practitioner prior to her final visit. Reasons for 
withdrawal from either phase of the study are listed in Ihble 6.3.
The distribution between active treatment with guar and the bran control for all 
patients, the obese and the lipid sub-groups are in given Table 6.4. Anti-hypertensive 
treatment was not changed over the course of the study. There were only 5 smokers 
in the 29 patients who completed the study on an intention-to-treat basis. The 
smokers were evenly distributed throughout all groups.
6.4.2. Blood Pressure
Mean supine systolic blood pressure for all patients, obese and lipid sub­
groups are shown in Figure 6.2. Supine diastolic blood pressure is plotted for all 
patients and the 2 sub-groups in Figure 6.3. Oneway ANOVA of the differences in 
blood pressures between entry and after 6 months of active treatment, showed no 
statistically significant difference between the guar and bran control for all patients 
or the 2 sub-groups.
The average difference of 11 mmHg between entry supine systolic blood 
pressures in the obese sub-group was not significant due to the variability of blood 
pressure within each treatment group (±16 mmHg in guar and ±10 mmHg in the 
bran controls). There was a similar difference of 8 mmHg in the lipid sub-group and 
this was also not significant due to the within treatment group variability (±16 
mmHg in the guar and ±  18 in the bran controls).
6.4.3. Weight
Mean weights for all patients and the 2 sub-groups are presented in Figure 6.4. 
Once the treatment code was broken, initial weights were found to be quite different 
between the treatment groups for all patients and the 2 sub-groups, with the guar 
average weight being more than 10 kilograms heavier than the bran control. Analysis
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Table 6.3. Reason for withdrawal from control or active treatment or stopping 
treatment.
Withdrew during placebo period
Did not return for Visit 1
Did not wish to participate in a 
clinical trial
Unable to tolerate bran control
Withdrew during active treatment
Unpalatable, difficult to mix with foods
Developed gastroenteritis, or diarrhoea 
or increased frequency of bowel motions
Failed to attend follow-up appointments
Depression, swollen ankles, nausea and vomiting
GP started thiazide
(but had also stopped treatment after episode 
of nausea/vomiting)
Guar
1
Bran Control
Continued study visits but stopped treatment
Difficult to remember to take
Fractured bone in foot, unable to move around 
(increased frequency of bowel motions)
Increased thirst and nausea
Skin rash
Guar
1
1
1
Bran Control
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Table 6.4. Group distributions.
All Patients
13 Guar
N =29
16 Bran Control
Obese Sub-Group
10 Guar
N =20
10 Bran Control
Lipid Sub-Group
8 Guar
N =18
10 Bran Control
6 men
7 women 
6 men
10 women
4 men
6 women 
3 men
7 women
3 men
5 women 
3 men
7 women
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Figure 6.2. Mean supine systolic blood pressure for all patients, obese and lipid
sub-groups.
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Figure 6.3. Mean supine diastolic blood pressure for all patients, obese and lipid
sub-groups.
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Figure 6.4. Mean weight in kilograms for all patients, obese and lipid
sub-groups.
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of co-variance (ANCOVA) using pre-study weight as the covariate, revealed no 
statistically significant difference in the changes in weight for either the guar or 
control groups over the course of the study for all patients, or for either of the 2 sub­
groups.
6.4.4. Lipids
Total cholesterol for all patients, obese and lipid sub-groups is presented in 
Figure 6.5, and other lipid results are presented in Table 6.5. Data are first presented 
for all patients and then for the obese and lipid sub-groups. There were no 
statistically significant differences in the lipid measurements between the treatments 
for all patients or in either of the 2 sub-groups analysed.
A small reduction (6%) in total cholesterol in the guar treatment group of the 
lipid sub-group was significant only when compared with initial values in that group 
by paired t-test (p<0.05, 95% C.I. -1.013,-0.012). A similar small reduction (7%) 
in LDL-cholesterol was not significant (p < 0.08,95% C.I. -0.947,0.072) when 
compared with initial values for that treatment group.
6.4.5. Tolerance and symptoms
The fibre preparations were poorly tolerated with overall 13 of the 29 patients 
analysed reporting changes in their bowel habits, 8 in the guar treatment group and 5 
taking the bran control (Table 6.6). Only 20 patients were able to reach the 
maximum dose of 3 sachets (15 g) per day (Thble 6.7). Of the 11 patients who 
stopped treatment, 8 were taking guar. An additional 2 patients in the bran control 
group admitted to very poor compliance over the course of the study (Thble 6.8). 
Finally, 5 of 6 patients in the guar group, while in the active treatment phase 
reported great difficulty in mixing it with foods and generally found treatment 
unpalatable.
6.5. Discussion
The current study design attempted to overcome many of the difficulties 
previously discussed by using a double-blind, placebo controlled design with a 6
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Figure 6.5. Mean total cholesterol for all patients, obese and lipid sub-groups.
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Table 6.5. Lipid values initially (after 1 month bran control) and after 6 months of 
treatment.
ALL PATIENTS Initial 6 Months
Triglycerides (mmol/l)
Guar Group
Bran Control Group
2.1 ±1.0  
1.7 ±0.9
2.2 ±0.9  
1.7 ±0.9
Total cholesterol (mmol/1)
Guar Group
Bran Control Group
7.3 ±1.3
6.3 ±1.1
7.1 ±1.2
6.2 ±1.1
HDL-cholesterol (mmol/l)
Guar Group
Bran Control Group
1.3 +0.3
1.4 ±0.5
1.3 ±0.3  
1.5 ±0.5
LDL-cholesterol (mmol/1)
Guar Group
Bran Control Group
5.2 ±1.2
4.3 ±0.9
5.1 +1.1 
4.3 ±1.0
VLDL-cholesterol (mmol/1)
Guar Group
Bran Control Group
0.8 +0.5  
0.6 ±0.3
0.8 +0.4  
0.6 ±0 .2
OBESE PATIENTS Initial 6 Months
Triglycerides (mmol/1)
Guar Group
Bran Control Group
2.3 ±1.0  
2.1 ±1.0
2.4 ±0.9  
2.0 ±0.9
Total cholesterol (mmol/1)
Guar Group
Bran Control Group
7.1 ±1.3  
6.0 ±1.2
7.0 ±1.3
6.0 ±1 .2
HDL-cholesterol (mmol/l)
Guar Group
Bran Control Group
1.3 ±0.3
1.3 ±0.5
1.3 ±0.3
1.4 ±0.5
LDL-cholesterol (mmol/1)
Guar Group
Bran Control Group
4.9 ±1.1  
4.0 ±1.0
5.0 ±1.2
4.0 ±1.0
VLDL-cholesterol (mmol/1)
Guar Group
Bran Control Group
0.9 ±0.5  
0.7 ±0.3
0.9 ±0.5  
0.6 ±0 .2
LIPID PATIENTS Initial 6 Months
Triglycerides (mmol/1)
Guar Group
Bran Control Group
2.0 ±0.8  
1.4 ±0.7
1.9 ±0.9  
1.4 ±0.4
Total cholesterol (mmol/1)
Guar Group
Bran Control Group
8.0 ±1.0  
7.0 ±0.4
7.5 ±1.1 
6.9 ±0.7
HDL-cholesterol (mmol/1)
Guar Group
Bran Control Group
1.4 ±0.3  
1.6 ±0.5
1.4 ±0.3  
1.7 ±0.4
LDL-cholesterol (mmol/1)
Guar Group
Bran Control Group
5.8 ±0.9
4.9 ±0.5
5.4 ±0.9  
4.9 ±0.6
VLDL-cholesterol (mmol/l)
Guar Group
Bran Control Group
0.8 ±0.5  
0.5 ±0.3
0.8 ±0.5  
0.5 ±0.2
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Table 6.6. Reported adverse effects of treatment - patients enrolled into active 
treatment phase.
G uar
Patient number Adverse Effects
102 none reported
104 increased frequency of bowel motions
108 slight increased frequency of diarrhoea
109 increase in abdominal cramping if took 3 sachets/day
112 diarrhoea and abdominal pain, diagnosed episode of
gastroenteritis
203 increased bowel frequency and flatulence, thirst and nausea
204 diarrhoea with 3 sachets/day
209 none reported
210 "turns stomach at times"
211 none reported
301 increased frequency of bowel motions
303 increased indigestion with 3 sachets/day, abdominal cramp and
constipation 
310 none reported
Bran Control
Patient number Adverse Effects
103 none reported
107 slight change in bowel habits
110 none reported
111 increased frequency of bowel motions
202 none reported
205 skin rash after 10 days of increasing dose, resolved once 
treatment stopped
206 none reported
207 none reported
208 improved previous problem with constipation
212 increased flatulence, episode gastroenteritis visit 3,
indigestion visit 4 
302 increased frequency of stools
304 none reported
305 none reported
307 depression, swollen ankles, nausea, vomiting
309 some tiredness at visit 2 with decreased frequency of bowel
motions
311 increased hunger
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Table 6.7. Maximum dose attempted by each patient during active treatment phase.
Guar
Patient number Maximum dose
102 3 sachets/day
104 3 sachets/day
108 3 sachets/day
109 2 sachets/day
112 1 sachet/day
203 2 sachets/day
204 2 sachets/day
209 1 sachets/day
210 3 sachets/day
211 2 sachets/day
301 3 sachets/day
303 3 sachets/day
310 2 sachets/day
Bran Control
Patient number Maximum dose
103 3 sachets/day
107 3 sachets/day
110 3 sachets/day
111 3 sachets/day
202 3 sachets/day
205 2 sachets/day
206 3 sachets/day
207 3 sachets/day
208 3 sachets/day
212 3 sachets/day
302 3 sachets/day
304 3 sachets/day in 2 doses
305 3 sachets/day
307 1 sachet/day
309 3 sachets/day
311 3 sachets/day
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Table 6.8. Reasons for stopping treatment or poor compliance during active 
treatment phase and first month of bran control study.
G uar
Patient num ber Reason given
102 Stopped after visit 3, difficult to take
104 Stopped after visit 2, fractured bone in foot-unable to get around
108 stopped before visit 2, difficult to mix with food
112 stopped several days after visit 1
201 +  stopped 2 weeks after visit 2 due to increased bowel motions
and diarrhoea
203 stopped after visit 3, increased thirst and nausea
209 failed to attend visit 2
211 stopped after visit 2, unable to tolerate in food
Bran Control
Patient num ber Reason given
101 +  +  stopped after episode of nausea and vomiting 2 weeks before
visit 3
205 stopped 10 days after visit 1, skin rash
206* taking sachets "as he minds", difficulty taking it regularly
207* intermittently stopped treatment, forgot to take them on holiday
307 depression, swollen ankles, nausea, vomiting 3 weeks after visit 1
Stopped during bran control period 
Patient num ber Reason given 
101(R) never returned for follow-up
109(R) found bran control difficult to mix with food, it "sickened" her
204(R) frequent bowel motions, some rectal bleeding
206(R) not attend for visit 1
211(R) decided didn't wish to participate in a clinical trial
308(R) developed indigestion and mild headache
312(R) unable to tolerate control, found it unpalatable
  decided didn't wish to participate in a clinical trial
+ did not return for follow-up, not included in analysis.
+ + patient's data not included in analysis, GP had prescribed thiazide. 
* poor compliance.
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month active treatment phase. Initial power calculations indicated that it had 92 % 
power to detect a 1 mmol/1 change in total cholesterol, 97% power to detect a one 
standard deviation change in weight, and 97% power to detect a one standard 
deviation change in supine systolic and diastolic pressure. Unfortunately, due to the 
high incidence of side effects and poor compliance, the study, analysed on an 
intention-to-treat basis, had 81% power to detect a 1 mmol/1 change in total 
cholesterol, 61% power to detect a one standard deviation change in weight, and 
76% power to detect a one standard deviation change in supine systolic and diastolic 
pressure.
Changes in total cholesterol in the hyperlipidaemic guar treatment group, 
although not significant when compared with the changes in the bran control group, 
are in keeping with the significant changes reported by other randomised controlled 
studies (Khan et al 1981, Simons et al 1982, Tuomilehto et al 1983, Kirsten et al 
1985, Landin et al 1992, Vuorinen-Markkola et al 1992). In addition, the patients 
recruited to this study had been on a low cholesterol/low fat and high dietary fibre 
diet for more than 6 months prior to entering the study, as had about half of the 
positive guar studies previously cited (Simons et al 1982, Tuomilehto et al 1983, 
Kirsten et al 1989).
In contrast, Lalor et al showed significant reductions in cholesterol only in a 
sub-group of hyperlipidaemics with total cholesterol > 6 . 5  mmol/1 (Lalor et al
1990). Of these more controlled, rigorous guar studies, Tuomilehto's all female 
study showed no significant reduction in total cholesterol despite the population being 
hyperlipidaemic (Tuomilehto et al 1980). The lack of change in Mclvor’s guar 
granola bar studies may well have been due to the guar preparation used and the fact 
that both study populations had normal cholesterol values initially (Mclvor et al 
1985, Mclvor et al 1986).
The lack of change in body weight in this study is also in keeping with most of 
the other studies of the effectiveness of guar in obese individuals (Simons et al 1982,
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Lalor et al 1990, Landin et al 1992). Again, in these other studies, only Tuomilehto's 
early study in 1980 demonstrated a 2.5 kg weight reduction in the guar group 
compared with 0.4 kg reduction in a placebo and 0.6 kg reduction in a no treatment 
group (Tuomilehto et al 1980).
The effect of guar on blood pressure has not been widely studied, although 
there has been work carried out on the effects of other forms of dietary fibre, with 
mixed results (Stasse-Wolthuis et al 1980, Wright et al 1979, Silman 1980, Fehily et 
al 1986). The effect of vegetarian diets on blood pressure has also been studied 
(Rouse et al 1984, Margetts et al 1985). Landin et al showed a significant reduction 
in both systolic and diastolic blood pressure after 6 weeks of guar in a normotensive 
population on no blood pressure lowering treatment (Landin et al 1992). These 
negative results in a treated group of hypertensives are in agreement with Wright's 
hypertensive group (Wright et al 1979) and Margett's normal population (Margett et 
al 1987). These last two studies used insoluble dietary fibre.
Twelve patients withdrew from the current study for reasons related to the trial 
treatment. There was no significant difference in the withdrawal rate between guar 
and the bran controls. Most studies described above, except Khan's in which the guar 
was in capsule form (Khan et al 1981), and which reported on side effects, noted a 
substantial number of participants reporting flatulence and increase frequency of 
bowel motions. These types of side effects are socially unacceptable and, therefore, 
limit the usefulness of guar preparations, even if more positive results had been 
found.
The place of more palatable forms of water soluble dietary fibre in the 
treatment of hyperlipidemia is being pursued. Jenkins et al published a cross-over 
study evaluating the addition of either soluble or insoluble forms of fibre to a low 
cholesterol/low fat diet in 43 volunteers. Total, LDL and HDL cholesterol were 
significantly lower when these individuals consumed the diet with additional soluble 
fibre. The diets were described as being 'well accepted'(Jenkins et al 1993), the
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opposite reaction to guar of most of the subjects in this study.
6.6. Conclusions
In conclusion, the results from the current guar study and review of the 
literature indicate that lipid lowering is the only risk factor addressable by increasing 
dietary soluble fibre intake. There is little or no evidence to support effects on either 
weight or blood pressure.
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Chapter 7. Hypertension to multiple risk intervention
7.0. Summary
A report of the impact of changing the emphasis of care in the nurse practitioner 
clinic from hypertension follow-up to multiple cardiovascular risk factor reduction is 
presented in this chapter.
7.1. Introduction
There was concern in the world of hypertension research with the realisation 
that lowering blood pressure did not have the efficacy anticipated, particularly in 
regards to coronary heart disease (CHD) mortality. In 1986 MacMahon et al 
compared the pooled mortality and morbidity results from nine randomised trials of 
anti-hypertensive drug treatment with the associated difference of an equivalent 
reduction in diastolic blood pressure in two large prospective, observational studies. 
The effect on stroke mortality was about 80% of predicted, but that for CHD 
mortality was only about 36% of predicted reductions. They postulated that this short 
fall may well have been influenced by other 'indicators of CHD risk' and/or the 
metabolic side effects of the anti-hypertensive drug treatment used in these trials 
(MacMahon et al 1986).
Weber, in reviewing 5 of these intervention trials, came to very similar 
conclusions (Weber, 1987), as did Reid in an editorial review in 1988 (Reid, 1988).
A subsequent meta-analysis, taking into account the more recent hypertension 
in the elderly trials' results, demonstrated that stroke rates in the treatment groups 
were reduced, in keeping with the potential predicted by the observational studies. 
However, the coronary heart disease mortality reductions were less than predicted, 
as previously found (Collins et al 1990).
7.1.1. Mhiltiple risk factor intervention
The epidemiological evidence, as reviewed in Chapter 1, indicates that there is 
a synergistic effect on mortality of increasing the number of risk factors, ie. that it is 
more than additive, in women (Isles et al 1992), as well as in men (Kannel et al
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1986, Shaper et al 1986, Isles et al 1992). Results from community surveys of risk 
factors over time indicate that changes in risk factor levels parallel ischaemic heart 
disease rate changes in general populations (Nissinen et al 1987, Sigfusson et al
1991).
The few large, prospective trials of community and high risk group multiple risk 
factor intervention have failed to show a consistent, significant impact on 
cardiovascular mortality. The WHO European Trial of Multifactorial Prevention of 
Coronary Heart Disease found no mortality differences between the intervention and 
control groups but did determine that the benefit of the interventions were 
significantly related to the extent which risk factors were changed (WHO European 
Collaborative Group 1986). Nor were there significant differences found in the 
Goteborg multifactor primary prevention trial (Wilhelmsen et al 1986).
The results from MRFIT in the United States and the Finnish Multifactorial 
Primary Prevention of Cardiovascular Diseases in Middle-aged Men Trial were 
equally disappointing (MRFIT Research Group 1990b, Strandberg et al 1991). Only a 
post-hoc analysis of the men who entered the MRFIT with diastolic blood pressure > 
100 mmHg on no anti-hypertensive drug treatment showed significant CHD and all 
cause mortality reductions in the special intervention compared to the usual care group 
(MRFIT Research Group 1990a).
7.1.2. Cardiovascular risk factors in the nurse practitioner hypertension clinic
High levels of cardiovascular risk factors had been noted in the Stobhill cohort 
(Chapter 3). Unfortunately, there was only limited success in dealing with most of 
them in the context of a hypertension follow-up clinic. A review of 175 patients who 
were continuous attenders for the first 4 years of follow-up, revealed statistically 
significant improvement in blood pressure control. At 4 years, 78% had systolic 
blood pressures within 10 mmHg of their target levels, and 93% had diastolic blood 
pressure within 5 mmHg of their target levels. There was also a statistically 
significant decrease in the percentage of males who reported that they smoked
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(Curzio et al 1987).
Unfortunately, body weight and the percentage of female smokers did not 
change. In addition, serum cholesterol and glucose increased from the first to the 
fourth year. These increases appeared to be limited to those patients taking a thiazide 
diuretic alone or in combination with other anti-hypertensive drug treatment (Ihble 
7.1) (Curzio et al 1987).
Of those patients with a cholesterol measurement recorded on the database, 
46.7% of the patients had values > 6.5 mmol/1, which is the level above which both 
the British Hyperlipidaemia Association (Shepherd et al 1987) and the European 
Atherosclerosis Society (EAS) (EAS Study Group 1987) recommend 'action'.
At this time then, the clinic was successful at doing what it set out to do, ie. 
control of blood pressure, but was far less so in dealing with other cardiovascular risk 
factors. There was now a need to address the other major known cardiovascular risk 
factors vigorously, as current knowledge indicated that the greatest benefit in 
multiple risk factor intervention appeared to be in those at higher risk.
7.2. Methods
Starting in 1987, a change in emphasis and focus within the clinic was instituted 
and the title was changed from 'Hypertension' clinic to 'Cardiovascular Risk Factor' 
clinic. At each visit, patients were reminded of the status of their other 
cardiovascular risk factors in addition to their blood pressures. The concept of 
'overall cardiovascular risk' was introduced, and patients advised as to whether they 
were at more or less risk due to the level of their risk factors. The additive nature of 
having more than one cardiovascular risk factor was included in the discussions. The 
patient information card given to every patient and updated after each clinic visit was 
revised to include weight and total cholesterol values (Figure 7.1).
Blood pressure, compliance to anti-hypertensive and lipid lowering drug 
regimens continued to be monitored. Thrget blood pressures were still used and at 
times further individualised based on overall risk, ie. a young male with polycystic
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Figure 7.1. Patient information card for the Cardiovascular Clinic.
To the patient: Stobhill General Hospital
1. Keep this card with you and bring it to  the clinic.
2. Show  it to  your family doctor when you attend 
his surgery.
3. If you have an accident or en ter hospital, show 
th is card.
5. Bring your tab lets each  visit.
6. If this appointm ent is not suitable please write to 
the  out-patient departm ent for an alternative 
d a ta
7. If you have a question about your blood pressure 
th a t needs to  be answered before your next 
appointm ent please feel free to telephone. 
(041-558-0111 ext 3087)
To the doctor:
If the drug dose is changed, please write the 
new dose on the card in the appropriate 
column, together with any blood pressures 
recorded by you, on the line below the next 
appointment date.
Further information or assistance in 
management can be obtained from:
Prof. Reid, Dr. Elliott or the Cardiovascular 
Clinic at Stobhill General Hospital 
(041 -558-0111  Ext. 3087)
8 3 -3 8 6 -22
Cardiovascular Clinic 
Information Card
N am e___________________
Address
Hospital N o ._________________
Please carry this card with you
Name of fam ily doctor
Dr.
MEDICATION and DOSE
Cholesterol Weight
BLOOD PRESSURE 
This Visit
Lying Standing
204
kidneys would have a target of 135/85.
The impact of increased weight on blood pressure had previously been stressed 
with obese patients, ie. those patients having BMIs > 30. This strategy continued, 
and the contributing role which obesity has in overall cardiovascular risk 
communicated. The patient dietary information as previously described in Chapter 2, 
was also continued.
Smoking status was reviewed on at least an annual basis. Identified smokers, 
were now strongly encouraged to stop smoking, and the impact of smoking on 
overall cardiovascular risk was emphasised. The pamphlet 'SO YOU WANT TO 
STOP SMOKING' (Scottish Health Education Group 1986) which describes a 
method of stopping smoking, was given to each smoker.
Patients with cholesterol values > 6 . 5  mmol/1 were invited to participate in 
the Cholesterol/Diet Study (see Chap 5). For those who declined or were already on 
lipid lowering medication, their diets were reviewed. Advice was given and/or 
followed-up by the clinic nurse practitioners. Those already receiving lipid lowering 
medication or with cholesterol values greater than 8.0 mmol/1 were given Diet II 
(Figure 5.2). Those who had not previously been on a lipid lowering diet, and whose 
cholesterol was between 6.5 and 8.0 mmol/1, were given Diet I (Figure 5.1). These 
diet sheets were devised by the Stobhill Dietetics Department and were also used in 
the Cholesterol/Diet study described in Chapter 5. At subsequent visits, diet was 
reviewed and difficulties discussed. If patients had particular difficulty or were 
diabetic, they were referred to the hospital dietitians for specialist advice. Patients 
with borderline cholesterol values, ie. between 6.0 and 6.5 mmol/1, were given 
advice regarding a 'healthy diet' and provided with guidelines developed by the Good 
Hearted Glasgow programme (Figure 7.2).
Total cholesterol was evaluated in relation to the levels at which 'no action' 
and 'action' has been recommended by the British Hyperlipidaemia Association 
(Shepherd et al 1987) and the European Atherosclerosis Society (Study Group 1987).
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Figure 7.2. Good Hearted Glasgow 'Healthy Eating' diet sheet (text only).
HEALTHIER EATING
Many of the modern diseases, including heart disease, are partly caused by 
faulty diet. Nearly all the experts agree that the average diet contains too 
much fat and sugar and not enough fibre. The following are suggestions for 
improvement:
1. CUT DOWN ON FAT
- avoid frying. Grill instead and let all the grease drain away.
- use less butter and margarine. Cut thicker slices of bread and spread 
the butter or margarine thinly.
- Try a low fat spread.
- Go easy on cakes, pastries and biscuits - many are surprisingly rich in fat, 
as well as sugar.
- Trim fat off meat. Look out for lean cuts.
- Make more use of fish and chicken.
- Save on cream, which is high in fat, serve natural yogurt instead, with 
fruit, salads, etc.
- Try semi-skimmed milk, instead of whole milk.
- Use a cheese which is lower in fat e.g. Edam, Camembert, Cheese Spread, 
Processed Cheese, or the new low fat 'Cheddar' type. Cottage cheese and 
skimmed milk are very low in fat.
Lack of fibre not only causes constipation, but it may be associated with other 
bowel disorders.
2. INCREASE FIBRE
- Eat more bread, especially wholemeal. All bread contains fibre, but 
wholemeal bread contains three times as much fibre as white bread.
- Eat more potatoes, but don't cook with fat (e.g. chips)
- Try more vegetable based dishes. Peas and beans can be substituted for 
part of the meat in a dish. This increases the fibre and reduces the fat.
- Choose a high fibre breakfast cereal e.g. muesli. 'Bran' cereals have a 
high fibre content. Avoid adding sugar.
To sum up, replace sweet and fatty foods, e.g. cakes, pastries, biscuits, 
chocolate, fizzy drinks and sweets with more bread, potatoes, fruit and 
vegetables.
Good Hearted 
Glasgow
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Thus those with cholesterol < 5.2 mmol/1, > 5.2 mmol/1 < 6.5 mmol/1 and > 6.5
mmol/1 were tabulated for each year and compared.
Alcohol intake was reviewed at least annually. Males reporting a greater than 
200 gms of alcohol intake per week (20 units), were advised to reduce consumption 
to 200 gms or less and females to less than 140 gms (14 units) per week. If gamma 
GT was greater than 40 iu/1 at annual review, alcohol intake was reviewed, and the 
above advice reinforced. The pamphlet 'That's the Limit' was used to support the 
advice given by the nurse practitioners (Health Education Authority 1886).
Data analysis was undertaken using Quattro Pro version 3 and version 4 as 
well as MINITAB version 8 for the personal computer. Means, standard deviations 
and percentages were analysed by one-way ANOVA, paired t-test and chi-square 
analysis as appropriate. As patients were not randomised, this is not a comparison of 
interventions but audit.
7.3. Results
The analysis group consisted of the 551 patients who had attended the clinic 
from 1987 or before, and who were still attending at the beginning of September 
1989. This permitted comparison of their risk factors and blood pressures between 
1987 on the old regimen and 1989 on the new regimen. Patients enrolled after 1987 
or who were no longer attending by 1989, were not included.
This sub-population included 250 males and 301 females, with an average age 
of 53.8 years. The males (average age of 54.9 years) were slightly older than the 
females (average age of 52.8 years) and the distribution of age by sex is presented in 
Figure 7.3.
There was no difference in average blood pressures over the 2 years of change 
to risk factor follow-up from hypertension follow-up. Mean values for initial, 1987 
and 1989 supine blood pressures with standard deviations are shown in Figure 7.4. 
and the percentage of patients with varying degrees of control for each time point are 
illustrated in Figure 7.5. for systolic blood pressure and in Figure 7.6. for diastolic 
blood pressure. There was an improvement in the percentage of patients with systolic
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Figure 7.4. Initial, 1987 and 1989 supine blood pressure means and standard deviations.
220
200
Systolic Blood Pressure
180
160
140
120
100 Diastolic Blood Pressure
1989Initial 1987
209
N
um
be
r 
of 
pa
tie
nt
s
Figure 7.5. Initial, 1987 and 1989 supine systolic blood pressure distributions.
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blood pressure within 10 mmHg of their target pressures which increased from 68% 
to 73%, and also in the percentage within 15 mmHg, which changed from 77.3% to 
81.7%. There was little change in the percentage within 5 mmHg of target diastolic 
pressure which remained satisfactory at 90% and 89% respectively, or in the 
percentage of those within 10 mmHg of target diastolic blood pressure which was 
95.7% and 93.7% respectively.
The greatest reduction in supine systolic blood pressure (15 mmHg) between 
1987 and 1989 was seen in patients whose systolic blood pressure was in the upper 
quartile in 1987 (p < 0.001). This reduction was significantly different from the 
reduction in the third quartile and the increases seen in quartiles 1 and 2. A similar 
profile was observed for supine diastolic blood pressure in which all the quartiles 
were significantly different (p < 0.001) (Figure 7.7). Thus those with the highest 
blood pressures experienced the greatest reductions in blood pressure.
Overall, average weight changed very little, decreasing by 0.4 ±5.3 kg 
between 1987 and 1989 in the total population. However, 1987 BMI values did show 
a statistically significant difference in weight reduction between 1.3 kg loss on 
average within the very obese group (BMI > 30) and the 0.3 kg gain in the desirable 
weight range group (BMI 20.00 - 24.99). This was also the case between the 1.0 kg 
loss in the mild-moderately obese group (BMI 25.00 - 30.00) and the 0,3 kg gain in 
the desirable weight group (p< 0.001) by one-way analysis of variance with Tukey 
post-hoc analysis. This is summarised using 95% confidence intervals in Figure 7.8.
The percentage of patients who identified themselves as smokers when 
reporting smoking/non-smoking status for both years, decreased marginally from 
30.6% to 29.5%. In total, 15 smokers (9.3%) reported that they had stopped 
smoking, and 43 reported a decrease in the number of cigarettes smoked per day. 
Unfortunately, 9 patients resumed smoking and 26 reported an increase in the 
number of cigarettes smoked per day. Of the 161 identified smokers in 1987, 36% 
reported they had either stopped smoking or decreased the number of cigarettes
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Figure 7.7. Mean changes in blood pressure by 1987 quartiles.
Systolic Blood Pressure p <  0.001
Quartile
LEVEL N MEAN STDEV -----+---------- i i i + i i i » i i i i i + i i I t i i i I i + i I
1 140 6.99 15.18 (---*")
2 136 2.22 14.49 (---*“ )
3 131 -3.45 16.67 (---*— )
4 135 14.67 22.42 ii
*i«i—
POOLED STDEV 17 .45 -16.0
o00ooo00 
• 
i
Confidence Intervals for Tukey Multiple Comparisons 
Quartile 1 2  3
2 -0.62 10.16
3 5.00 15.89 0.19 11.15
4 16.26 27.06 11.45 22.33 5.72 16.71
Diastolic Blood Pressure p < 0 .001
Quartile
LEVEL N MEAN STDEV  +----------+--------- +-------
1 137 5.657 10.852 (— *--- )
2 142 1.458 8.276 (—  *--)
3 137 -1.978 8.138 (— *— )
4 126 -7.548 12.284 (---*— )
 +  +  + ----------------
POOLED STDEV = 9.976 -5.0 0.0 5.0
Confidence Intervals for Tukey Multiple Comparisons
Quartile 1 2  3
2 1.133 7.266
3 4.541 10.729 0.369 6.502
4 10.044 16.365 5.871 12.139 2.409 8.730
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smoked per day while 22 % had either resumed smoking or increased the number of 
cigarettes smoked per day. There was a net reduction of 6 smokers (3.7%) between 
the two years.
Total plasma cholesterol decreased significantly from 6.5 ±1.3 mmol/1 in 
1987 to 6.3 ±1.2 mmol/1 in 1989 (p < 0.001). The shift in the proportion of 
patients with values > 6 . 5  mmol/1, > 5 . 2  and < 6 . 5  mmol/1 and < 5 . 2  mmol/1 
along with cumulative distributions for each year are given in Figure 7.9. Chi-square 
analysis of the proportional shift demonstrated it to be statistically significant 
(2P=12.36, df=2,  p < 0.005). The change in cholesterol was also evaluated by 
comparing the average reduction between the quartiles, and as with blood pressure 
and weight, those in the upper quartiles experienced significant reductions 
(p<  0.001) (Figure 7.10). The percentage differences in the cholesterol reductions 
between quartiles are +1.8%, -2.3%, -7.0% and -11.5%.
There were no differences in reported alcohol use (Thble 7.2). Gamma GT 
values are also given in the table for all patients with values in 1987 and 1989 as well 
as for those patients with reported alcohol intake >  200 gms/week (20 units). There 
was no correlation in either year between reported levels of alcohol intake and 
Gamma GT values (r=0.2, both years).
Changes in the use of diuretics in this population are shown in Thble 7.3. Also 
noted is the change in diuretic use in those individuals with total plasma cholesterol 
> 6 . 5  mmol/1. There is a statistically significant reduction in the use of diuretics 
overall (X2=4.875, d f =l ,  p<0.05) and especially in those individuals with 
cholesterol >  6.5 mmol/1 (X2=15.1, d f= l ,  p <  0.0005). For comparison, the use of 
atenolol, which changed very little over this time course, is shown.
In conclusion, the risk factor changes seen after two years of a multiple risk 
factor intervention approach are summarised in Thble 7.4 with the 1987 values 
compared with 1989.
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Figure 7.9. The shift in the distribution of total cholesterol between 1987 and 1989.
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0 .0%
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mmol/1
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> 6 . 5  mmol/1 
> 5 .2  < 6 .5  mmol/1
<  5 .2  mmol/1
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Figure 7.10. Mean changes in cholesterol by 1987 quartiles.
Quartile
LEVEL N 
1 128
2 145
3 105
4 112
MEAN
0.0914
-0.1407
-0.4857
-0.9473
STDEV
0.7057
0.6678
0.7412
0.9307
POOLED STDEV = 0.7600
BASED ON POOLED STDEV
( — * — ) 
( — * — )
( — * — )
( — * — )
-0.80 -0.40 -0.00
Confidence Intervals for Tukey Multiple Comparisons
Quartile 1 2 3
2 -0.0045 0.4687
3 0.3202 0.8340 0.0950 0.5950
4 0.7863 1.2911 0.5612 1.0520 0.1966 0.7266
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Table 7.2. Changes in reported alcohol intake and gamma GT between 1987 
and 1989.
1987 1989
Percentage of patients 
reporting alcohol intake 
>  200 gms/wk (20 units)
9.5% 8.4%
Gamma GT (iu/1) 35 ±44 34 ±49
Gamma GT (iu/1) for those reporting 
>  200 gms/wk (20 units)
60 ±43 62 ±88
Gamma GT (iu/1) for those reporting 
>200 gms/wk (20 units) in 1987
60 ±43 61 ±65
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Table 7.3. Diuretic drug use in 1987 and 1989.
1987 1989
Percentage of all patients 44% 37%*
prescribed diuretics
Percentage of only those patients
prescribed diuretics with 51% 33%**
cholesterol > 6 . 5  mmol/1
Percentage of all patients 54% 53%
prescribed atenolol
*p <  0.05
**p <  0.001
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Table 7.4. Summary of risk factors for change in clinic emphasis.
N=551
1987 1989
Blood pressure 150 ±  19 1 4 8 + 2 0
(mmHg) 84 ±10 84 ±10
Smokers 31 % 29 %
Alcohol intake 9.5% 8.4%
> 200 gms/week 
(20 units)
% Gamma GT 8.2% 6.9%
> 80 iu/1
BMI >  30 24 % 23 %
Cholesterol 6.5 ±1.3 6.2 ±1.2
(mmol/1)
Cholesterol
> 6.5 mmol/1 44 % 35 %
>5.2  <.6.5 mmol/1 40 % 43 %
< 5.2 mmol/1 15 % 22 %
* p <  0.001
** p <  0.005 X1 =  12.36, df=2
*
* *
220
7.4. Discussion
This assessment demonstrates the feasibility of altering the emphasis of care in 
an outpatient nurse practitioner clinic setting. There was a small improvement in the 
percentage of patients with systolic blood pressure within 10 mmHg and 15 mmHg of 
their target pressures and no deterioration in the high level of diastolic blood pressure 
control in this population. Total plasma cholesterol significantly decreased as did the 
percentage of patients with values > 6.5 mmol/1, 34.9% of the population continued 
to have cholesterol values > 6 . 5  mmol/1. Weight decreased significantly in those 
with BMI >  30 in 1987. Unfortunately, there was no significant change in reported 
smoking habits or alcohol intake in those reporting more than 200 gms/week in 1987.
The greatest reductions in blood pressure, weight and cholesterol were 
observed in those in the highest quartile for each in 1987. This indicated that those at 
highest risk, are in fact those who are most able to reduce their risks through multi­
factor intervention. There was a similar conclusion drawn in the British Family Heart 
Study (Family Heart Study Group 1994).
The overall population results are generally modest, but are better in some 
respects than reports of risk factor changes in other hypertensive populations, and are 
in keeping with the changes reported from controlled trials of multiple risk factor 
intervention, which also evaluated the effect on mortality. Comparison with all 
factors addressed in the nurse practitioner clinic is impossible as other studies 
focused on different combinations of factors. In addition the majority of the 
controlled trials have been conducted in middle-aged men.
However, it is interesting to consider the reports of clinical experience of risk 
factor change in other hypertension clinics. First, most reports note a substantial 
percentage of their populations with controlled blood pressure. In the Dalby, Sweden 
population, about 75% of the population had blood pressure within their targets &f 
<  160/95 mmHg for 40-59 year olds, <  180/100 mmHg for 60+ year olds, and 5-10 
mmHg lower for diabetics. All of these targets were higher than the ones used in the
221
nurse practitioner clinic. The cholesterol levels were not used for comparison with 
the Dalby control group until 1989. However, Lindholm did declare the need for full 
risk factor intervention in such populations (Lindholm, 1991).
Straznicky et al reported on 5 years of follow-up dealing with risk factors in 
the setting of an Australian hypertension clinic, in 131 men and women. A number 
of factors are compared with the nurse practitioner clinic values for comparable data, 
in Thble 7.5. The Australians were heavier, smoked less and had lower cholesterols. 
The level of achieved diastolic blood pressure was similar, while more Australians 
stopped smoking, but there was a greater effect of dietary intervention in the nurse 
practitioner clinic. They concluded that the programme 'produced little evidence of 
improvement in risk factors...' despite a high proportion of patients having 
controlled blood pressure and decreasing the percentage of smokers by half 
(Straznicky et al 1991).
As for the controlled intervention trials, the Oslo Study interventions were 
dietary to lower serum cholesterol, and stop smoking advice. Initially risk factor 
levels were high in that mean cholesterol was 8.5 mmol/1 in each group, and 79% 
were smokers (Hjermann et al 1981). These values are far higher than the 6.5 
mmol/1 average total serum cholesterol, and 30.6% smokers in the nurse practitioner 
clinic population. The resultant changes in the Oslo Study were greater than those 
that were achieved in the nurse practitioner clinic. Total serum cholesterol decreased 
by 13% in the Oslo intervention group compared with the control group during the 5 
years. This is greater than the 5% reduction seen over 2 years in the nurse 
practitioner clinic. Smoking levels expressed as number of cigarettes smoked per 
man per day decreased by 45% in the Oslo Study intervention group. An equivalent 
calculation for the nurse practitioner clinic population yielded a reduction of 11 % for 
the number of cigarettes smoked per person per day between 1987 and 1989.
The hypertensive population within the Primary Prevention Trial in Goteberg, 
Sweden were cared for in a specialist follow-up clinic staffed by a combination of
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Table 7.5. Comparison of risk factors in an Australian outpatient hypertension clinic
and the nurse practitioner clinic.
Australian Clinic Nurse Practitioner Clinic
N = 131 N =  551
Entry diastolic 101+17 102+15
blood pressure (mmHg)
Last visit diastolic 82 +10 84 ±10
blood pressure (mmHg)
Percentage with
diastolic blood 83% 77%
pressure <  90 mmHg
Total cholesterol 6.0 ±1.1 6.5 ±1.3
(mmol/1) in 1987
Total cholesterol 6.1 ±1.1 6.3 ±1.2
(mmol/1) in 1989
Percentage continuing
to smoke cigarettes 9.9% 29.5 %
at last visit
Percentage above desirable
weight range
BMI (20.00 - 24.99)
Men 88.7% 67.6%
Women 85.3% 56.8%
Mean weight reduction 1.4 0.4
(kg)
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nurses and physicians. Patients were advised to stop smoking and lower the content 
of saturated fat in their diets if total cholesterol was > 6 . 7  mmol/1. The blood 
pressure target used by this group was < 160/95 mmHg. A summary of blood 
pressure, cholesterol and smoking in this population in comparison with the nurse 
practitioner clinic population is given in Table 7.6. After 10 years, blood pressure 
and cholesterol levels were similar to those achieved at two years in the nurse 
practitioner clinic, and they achieved a significant reduction in the percentage of 
smokers (Samuelsson, 1985). As previously noted, this sub-group demonstrated a 
significant reduction in cardiovascular and coronary morbidity in those individuals 
who were able to achieve a substantial reduction in both blood pressure and serum 
cholesterol (Samuelsson et al 1987).
In the Multiple Risk Factor Intervention Trial (MRFIT) the methods used to 
address each risk factor were similar to ones employed here: drug treatment to lower 
blood pressure, dietary advice to lower serum cholesterol, and stop smoking advice 
to reduce the number of smokers. Reductions in the MRFIT were greater in the 
special intervention group. A summary of the MRFIT intervention group's results at 
2 years and nurse practitioner clinic data for the same factors are given in Table 7.7 
(MRFIT Research Group 1982). The level of achieved blood pressure and total 
cholesterol were similar for both, but MRFIT had a slightly higher percentage of 
patients continuing to smoke.
7.5. Conclusions
In conclusion the implementation of a multiple risk factor approach in a 
hypertension follow-up clinic did not adversely affect blood pressure control. This 
approach had a small but significant impact on hyperlipidaemia, but only a limited 
effect on obesity, despite a statistically significant reduction in weight for those with 
BMI >  30 in 1987. In addition, it was noted that those in the highest quartile of 
blood pressure, weight and total cholesterol experienced significant reductions in 
response to a change in emphasis of care from hypertension to multiple risk factor.
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Table 7.6. Comparison of risk factors between hypertension follow-up clinic of
Goteborg Primary Prevention Trial and the nurse practitioner clinic.
Goteborg+ Clinic Nurse Practitioner Clinic
Initially 5 yrs 10 yrs Initially 2 yrs
Average
Diastolic 106 ±13 91 ±9 89 ±8  102 ±15 84 ±10
Blood pressure
(mmHg)
Total serum
Cholesterol 6.6 ±1.2   6.2 ±1.5 6.5 ±1 .2  6.2 ±1.3
(mmol/1)
Percentage
Reporting 34%   24% 31% 30%
Cigarette smoking
+ (Samuelsson 1985)
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Table 7.7. Comparison of risk factors between MRFIT Special Intervention Group at
24 months of follow-up and the nurse practitioner clinic.
MRFIT + Nurse Practitioner Clinic
N=5,995 N=551
Average diastolic
Blood pressure 83 84
(mmHg)
Total serum
Cholesterol 6.2 6.2
(mmol/1)
Percentage reporting
Cigarette smoking 35 % 29 %
-{-(Multiple Risk Factor Intervention Trial Research Group 1982)
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Finally, this study has demonstrated the need for the development of 
alternative strategies to encourage patients to stop smoking, modify alcohol intake 
and lose weight, as well as the identification of additional methods for further 
reducing hyperlipidaemia.
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Chapter 8. Final discussion and conclusions
8.0. Summary
A discussion of the impact of 8 years of nurse practitioner care is presented in 
this chapter as well as an assessment of the various cardiovascular risk factor 
reduction interventions investigated.
8.1. Introduction
The project has provided the opportunity to assess the impact of care provided 
by nurse practitioners with a computerised patient information system over an 
extended period of time in a Scottish urban setting. Nurse practitioner care was 
evaluated by determining the achieved level of blood pressure control each year and 
the results of cardiovascular risk factor interventions in Chapters 3 and 7, and, by 
comparison with patients enrolled in conventional hypertension clinics (CHC) in 
Chapter 4. In addition, the success or otherwise of a variety of cardiovascular risk 
factor interventions have been evaluated singly or in combination.
8.2. The nurse practitioner clinic
Although the major clinical trials in hypertension, including the HDFP 
(Robinson 1974), MRC mild hypertension trial (Barnes 1981), the Goteberg Primary 
Prevention Trial (Samuelsson 1985) and the MRC hypertension in the elderly trial 
(MRC Working Party 1992), have used nurses to care for patients and carry out the 
trials, few trials have been set up to evaluate the care of high risk individuals by 
nurses specifically or as a variable (Ramsay et al 1982, Watkins & Wagner 1982). 
However, a number of studies have looked at the health promotion role in general 
practice (Fullard et al 1984, Mant et al 1989, Robson et al 1989, OXCHECK Study 
Group 1994, Family Heart Study Group 1994).
This is one of the largest reported populations (1091 patients) to be followed by 
nurse practitioners. The few large population studies evaluating nurse practitioner 
care, have all been based in the community and for shorter durations of time (Runyan 
1975, Abramson et al 1981). Many of the outpatient studies have been small without a
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control group (Schulman & Wood 1972, Clark & Dunn 1976, Laurent 1980).
More patients continued to attend the nurse practitioner clinic after 4 years than 
conventional hypertension care (69% vs 35%), and there was more current relevant 
clinical data for each patient (Chapter 3). After 8 years, 65% of the patients enrolled 
in the nurse practitioner clinic continued to attend, and 53% of those had attended for 
5 or more years. This is directly comparable to the rates observed in an Australian 
medical clinic (Straznicky et al 1991).
No other studies have been identified which have attempted to investigate the 
impact of nurse practitioner care on mortality. The study reported in Chapter 3 had 
limited power and showed no significant difference between the groups, but there were 
fewer deaths (25 vs 29), and fewer cardiovascular deaths amongst the patients 
attending the nurse practitioner clinic.
8.3. Computer based patient information system
Computer-based patient information systems are now commonplace. The 
original version of the Stobhill programme was one of the first microcomputer based 
programmes published to follow-up hypertensive patients (Kelman et al 1982). It has 
been followed by many others including one in Australia (Straznicky et al 1991). In 
the United Kingdom, only the DHSS Hypertension Care Computing Project (Beilin et 
al 1974), the Glasgow Blood Pressure Clinic (Glasgow Blood Pressure Clinic 1972) 
and the Aberdeen shared care scheme (Petrie et al 1985), all mainframe computer 
projects, have followed hypertensive patients longer.
The compact dataset has facilitated the collection of data. As seen in Chapter 4, 
smoking follow-up was virtually unavailable in the Conventional Hypertension Care 
group, whereas the completeness of information in the Nurse Practitioner Clinic was 
far greater than that reported for paper based systems. For example, Stem found that 
56% of 2371 hypertensives cared for in general practice, had no record of each 
individual's smoking habit, 69% had no record of weight, and cholesterol was not 
reported on (Stem 1986).
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8.4. Cardiovascular risk factor intervention
The greatest impact on cardiovascular risk factors in the nurse practitioner clinic 
was seen in those individuals with values in the highest quartile for blood pressure, 
weight and total cholesterol (Chapter 7). The effect of 'regression to the mean' in 
these patients cannot be ruled out totally, but the rise in the lowest quartile is less than 
half the reductions seen in the highest quartile for each variable. This is of particular 
importance, as these are the individuals who have the highest cardiovascular risk as 
shown by epidemiological surveys (Pooling Project Research Group 1978, Kannel et al 
1986, Isles et al 1992, Law et al 1994) but who have also been shown to benefit most 
from intervention (Smith et al 1993).
The results of international studies of multiple cardiovascular risk factor 
interventions and their effects on mortality have been disappointing (MRFIT Research 
Group 1990, Miettinen et al 1985, WHO European Collaborative Group 1986). The 
impact of risk factor intervention in the nurse practitioner clinic is consistent with the 
reductions seen in these international controlled trials and are in keeping with the 
results obtained by other clinical groups (Straznicky et al 1991).
8.4.1. Blood pressure
The nurse practitioner clinic has been most successful at dealing with 
hypertension. Blood pressure was relatively easily controlled soon after referral to the 
clinic. This was true for those individuals enrolled during the first year, many of 
whom came from medical follow-up clinics, as well as those enrolled in subsequent 
years from general practice referrals (Chapter 3). The success in terms of blood 
pressure control exceeded that achieved by the Glasgow Blood Pressure Clinic in its 
early years (Johnston et al 1980). Blood pressure control is important as Isles et al and 
Bulpitt et al has shown that the achieved level of blood pressure predicts mortality 
outcome (Isles et al 1986, Bulpitt et al 1988).
Blood pressure control in the nurse practitioner clinic was better than 
conventional hypertension care offered within the Glasgow Blood Pressure Clinic at
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one year for both systolic and diastolic blood pressure, and the significant difference in 
the degree of diastolic blood pressure control was still present after 4 years of follow- 
up for those patients continuing to attend (Chapter 4). Blood pressure control was 
better than that reported in Stem's review of management in general practice (Stem 
1986).
Guar has no significant effect on blood pressure compared with a bran control, 
over a 6 month treatment period, in the hypertensives with or without hyperlipidaemia 
or obesity (Chapter 6).
There was no loss of blood pressure control with the change of emphasis in care 
from hypertension follow-up to multiple risk factor intervention. Indeed, a small 
improvement in the percentage of patients with systolic blood pressure within 10 
mmHg of their target levels were noted (Chapter 7). These results are in keeping with 
those reported for the MRFIT intervention group (MRFIT 1982), the Goteborg 
Primary Prevention Trial (Samuelsson 1985), and the Medical Research Council's trial 
of treatment of hypertension in older adults (MRC Working Party 1992) as well as the 
clinical experience reported from Australia (Straznicky et al 1991) and Lindholm in 
Sweden (Lindholm 1991).
8.4.2. Weight
Average body weight did not significantly increase over time in the clinic, nor 
did it decrease (Chapter 3). There were positive reductions in weight in the severely 
obese (BMI >30). There was a mean loss over 4 years of 2.8 kg compared to a loss 
of 0.5 kg in the conventional hypertension clinic group (Chapter 4). A similar 
reduction in weight was found over the 6 months of the cholesterol diet study in which 
the group receiving intensive specialist low saturated, high polyunsaturated fat, high 
fibre diet counselling by dietitians lost significantly more weight (2.6 kg) than the non­
intervention group's 0.5 kg (Chapter 5). There was no change in weight with 6 month 
treatment with Guar (Chapter 6).
A modest, but significant difference in weight reduction also occurred with the
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change in emphasis from hypertension follow-up to multiple risk factor intervention. 
The obese sub-group (BMI > 30) had the greater reduction in weight of 1.3 kg on 
average, compared with the mild to moderate obese sub-group (BMI 25-30) with a 
weight reduction of 1.0 kg on average, while in contrast, the desirable weight sub­
group (BMI 20-25) gained 0.3 kg on average (Chapter 7). These results are in keeping 
with clinical reports (Straznicky et al 1991).
8.4.3. Plasma total cholesterol
Plasma total cholesterol and glucose measurements were measured at least 
annually from 1985 and were always recorded in the database . An initial rise in both 
measurements over the first 4 years of attendance appeared to be associated with the 
long term use of thiazide diuretics (Chapter 7). These results stimulated further 
research studies and changes in care including the cholesterol diet study (Chapter 5), 
the Guar Gum study (Chapter 6) and the change in emphasis of care to multiple risk 
intervention (Chapter 7).
There was a change in plasma total cholesterol within the patients attending at 
the time of the change of emphasis to multiple risk factor intervention. This change 
was small in absolute terms (0.2 mmol/1 on average), but it significantly shifted the 
distribution. The percentage of patients with cholesterol > 6 . 5  mmol/1 decreased from 
44% to 35%, and those with values < 5 . 2  mmol/1 increased from 16% to 19%. In 
addition, the patients with cholesterols in the highest quartile in 1987, had reduced 
their cholesterols by 11.5% (Chapter 7).
However, there were only modest changes in cholesterol under the controlled 
conditions of the cholesterol diet study and these were significant in the 'advice' group 
only after 1 month, but not at 6 months. The changes in total cholesterol at entry into 
the study compared with the previous annual review value were at least as great as that 
which occurred within the study. Cumulative change from last annual review to the 
end of the 6 month intervention showed a 12% reduction in the Advice Group and a 
7% reduction in the No Advice Group (Chapter 5).
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Ramsay et al questioned the effectiveness of dietary intervention for hyperlipidaemia 
due to its limited impact (Ramsay et al 1991). However, this limited effect may be due 
to a dilution of risk when populations are analysed without special reference to 
evaluating quartile changes.
In the Guar study, the observed lipid lowering in the hyperlipidaemic group was 
non-significant. The limited power of the study was brought about by substantial 
withdrawals in both the bran 'run in' and active treatment phases, due to socially 
unacceptable side effects including flatulence and increased bowel motions (Chapter 
6).
8.4.4. Smoking
Reported smoking levels decreased very slowly over time (Chapter 3). Changes 
in smoking behaviour, including a decrease in the number of cigarettes smoked and 
stopping, showed greater activity in the assessment made between years 6 and 8 (36% 
of smokers) with the change in emphasis of care (Chapter 7) than between years 4 and 
5 of routine follow-up (23.1% of smokers). Unfortunately, the percentage of those 
resuming smoking or increasing the reported number of cigarettes smoked was greater 
at 22% between year 6 and 8 than the 10% between year 4 and 5. These results are in 
keeping with a number of 'stop smoking' studies (Sanders et al 1989). It is only with 
the advent of nicotine patches that significant decreases in smoking rates have been 
achieved (Imperial Cancer Research Fund General Practice Research Group 1993).
8.5. Conclusions
In conclusion the following have been shown:
1. Nurse practitioner care is at least as good as conventional medical care for the long 
term follow up of hypertensive patients.
2. Nurse practitioner care is more effective in terms of maintaining follow-up and 
adherence to management protocols.
3. A microcomputer patient information system can facilitate the every day 
management of an outpatient clinic as well as providing data for research and audit.
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4. A nurse practitioner clinic with a computer based patient information system is 
capable of responding to and integrating the developments in knowledge and 
understanding which demand change in the provision of care.
5. Dietary intervention for hypercholesterolaemia is only a starting point in addressing 
the cardiovascular risk associated with raised cholesterol.
6. Guar gum has no effect on weight or blood pressure in hypertensives with or 
without hyperlipidaemia or obesity. The lipid lowering effect observed in some 
clinical trials was not confirmed due to the limited power of the study brought about 
by the high level of socially unacceptable side effects.
7. The success of current strategies for decreasing overall cardiovascular risk by 
decreasing levels of established risk factors, such as smoking, excessive alcohol 
consumption and weight is limited.
8.6. Future considerations
Considerations for the future following from this work are:
1. that an extensive education programme be set up for nurses to facilitate the 
expansion of care provided by nurse practitioners.
2. nurse practitioner clinics be associated with academic centres of excellence 
interested in the care of hypertensive patients, to continue the evaluation of new 
aspects of care using this model.
3. that studies to assess the long term mortality of this population be carried out to 
investigate:
a) the overall impact of nurse practitioner follow-up,
b) the change in emphasis from hypertension follow-up to multiple cardiovascular 
risk intervention.
4. further studies be undertaken to develop alternative pharmacological and 
non-pharmacological interventions to decrease overall cardiovascular risk. In 
particular, new strategies to provide more effective weight and cholesterol 
reduction, and smoking cessation are urgently required.
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Abbreviations
ACE inhibitor Angiotension converting enzyme inhibitor.
ANOVA Analysis of variance.
ANCOVA Analysis of co-variance.
BMI Body mass index, calculated: weight (kg)/height (m)2.
CHC Convention hypertension clinics.
CHD Coronary heart disease.
DART Diet and Reinfarction Trial.
DBF Diastolic blood pressure.
DHSS Department of Health and Social Security.
ECG Electrocardiogram.
EW PHE European Working Party on High blood pressure in the Elderly, 
g Grams.
GammaGT Gammaglutamyltransferase.
GBPC Glasgow Blood Pressure Clinic.
GP General practitioner.
HDFP Hypertension Detection and Follow-up Program.
HDL cholesterol High density lipoprotein cholesterol.
IHD Ischaemic heart disease. 
iu/1 International units per litre, 
kg Kilograms.
LDL cholesterol Low density lipoprotein cholesterol.
M I Myocardial infarction. 
mmHg Millimetres of mercury. 
mmol/1 millimoles per litre.
MONICA Monitoring of trends and determinants in cardiovascular disease study. 
MRC Medical Research Council.
M RFIT Multiple Risk Factor Intervention Trial.
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Abbreviations continued
NPC Nurse practitioner clinic.
SBP Systolic blood pressure.
STARS St Thomas' Atherosclerosis Regression Study. 
ummol/1 micromoles per litre.
VA Veterans Administration.
VLDL cholesterol Very low density lipoprotein cholesterol. 
WHO World Health Organisation.
WSDF Water soluble dietary fibre.
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